MXPA06001203A

MXPA06001203A - Pyridyl derivatives and their use as therapeutic agents

Info

Publication number: MXPA06001203A
Application number: MXPA/A/2006/001203A
Authority: MX
Inventors: Abreo Melwyn; F Harvey Daniel; A Kondratenko Mikhail; Li Wenbao; Kamboj Rajender; Kodumuru Vishnumurthy; D Winther Michael; W Gschwend Heinz; Liu Shifeng; Sviridov Serguei; Sun Shaoyi; Tu Chi; J Hudson Cindy; Raina Vandna; Zhang Zaihui; Seid Bagherzadeh Mehran
Original assignee: Abreo Melwyn; W Gschwend Heinz; F Harvey Daniel; J Hudson Cindy; Kamboj Rajender; Kodumuru Vishnumurthy; A Kondratenko Mikhail; Li Wenbao; Liu Shifeng; Raina Vandna; Seid Bagherzadeh Mehran; Sun Shaoyi; Sviridov Serguei; Tu Chi; D Winther Michael; Xenon Pharmaceuticals Inc; Zhang Zaihui
Priority date: 2003-07-30
Filing date: 2006-01-30
Publication date: 2006-12-13

Abstract

Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I):wherein:W is -O-, -N(R1)-, C(O) , S(O)t;(where t is 0, 1 or 2), N(R1)S(O)2 , S(O)2N(R1) , C(O)N(R1) or N(R1)C(O)N(R1);and V is C(O) , C(S) , C(O)N(R1)-, C(O)O-, S(O)2-, S(O)2N(R1)- or C(R11)H;and x, y, R1, R2, R3, R4, R5, R6, R7, R7a, R8, R8a, R9, R9a, R10 and R10a are defined herein. Pharmaceutical compositions comprising the compounds of formula (I) are also disclosed.

Description

DERIVATIVES OF PIRIDIL AND ITS USE AS THERAPEUTIC AGENTS FIELD OF THE INVENTION The present invention relates generally to the field of stearoyl-CoA desaturase inhibitors, such as pyridazine derivatives, and the uses for said compounds in the treatment and / or prevention of various human diseases, including those mediated by desaturase enzymes of Stearoyl-CoA (SCD), preferably SCD1, especially diseases related to elevated lipid levels, cardiovascular disease, diabetes, obesity, metabolic syndrome, and the like.

BACKGROUND OF THE INVENTION Acyl desaturase enzymes catalyze the formation of double bonds in fatty acids derived from either dietary sources or novel syntheses in the liver. Mammals synthesize at least three fatty acid desaturases of different chain length specificity that catalyze the addition of double bonds at the delta-9, delta-6, and delta-5 positions. Stearoyl-CoA desaturases (SCDs) introduce a double bond at the C9-C10 position of saturated fatty acids. The preferred substrates are palmitoyl-CoA (16: 0) and stearyl-CoA (18: 0), which are converted to palmitoloyl-CoA (16: 1) and oleoyl-CoA (18: 1), respectively. The resulting monosaturated fatty acids are substrates for incorporation into phospholipids, triglycerides, and cholesteryl esters. A number of mammalian SCD genes have been cloned. For example, two genes have been cloned from rats (SCD1, SCD2) and four SCD genes have been isolated from mice (SCD 1, 2, 3, and 4). Since the basic biochemical role of SCD has been known since the 1970's (Jeffcoat, R. et al., Elsevier Science (1984), Vol. 4, pp. 85-112; de Antueno, RJ, Lipids (1993), Vol. 28 , No. 4, pp. 285-290), has only recently been directly implicated in human disease processes. A single SCD gene, SCD1 has been characterized in humans. SCD1 is disclosed in Brownie et al., PCT published patent application, WO 01/62954, the disclosure of which is incorporated herein by reference in its entirety. Recently a second human SCD isoform has been identified, and because it carries a small sequence homology for alternating mouse and rat isoforms it has been named SCD5 or human hSCD5 (PCT published patent application, WO 02/26944, incorporated herein by reference in its entirety). To date, the small molecule drug type compounds are known to specifically inhibit or modulate SCD activity. Certain long-chain hydrocarbons have historically been used to study the activity of SCD. Known examples include fatty acids, cyclopropenoid fatty acids, and certain conjugated linoleic acid isomers. Specifically, conjugated linoleic acid cis-12, trans-10 is believed to inhibit the activity of the SCD enzyme and reduce the abundance of SCD1 mRNA while conjugated linoleic acid cis-9, trans-11 does not. The cyclopropenoid fatty acids such as those found in sterile and cotton seeds are also known to inhibit SCD activity. For example, (8- (2-octylcyclopropenyl) octanoic acid) stearyl acid and (7- (2-octylcyclopropenyl) heptanoic acid) mavicic acid are C18 and C16 derivatives of esterculoyl and malvaloyl fatty acids, respectively, having rings of cyclopropene in its C9-C10 positions. These agents are believed to inhibit SCD enzymatic activity through direct interaction with the enzyme, thus inhibiting delta-9 desaturation. Other agents that can inhibit SCD activity include thia-fatty acids, such as thia-stearic acid (also called 8-noni-thiooctanoic acid) and other fatty acids with a sulfoxy moiety. These known modulators of delta-9 desaturase activity are not useful for treating diseases and disorders linked to the biological activity of SCD1. None of the known SCD inhibitor compounds are selective for SCD or desaturases delta-9, since they also inhibit other desaturases and enzymes. Thia-fatty acids, conjugated linoleic acids and cyclopropene fatty acids (malvial acid and sterocholine acid) are also not useful at reasonable physiological doses, nor with specific inhibitors of the biological activity of SCD1, rather they demonstrate the cross-inhibition of other desaturases , in particular the desaturases delta-5 and delta-6 through fatty acids of cyclopropene. The absence of small molecule inhibitors of SCD enzyme activity is a major scientific and medical disillusionment because the evidence now is to compel SCD activity to be directly involved in disease processes in ordinary humans: See , for example, Attie, AD et al., "Relationship between stearoyl-CoA desaturase activity and plasma triglycerides in human and mouse hypertriglyceridemia", J. Lipid Res. (2002), Vol. 43, No. 11, pp. 1899-907; Cohen, P. et al., "Role for stearoyl-CoA desaturase-1 in leptin-mediated weight loss", Science (2002), Vol. 297, No. 5579, pp. 240-3, Ntambi, J. M. et al., "Loss of stearoyl-CoA desaturase-1 function protects mice against adiposity", Proc. Nati Acad. Sci. U S A. (2002), Vol. 99, No. 7, pp. 11482-6. The present invention solves this problem by introducing new classes of compounds that are useful in the modulation of SCD activity and the regulation of lipid levels, especially plasma lipid levels, and which are useful in the treatment of SCD-mediated diseases such as diseases related to dyslipidemia and lipid metabolism disorders, especially diseases related to high lipid levels, cardiovascular disease, diabetes, obesity, metabolic syndrome and the like.

Related Literature The Patent of E.U.A. No. 6,677,452 discloses novel pyridinecarboxamide or sulfonamide derivatives. PCT Published Patent Application, WO 03/075929, WO 03/076400 and WO 03/076401, disclose compounds having histone deacetylase that inhibit enzymatic activity.

COMPENDIUM OF THE INVENTION The present invention provides pyridazine derivatives that modulate the activity of stearyl-CoA desaturase. Methods for the use of such derivatives to modulate stearoyl-CoA desaturase activity and pharmaceutical compositions comprising said derivatives are also encompassed. Accordingly, in one aspect, the invention provides methods for inhibiting human stearoyl-CoA desaturase (hSCD) activity comprising contacting a source of hSCD with a compound of formula (I): wherein: x and y are each independently 1, 2 or 3; W is -O-, -N (R1) -, -C (R1) 2-, -C (O) -, -OC (O) -, -S (O) t-; (where t is 0, 1 or 2), -N (R1) S (O) t- (where t is 1 or 2), -S (O) 2N (R1) -, -C (O) N (R1) -, -C (S) N (R1) -, -OS (O) 2N (R1) -, -C (O) N (R1) -; -OC (S) N (R1) -, -N (R1) C (O) N (R1) - or -N (R1) C (S) N (R1) -; V is -C (O) -, -C (S) -, -C (O) N (R1) --C (O) O-, -C (S) O-, -S. { O) (where t is 1 or 2), -S (O) tN (R1) - (where t is 1 or 2) or -C (R11) H; each R1 is independently selected from the group consisting of hydrogen, alkyl of 1 to 6 carbon atoms, hydroxyalkyl of 2 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms and aralkyl of 7 to 19 carbon atoms; R2 is selected from the group consisting of alkyl of 1 to 12 carbon atoms, alkenyl of 2 to 12 carbon atoms, hydroxyalkyl of 2 to 12 carbon atoms, hydroxyalkenyl of 2 to 12 carbon atoms, alkoxyalkyl of 2 to 12 atoms carbon, cycloalkyl of 3 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms, aryl, aralkyl of 7 to 12 carbon atoms, heterocyclyl of 3 to 12 carbon atoms, heterocyclylalkyl of 3 to 12 carbon atoms, heteroaryl of 1 to 12 carbon atoms, and heteroarylalkyl of 3 to 12 carbon atoms; or R2 is a multi-ring structure having from 2 to 4 rings, wherein the rings are independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl and wherein some or all of the rings may be fused together with the other; R3 is selected from the group consisting of alkyl of 1 to 12 carbon atoms, alkenyl of 2 to 12 carbon atoms, hydroxyalkyl of 2 to 12 carbon atoms, hydroxyalkenyl of 2 to 12 carbon atoms, alkoxyalkyl of 2 to 12 carbon atoms. carbon, cycloalkyl of 3 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms, aryl, aralkyl of 7 to 12 carbon atoms, heterocyclyl of 3 to 12 carbon atoms, heterocyclylalkyl of 3 to 12 carbon atoms, heteroaryl from 1 to 12 carbon atoms and heteroarylalkyl of 3 to 12 carbon atoms; or R3 is a multi-ring structure having from 2 to 4 rings, wherein the rings are independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl and wherein some or all of the rings may be fused together with the other; R4, R5 and R6 are each independently selected from hydrogen, fluoro, chloro, methyl, methoxy, trifluoromethyl, cyano, nitro or -N (R13) 2; R7, R7a, R8, R8a, R9, R9a, R10 and R10a are each independently selected from hydrogen or alkyl of 1 to 3 carbon atoms; or R7 and R7a together, or R8 and R8a together, or R9 and R9a or R10 and R10a together are an oxo group, provided that when V is -C (O) -, R7 and R7a together or R8 and R8a together do not form a oxo group, while the rest of R7, R7a, R8, R8a, R9, R9a, R10 and R10a each is independently selected from hydrogen, or alkyl of 1 to 3 carbon atoms; or one of R10 and R10a, R7, and R7a together with one of R8, R8a, R9 and R9a form an alkylene bridge, while the remainder of R10 and R10a, R7, R7a, R8, R8a, R9, and R9a each it is independently selected from hydrogen or alkyl of 1 to 3 carbon atoms; R1 is hydrogen or alkyl of 1 to 3 carbon atoms; and each R13 is independently selected from hydrogen or alkyl of 1 to 6 carbon atoms; a stereoisomer, enantiomer or tautomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable composition thereof or a prodrug thereof.

In another aspect, the invention provides methods for treating a disease or condition mediated by stearoyl-CoA (SCD) desaturase in a mammal, wherein the method comprises administering to the mammal in need thereof a therapeutically effective amount of a compound of the invention. Formula (I) as stated above. In another aspect, the invention provides compounds of the formula (I) having the following formula (lia): wherein: x and y are each independently 1, 2 or 3; R1 is selected from the group consisting of hydrogen, alkyl of 1 to 12 carbon atoms, hydroxyalkyl of 2 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms and aralkyl of 7 to 19 carbon atoms; R 2 is selected from the group consisting of alkyl of 7 to 12 carbon atoms, alkenyl of 3 to 12 carbon atoms, hydroxyalkyl of 7 to 12 carbon atoms, alkoxyalkyl of 2 to 12 carbon atoms, hydroxyalkenyl of 3 to 12 atoms of carbon, cycloalkyl of 3 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms, aralkyl of 13 to 19 carbon atoms, heteroaryl of 1 to 12 carbon atoms, heterocyclylalkyl of 3 to 12 carbon atoms, heterocyclyl of 3 to 12 carbon atoms, and heteroarylalkyl of 3 to 12 carbon atoms, provided that R2 is not pyrazinyl, pyridinonyl, pyrrolidonone or imidazolyl; or R2 is a multi-ring structure having from 2 to 4 rings wherein the rings are independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl, wherein some or all of the rings may be fused with each other; R3 is selected from the group consisting of alkyl of 3 to 12 carbon atoms, alkenyl of 3 to 12 carbon atoms, hydroxyalkyl of 3 to 12 carbon atoms, hydroxyalkenyl of 3 to 12 carbon atoms, alkoxy of 3 to 12 atoms carbon, alkoxyalkyl of 3 to 12 carbon atoms, cycloalkyl of 3 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms, aryl, aralkyl of 7 to 19 carbon atoms, heterocyclyl of 3 to 12 carbon atoms, heterocyclylalkyl of 3 to 12 carbon atoms, heteroaryl of 1 to 12 carbon atoms and heteroarylalkyl of 3 to 12 carbon atoms; or R3 is a multi-ring structure having from 2 to 4 rings wherein the rings are independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl and wherein some or all of the rings may be fused with each other; R4, R5 and R6 are each independently selected from hydrogen, bromine, fluorine, chlorine, methyl, methoxy, trifluoromethyl, cyano, nitro or -N (R13) 2; R7, R7a, R8, R8a, R9, R9a, R10 and R10a are each independently selected from hydrogen or alkyl of 1 to 3 carbon atoms; or R9 and R9a together, or R10 and R10a together form an oxo group, while the remainder of R7, R7a, R8, R8a, R9, R9a, R10, and R10a are each independently selected from hydrogen or alkyl of 1 to 3 atoms of carbon; or one of R7, R7a, R10, and R10a, together with one of, R8, R8a, R9, R, form an alkylene bridge, while the rest of R 10, R, 10a R7, R7a, R8, R8a, R9, and R9a are each independently selected from hydrogen or alkyl of 1 to 3 carbon atoms; and each R13 is independently selected from hydrogen or alkyl of 1 to 6 carbon atoms; a stereoisomer, enantiomer or tautomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically composition thereof or a prodrug thereof. In another aspect, the invention provides compounds of the formula (1) having the following formula (lb): where: x e and each independently 1.2 or 3; R1 is selected from the group consisting of hydrogen, alkyl of 1 to 12 carbon atoms, hydroxyalkyl of 2 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms and aralkyl of 7 to 19 carbon atoms; R2 is selected from the group consisting of alkyl of 1 to 12 carbon atoms, alkenyl of 2 to 12 carbon atoms, hydroxyalkyl of 2 to 12 carbon atoms, hydroxyalkenyl of 2 to 12 carbon atoms, alkoxy of 1 to 6 carbon atoms, alkoxyalkyl of 3 to 12 carbon atoms, cycloalkyl of 3 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms, aralkyl of 7 to 19 carbon atoms, heterocyclyl of 3 to 12 carbon atoms, heterocyclylalkyl of 3 to 12 carbon atoms, heteroaryl of 1 to 12 carbon atoms and heteroarylalkyl of 3 to 12 carbon atoms; or R2 is a multi-ring structure having from 2 to 4 rings wherein the rings are independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl, wherein some or all of the rings may be fused with one another; R3 is phenyl optionally substituted by one or more substituents selected from the group consisting of halogen, cyano, nitro, hydroxy, alkyl of 1 to 6 carbon atoms, trihaloalkyl of 1 to 6 carbon atoms, trihaloalkoxy of 1 to 6 carbon atoms , alkylsulfonyl of 1 to 6 carbon atoms, -N (R12) 2, -OC (0) R12, -C (O) OR12, -S (O) 2N (R12) 2, cycloalkyl, heterocyclyl, heteroaryl and heteroarylcycloalkyl, provided that R3 is not phenyl substituted with optionally substituted thienyl; R4, R5 and R6 are each independently selected from hydrogen, bromine, fluorine, chlorine, methyl, methoxy, trifluoromethyl, cyano, nitro or -N (R13) 2; R7, R7a, R8, R8a, R9, R9a, R10, and R10a are each independently selected from hydrogen or alkyl of 1 to 3 carbon atoms; or R9 and R9a together, or R0 and R10a together form an oxo group, while the remainder of R7, R7a, R8, R8a, R9, R9a, R10, and R10a are each independently selected from hydrogen or alkyl from 1 to 3 carbon atoms; or one of R7, R7a, R10 and R10a, together with one of R8, R8a, R9 and R9a, form an alkylene bridge, while the remainder of R 0, R 10a, R 7, R 7a, R 8, R 8a, R 9, and R 9a each are independently selected from hydrogen or alkyl of 1 to 3 carbon atoms; and each R12 is independently selected from hydrogen, alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms, aryl or aralkyl; and each R13 is independently selected from hydrogen or alkyl of 1 to 6 carbon atoms; a stereoisomer, enantiomer or tautomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically composition thereof or a prodrug thereof. In another aspect, the invention provides compounds of the formula (I) having the following formula (III): where: x e and each independently 1, 2 or 3; Va is -C (O) -, -C (S) -, -C (O) N (R1) -, -C (S) N (R1) -, -C (O) O-, -C (S ) O-, -S (O) t- (where t is 1 or 2) or -S (O). { N (R1) - (where t is 1 or 2); each R1 are independently selected from the group consisting of hydrogen, alkyl of 1 to 12 carbon atoms, hydroxyalkyl of 2 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms and aralkyl of 7 to 19 carbon atoms; R2 is selected from the group consisting of alkyl of 1 to 12 carbon atoms, alkenyl of 2 to 12 carbon atoms, hydroxyalkyl of 2 to 12 carbon atoms, hydroxyalkenylalkyl of 2 to 12 carbon atoms, alkoxy of 1 to 6 atoms carbon, alkoxyalkyl of 3 to 12 carbon atoms, cycloalkyl of 3 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms, aryl, aralkyl of 7 to 19 carbon atoms, heterocyclyl of 3 to 12 carbon atoms, heterocyclylalkyl of 3 to 12 carbon atoms, heteroaryl of 1 to 12 carbon atoms and heteroarylalkyl of 3 to 12 carbon atoms; or R2 is a multi-ring structure having from 2 to 4 rings wherein the rings are independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl, wherein some or all of the rings may be fused with each other; R3 is selected from the group consisting of alkyl of 1 to 12 carbon atoms, alkenyl of 2 to 12 carbon atoms, hydroxyalkyl of 2 to 12 carbon atoms, hydroxyalkyl of 2 to 12 carbon atoms, alkoxyalkyl of 2 to 12 atoms carbon, cycloalkyl of 3 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms, aryl, aralkyl of 7 to 19 carbon atoms, heterocyclyl of 3 to 12 carbon atoms, heterocyclylalkyl of 3 to 12 carbon atoms, heteroaryl of 1 to 12 carbon atoms and heteroarylalkyl of 3 to 12 carbon atoms; or R3 is a multi-ring structure having from 2 to 4 rings wherein the rings are independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl and wherein some or all of the rings may be fused with each other; R4, R5 and R6 are each independently selected from hydrogen, bromine, fluorine, chlorine, methyl, methoxy, trifluoromethyl, cyano, nitro or -N (R13) 2; R7, R7a, R8, R8a, R9, R9a, R10, and R10a are each independently selected from hydrogen or alkyl of 1 to 3 carbon atoms; or R7 and R7a together, or R8 and R8a together, or R9 and R9a together, or R10 and R10a together are an oxo group, provided that when Va is -C (O) -, R7 and R .7a together or R and R together they do not form an oxo group, while the rest of R7, R7a, R8, R8a, R9, R9a, R10, and R0a each are independently selected from hydrogen or alkyl of 1 to 3 carbon atoms; or one of R10, R10a, R7 and R7a, together with one of R8, R8a, R9 and R9a form an alkylene bridge, while the remainder of R0, R10a, R7, R7a, R8, R8a, R9, and R9a each one is independently selected from hydrogen or alkyl of 1 to 3 carbon atoms; and each R13 is independently selected from hydrogen or alkyl of 1 to 6 carbon atoms; a stereoisomer, enantiomer or tautomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically composition thereof or a prodrug thereof. In another aspect, the invention provides compounds of the formula (I) that have the following formula (IV): where: x e and each independently 1, 2 or 3; Va is -C (O) -, -C (S) -, -C (O) N (R1) -, -C (S) N (R1) -, -C (0) 0-, -C (S ) O-, -S (O) t- (where t is 1 or 2) or -S (O) tN (R1) - (where t is 1 or 2); each R1 is independently selected from the group consisting of hydrogen, alkyl of 1 to 12 carbon atoms, hydroxyalkyl of 2 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms and aralkyl of 7 to 19 carbon atoms; R2 is selected from the group consisting of alkyl of 1 to 12 carbon atoms, alkenyl of 2 to 12 carbon atoms, hydroxyalkyl of 2 to 12 carbon atoms, hydroxyalkenyl of 2 to 12 carbon atoms, alkoxyalkyl of 3 to 12 atoms carbon, cycloalkyl of 3 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms, aryl, aralkyl of 7 to 19 carbon atoms, heterocyclyl of 3 to 12 carbon atoms, heterocyclylalkyl of 3 to 12 carbon atoms, heteroaryl of 1 to 12 carbon atoms and heteroarylalkyl of 3 to 12 carbon atoms; or R2 is a multi-ring structure having from 2 to 4 rings wherein the rings are independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl, wherein some or all of the rings may be fused with each other; R3 is selected from the group consisting of alkyl of 1 to 12 carbon atoms, alkenyl of 2 to 12 carbon atoms, hydroxyalkyl of 2 to 12 carbon atoms, hydroxyalkenyl of 2 to 12 carbon atoms, alkoxyalkyl of 2 to 12 atoms carbon, cycloalkyl of 3 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms, aryl, aralkyl of 7 to 19 carbon atoms, heterocyclyl of 3 to 12 carbon atoms, heterocyclylalkyl of 3 to 12 carbon atoms, heteroaryl of 1 to 12 carbon atoms and heteroarylalkyl of 3 to 12 carbon atoms; or R3 is a multi-ring structure having from 2 to 4 rings wherein the rings are independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl and wherein some or all of the rings may be fused with each other; R4, R5 and R6 are each independently selected from hydrogen, bromine, fluorine, chlorine, methyl, methoxy, trifluoromethyl, cyano, nitro or -N (R13) 2; R7, R7a, R8, R8a, R9, R9a, R10, and R10a are each independently selected from hydrogen or alkyl of 1 to 3 carbon atoms; or R7 and R7a together, or R8 and R8a together, or R9 and R9a together, or R10 and R10a together are an oxo group, provided that when Va is -C (O) -, R7 and R7a together or R8 and R8a together do not they form an oxo group, while the rest of R7, R7a, R8, R8a, R9, R9a, R10, and R10a each are independently selected from hydrogen or alkyl of 1 to 3 carbon atoms; or one of R10, R10a, R7 and R7a, together with one of R8, R8a, R9 and R9a form an alkylene bridge, while the remainder of R10, R0a, R7, R7a, R8, R8a, R9, and R9a are independently selected from hydrogen or alkyl of 1 to 3 carbon atoms; and each R 3 is independently selected from hydrogen or alkyl of 1 to 6 carbon atoms; a stereoisomer, enantiomer or tautomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically composition thereof or a prodrug thereof. In another aspect, the invention provides compounds of the formula (I) having the following formula (V): where: x e and each independently 1, 2 or 3; Wa is -O-, -N (R1) - or S (O) t- (where t is 0, 1 or 2); Va is -C (O) -, -C (S) -, -C (O) N (R1) -, -C (S) N (R1) -, -C (O) O-, -C (S ) O-, -S (O) t- (where t is 1 or 2) or -S (O) tN (R1) - (where t is 1 or 2); each R are independently selected from the group consisting of hydrogen, alkyl of 1 to 12 carbon atoms, hydroxyalkyl of 2 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms and aralkyl of 7 to 19 carbon atoms; R2 is selected from the group consisting of alkyl of 1 to 12 carbon atoms, alkenyl of 2 to 12 carbon atoms, hydroxyalkyl of 2 to 12 carbon atoms, hydroxyalkenyl of 2 to 12 carbon atoms, alkoxyalkyl of 3 to 12 atoms carbon, cycloalkyl of 3 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms, aryl, aralkyl of 7 to 19 carbon atoms, heterocyclyl of 3 to 12 carbon atoms, heterocyclylalkyl of 3 to 12 carbon atoms, heteroaryl with 1 to 12 carbon atoms and heteroarylalkyl with 3 to 12 carbon atoms; or R2 is a multi-ring structure having from 2 to 4 rings wherein the rings are independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl, wherein some or all of the rings may be fused with each other; R3 is selected from the group consisting of alkyl of 1 to 12 carbon atoms, alkenyl of 2 to 12 carbon atoms, hydroxyalkyl of 2 to 12 carbon atoms, hydroxyalkenyl of 2 to 12 carbon atoms, alkoxyalkyl of 2 to 12 atoms carbon, cycloalkyl of 3 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms, aryl, aralkyl of 7 to 19 carbon atoms, heterocyclyl of 3 to 12 carbon atoms, heterocyclylalkyl of 3 to 12 carbon atoms, heteroaryl of 1 to 12 carbon atoms, and heteroarylalkyl of 3 to 12 carbon atoms; or R3 is a multi-ring structure having from 2 to 4 rings wherein the rings are independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl and wherein some or all of the rings may be fused with one another; R4, R5 and R6 are each independently selected from hydrogen, bromine, fluorine, chlorine, methyl, methoxy, trifluoromethyl, cyano, nitro or -N (R13) 2; R7, R7a, R8, R8a, R9, R9a, R10, and R10a are each independently selected from hydrogen or alkyl of 1 to 3 carbon atoms; or R7 and R7a together, or R8 and R8a together, or R9 and R9a together, or R10 and R10a together are an oxo group, provided that when Va is -C (O) -, R7 and R7a together R8 and R8a together do not form an oxo group, while the rest of R7, R7a, R8, R8a, R9, R9a, R10, and R10a each are independently selected from hydrogen or alkyl of 1 to 3 carbon atoms; or one of R10, R10a, R7 and R7a, together with one of R8, R8a, R9 and R9a form an alkylene bridge, while the remainder of R10, R10a, R7, R7a, R8, R8a, R9, and R9a each they are independently selected from hydrogen or alkyl of 1 to 3 carbon atoms; and each R13 is independently selected from hydrogen or alkyl of 1 to 6 carbon atoms; a stereoisomer, enantiomer or tautomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically composition thereof or a prodrug thereof. In another aspect, the invention provides compounds of formula (I) having the following formula (la): where: x e and each independently 1, 2 or 3; W is -N (R1) S (O) t- (where t is 1 or 2); V is -C (O) -, -C (S) -, -C (O) N (R1) -, -C (S) N (R1) -, -C (O) O-, -C (S ) O, -S (O) - (where t is 1 or 2), -S (O) tN (R1) - (where t is 1 or 2) or -C (R11) H; each R1 are independently selected from the group consisting of hydrogen, alkyl of 1 to 12 carbon atoms, hydroxyalkyl of 2 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms and aralkyl of 7 to 19 carbon atoms; R2 is selected from the group consisting of alkyl of 1 to 12 carbon atoms, alkenyl of 2 to 12 carbon atoms, hydroxyalkyl of 2 to 12 carbon atoms, hydroxyalkyl of 2 to 12 carbon atoms, alkoxyalkyl of 2 to 12 atoms carbon, cycloalkyl of 3 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms, aryl, aralkyl of 7 to 19 carbon atoms, heterocyclyl of 3 to 12 carbon atoms, heterocyclylalkyl of 3 to 12 carbon atoms, heteroaryl of 1 to 12 carbon atoms, and heteroarylalkyl of 3 to 12 carbon atoms; or R2 is a multi-ring structure having from 2 to 4 rings wherein the rings are independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl and wherein some or all of the rings may be fused with one another; R3 is selected from the group consisting of alkyl of 1 to 12 carbon atoms, alkenyl of 2 to 12 carbon atoms, hydroxyalkyl of 2 to 12 carbon atoms, hydroxyalkenyl of 2 to 12 carbon atoms, alkoxyalkyl of 2 to 12 carbon atoms, cycloalkyl of 3 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms, aryl, aralkyl of 7 to 19 carbon atoms, heterocyclyl of 3 to 12 carbon atoms carbon, heterocyclylalkyl of 3 to 12 carbon atoms, heteroaryl of 1 to 12 carbon atoms and heteroarylalkyl of 3 to 12 carbon atoms; or R3 is a multi-ring structure having from 2 to 4 rings wherein the rings are independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl and wherein some or all of the rings may be fused with each other; R4, R5 and R6 are each independently selected from hydrogen, bromine, fluorine, chlorine, methyl, methoxy, trifluoromethyl, cyano, nitro or -N (R13) 2; R7, R7a, R8, R8a, R9, R9a, R10, and R10a are each independently selected from hydrogen or alkyl of 1 to 3 carbon atoms; or R7 and R7a together, or R8 and R8a together, or R9 and R9a together, or R10 and R10a together are an oxo group, provided that when V is -C (O) -, R7 and R7a together or R8 and R8a together do not they form an oxo group, while the rest of R7, R7a, R8, R8a, R9, R9a, R0, and R10a each are independently selected from hydrogen or alkyl of 1 to 3 carbon atoms; or one R10, R10a, R7 and R7a, together with one of R8, R8a, R9 and R9a form an alkylene bridge, while the remainder of R10, R10a, R7, R7a, R8, R8a, R9, and R9a each are independently selected from hydrogen or alkyl of 1 to 3 carbon atoms; R11 is hydrogen or alkyl of 1 to 3 carbon atoms; and each R 3 is independently selected from hydrogen or alkyl of 1 to 6 carbon atoms; a stereoisomer, enantiomer or tautomer thereof, a pharmaceutically acceptable salt, a pharmaceutically composition thereof or a prodrug thereof. In another aspect, the invention provides methods for treating a disease or condition mediated by SCD in a mammal, preferably a human, wherein the methods comprise administering to the mammal in need thereof a therapeutically effective amount of a compound of the invention as It was established earlier. In another aspect, the invention provides compounds or pharmaceutical compositions useful in the treatment, prevention and / or diagnosis of a disease or condition related to the biological activity of SCD, such as diseases encompassed by cardiovascular disorders and / or the metabolic syndrome (including dyslipidemia)., insulin resistance and obesity). In another aspect, the invention provides methods for preventing or treating a disease or condition related to elevated lipid levels, such as plasma lipid levels, especially high triglyceride or cholesterol levels, in a patient afflicted with such elevated levels, which comprises administering to said patient a therapeutically or prophylactically effective amount of a composition as described herein. The present invention also relates to novel compounds that have the therapeutic ability to reduce lipid levels in an animal, especially triglyceride and cholesterol levels. In another aspect, the invention provides pharmaceutical compositions comprising the compounds of the invention as set forth above, and pharmaceutically acceptable excipients. In one embodiment, the present invention relates to a pharmaceutical composition comprising a compound of the invention in a pharmaceutically acceptable carrier and in an amount effective to modulate the level of triglyceride, or to treat diseases related to dyslipidemia and disorders of lipid metabolism , when administered to an animal, preferably a mammal, preferably a human patient. In one embodiment of said composition, the patient has a high lipid level, such as elevated triglycerides or cholesterol in the plasma, before the administration of said compound and said compound is present in an amount effective to reduce said lipid level. In another aspect, the invention provides methods for treating a patient from, or protecting a patient from development, a disease or condition mediated by stearoyl-CoA desaturase (SCD), which method comprises administering to a patient afflicted with said disease or condition. , or at risk of developing said disease or condition, a therapeutically effective amount of a compound that inhibits the activity of SCD in a patient when administered thereto. In another aspect, the invention provides methods for treating a variety of diseases involving lipid metabolism using compounds identified by the methods described herein. Accordingly, a variety of compounds having said activity are described herein, based on a classification assay to identify, from a collection of test compounds, a therapeutic agent that modulates the biological activity of said SCD and is useful in the treatment of a human disorder or condition related to serum lipid levels, such as triglycerides, VLDL, HDL, LDL, and / or total cholesterol.

DETAILED DESCRIPTION OF THE INVENTION Definitions As used in the specification and the appended claims, unless otherwise specified, the following terms have the meaning indicated: Certain chemical groups mentioned herein are preceded by an abbreviated notation indicating the total number of carbon atoms that are they will find in the indicated chemical group. For example; C7-C2 alkyl describes an alkyl group, as defined above, having a total of 7 to 12 carbon atoms, and C4-C12 cycloalkylalkyl describes a cycloalkylalkyl group, as defined above, which has a total of 4 to 12 carbon atoms. The total number of carbons in the abbreviated notation does not include carbons that may exist in substituents of the described group. Accordingly, as used in the specification and the appended claims, unless otherwise specified, the following terms have the indicated meaning: "ethoxy" refers to a radical -OCH3. "Ciano" refers to the radical -CN. "Nitro" refers to the radical -NO2. "Trifluoromethyl" refers to the radical -CF3. "Oxo" refers to the substituent = O. "Tioxo" refers to the substituent = S. "Alkyl" refers to a straight or branched hydrocarbon chain radical consisting solely of carbon and hydrogen atoms, not containing unsaturation, having one to twelve carbon atoms, preferably one to eight carbon atoms or one to six carbon atoms, and which is linked to the rest of the molecule through a single bond, for example, methyl, ethyl, n-propyl, 1-methyloxy (iso-propyl), n-butyl, n- pentyl, 1,1-dimethylethyl (t-butyl), and the like. Unless specifically stated otherwise in the specification, an alkyl group may be optionally substituted by one of the following groups: alkyl, alkenyl, halogen, haloalkenyl, cyano, nitro, aryl, cycloalkyl, heterocyclyl, heteroaryl, -OR14, - OC (O) -R14, -N (R14) 2, -C (O) R14, -C (0) OR14, -C (O) N (R14) 2, -N (R14) C (O) OR16, -N (R14) C (O) R16, -N (R4) (S (O) tR16) (where t is 1 to 2), -S (O) tOR16 (where t is 1 to 2) ), -S (O) tR16 (where t is from 0 to 2), and -S (O) tN (R14) 2 (where t is from 1 to 2) wherein each R14 is independently hydrogen, alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl (optionally substituted with one or more halogen groups), aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl; and each R 6 is alkyl, haloalkyl, cycloalkyl, cycloalkylalkyal, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl, and wherein each of the above substituents is unsubstituted unless otherwise indicated. "Alkyl of 1 to 3 carbon atoms" refers to an alkyl radical as defined above containing one to three carbon atoms. The alkyl radical of 1 to 3 carbon atoms may be optionally substituted as defined by an alkyl group. "Alkyl of 1 to 6 carbon atoms" refers to an alkyl radical as defined above containing from one to six carbon atoms. The alkyl of 1 to 6 carbon atoms may be optionally substituted as defined by an alkyl group.

"Alkyl of 1 to 12 carbon atoms" refers to an alkyl radical as defined above containing from one to twelve carbon atoms. The alkyl radical of 1 to 12 carbon atoms may be optionally substituted as defined by an alkyl group.

"Alkyl of 2 to 6 carbon atoms" refers to an alkyl radical as defined above containing from two to six carbon atoms. The alkyl radical of 2 to 6 carbon atoms may be optionally substituted as defined by an alkyl group. "Alkyl of 3 to 6 carbon atoms" refers to an alkyl radical as defined above containing from three to six carbon atoms. The alkyl radical of 3 to 6 carbon atoms may be optionally substituted as defined by an alkyl group. "Alkyl of 3 to 12 carbon atoms" refers to an alkyl radical as defined above containing from three to twelve carbon atoms. The alkyl radical of 3 to 12 carbon atoms may be optionally substituted as defined by an alkyl group. "Alkyl of 6 to 12 carbon atoms" refers to an alkyl radical as defined above containing from six to twelve carbon atoms. The alkyl radical of 6 to 12 carbon atoms may be optionally substituted as defined by an alkyl group. "Alkyl of 7 to 12 carbon atoms" refers to an alkyl radical as defined above containing from seven to twelve carbon atoms. The alkyl radical of 7 to 12 carbon atoms may be optionally substituted as defined by an alkyl group.

"Alkenyl" refers to a straight or branched hydrocarbon chain radical group consisting solely of carbon and hydrogen atoms, containing at least one double bond, having from two to twelve carbon atoms, preferably one to eight carbon atoms and which is linked to the rest of the molecule through a single bond, for example, ethenyl, prop-1-enyl, but-1-enyl, pent-1-enyl, penta-1,4-dienyl , and similar. Unless specifically stated otherwise in the specification, an alkenyl group may be optionally substituted by one of the following groups: alkyl, halogenalkenyl, haloalkenyl, haloalkenyl, cyano, nitro, aryl, aralkyl cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl heteroaryl , heteroarylalkyl, -OR14, -OC (O) -R14, -N (R1) 2, -C (O) R14 -C (O) OR14, -C (O) N (R14) 2, -N (R14) C (O) OR16, -N (R14) C (O) R16 -N (R14) (S (O) tR16) (wherein t is 1 to 2), -S (O) tOR16 (where t is from 1 to 2), -S (O) tR16 (where t is from 0 to 2), and -S (O) tN (R14) 2 (where t is from 1 to 2) where each R14 is independently hydrogen, alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl; and each R16 is alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl, and wherein each of the above substituents is unsubstituted. "Alkenyl of 3 to 12 carbon atoms" refers to an alkenyl radical as defined above containing from three to twelve carbon atoms. The alkenyl radical of 3 to 12 carbon atoms may be optionally substituted as defined for an alkenyl group. "C 2 -C 12 alkenyl" refers to an alkenyl radical as defined above containing from 2 to 12 carbon atoms. The Alkenyl radical of 2 to 12 carbon atoms may be optionally substituted as defined above by an alkenyl group. "Alkylene" and "alkylene chain" refers to a straight or branched divalent hydrocarbon chain, which binds the rest of the molecule to a radical group, consisting solely of carbon and hydrogen, not containing unsaturation and having from one to twelve carbon atoms, preferably having from one to eight carbons, for example, methylene, ethylene, propylene, n-butylene, and the like. The alkylene chain can be linked to the rest of the molecule and the radical group through a carbon within the chain or through any of two carbons within the chain. "Alkenylene" and "alkenylene chain" refers to a straight or branched divalent hydrocarbon chain that links the remainder of the molecule to a radical group, consisting solely of carbon and hydrogen, containing at least one double bond and which has from two to twelve carbon atoms, for example, ethenylene, propenylene, n-butenylene, and the like. The alkenylene chain is linked to the rest of the molecule through a single bond and to the radical group through a double bond or an individual bond. The binding points of the alkenylene chain to the rest of the molecule and to the radical group can be through a carbon or any of two carbons within the chain. "Alkylene bridge" refers to a straight or branched divalent hydrocarbon bridge, which links two different carbons of the same ring structure, consisting solely of carbon and hydrogen, not containing unsaturation and having from one to twelve carbon atoms , preferably having from one to eight carbons, for example, methylene, ethylene, propylene, n-butylene, and the like. The alkylene bridge can link any two carbons within the ring structure. "Alkoxy" refers to a radical of the formula -ORa wherein Ra is an alkyl radical as defined above. The alkyl part of the alkoxy radical it may be optionally substituted as defined above by an alkyl radical. "Alkyl of 1 to 6 carbon atoms" refers to an alkoxy radical as defined above containing from one to six carbon atoms. The alkyl part of the alkyl radical of 1 to 6 carbon atoms may be optionally substituted as defined above by an alkyl group. "Alkoxy of 1 to 12 carbon atoms" refers to an alkoxy radical as defined above containing from one to twelve carbon atoms. The alkyl part of the alkoxy radical of 1 to 12 carbon atoms may be optionally substituted as defined above by an alkyl group. "Alkoxy of 3 to 12 carbon atoms" refers to an alkoxy radical as defined above containing from three to twelve carbon atoms. The alkyl part of the alkoxy radical of 3 to 12 carbon atoms may be optionally substituted as defined above by an alkyl group. "Alkoxyalkyl" refers to a radical of the formula -Ra-O-Ra wherein each Ra is independently an alkyl radical as defined above. The oxygen atom can be bonded to any carbon in any alkyl radical. Each alkyl part of the alkoxyalkyl radical may be optionally substituted as defined above by an alkyl group. "Alkoxyalkyl of 2 to 12 carbon atoms" refers to an alkoxyalkyl radical as defined above containing from two to twelve carbon atoms. Each alkyl part of the alkoxyalkyl radical of 2 to 12 carbon atoms may be optionally substituted as defined above by an alkyl group. "C 3 -alkoxyalkyl" refers to an alkoxyalkyl radical as defined above containing three carbon atoms. Each alkyl part of the alkoxyalkyl radical of 3 carbon atoms may be optionally substituted as defined above by an alkyl group. "Alkoxyalkyl of 3 to 12 carbon atoms" refers to an alkoxyalkyl radical as defined above containing from three to twelve carbon atoms. Each alkyl part of the alkoxy of 3 to 12 atoms of the carbonylalkyl radical may be optionally substituted as defined above by an alkyl group. "Alkylsulfonyl" refers to a radical of the formula -S (O) 2Ra wherein Ra is an alkyl group as defined above. The alkyl part of the alkylsulfonyl radical may be optionally substituted as defined above by an alkyl group. "C 1 -C 6 -alkylsulfonyl" refers to an alkylsulfonyl radical as defined above having from one to six carbon atoms. The alkylsulfonyl group of 1 to 6 carbon atoms may be optionally substituted as defined above by an alkylsulfonyl group. "Aryl" refers to an aromatic monocyclic or multicyclic hydrocarbon ring system consisting solely of hydrogen and carbon and containing from 6 to 19 carbon atoms, preferably from 6 to 10 carbon atoms, wherein the ring system may be partially or completely saturated. Aryl groups include, but are not limited to, groups such as fluorenyl, phenyl, and naphthyl. Unless specifically stated otherwise in the specification, the term "aryl" or the prefix "ar-" (such as in "aralkyl) is intended to include optionally substituted aryl radicals through one or more substituents selected from the group consisting of alkyl, alkenyl, halogen, haloalkyl, haloalkenyl, cyano, nitro, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R15-OR14, -R15-OC (O) -R14, -R15-N ( R14) 2, -R15-C (O) R14, -R15-C (O) OR14, -R15-C (O) N (R14) 2, -R15-N (R14) C (O) OR16, -R15 -N (R14) C (O) R16, -R15-N (R14) (S (O) tR16) (where t is from 1 to 2), -R15-S (Q) tOR16 (where t is from 1 to 2), -R15-S (O) tR16 (where t is from 0 to 2), and -R15-S (O) tN (R1) 2 (where t is from 1 to 2) where each R14 is independently hydrogen, alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl; each R15 is independently a direct bond or straight or branched alkenylene alkyl chain; and each R16 is alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl, and wherein each of the above substituents is unsubstituted. "Aralkyl" refers to a radical of the formula -RaRb wherein Ra is an alkyl radical as defined above and R is one or more aryl radicals as defined above, for example, benzyl, diphenylmethyl and the like. The aryl part of the alkyl radical may be optionally substituted as described above for an aryl group. "Aralkyl of 7 to 12 carbon atoms" refers to an aralkyl group as defined above containing from seven to twelve carbon atoms. The aryl portion of the aralkyl radical of 7 to 12 carbon atoms may be optionally substituted as described above by an aryl group. The alkyl part of the aralkyl radical of 7 to 12 carbon atoms may be optionally substituted as defined above by an alkyl group. "Aralkyl of 3 to 19 carbon atoms" refers to an aralkyl group as defined above containing from thirteen to nineteen carbon atoms. The aryl portion of the aralkyl radical of 3 to 19 carbon atoms may be optionally substituted as described above by an aryl group. The alkyl part of the aralkyl radical of 3 to 19 carbon atoms may be optionally substituted as defined above by an alkyl group. "Aralkenyl" refers to a radical of the formula -RcRb wherein Rc is an alkenyl radical as defined above and R is one or more aryl radicals as defined above, which may be optionally substituted as described above. The aryl portion of the aralkenyl radical may be optionally substituted as described above by an aryl group. The alkenyl part of the aralkenyl radical may be optionally substituted as defined above by an alkenyl group. "Aryloxy" refers to a radical of the formula -ORb wherein Rb is an aryl group as defined above. The aryl portion of the aryloxy radical may be optionally substituted as defined above. "Aryl-alkyl of 1 to 6 carbon atoms" refers to a radical of the formula -Rh-Rj; wherein Rh is an unbranched alkyl radical having from one to six carbons and R i is an aryl group linked to the terminal carbon of the alkyl radical. "Cycloalkyl" refers to a non-aromatic monocyclic or bicyclic hydrocarbon radical consisting solely of carbon and hydrogen atoms, having from three to fifteen carbon atoms, preferably having from three to twelve carbon atoms, and which is saturated or unsaturated and is bound to the rest of the molecule through a single bond, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, decalinyl and the like. Unless otherwise specifically stated in the specification, the term "cycloalkyl" is intended to include cycloalkyl radicals which are optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, halogen, haloalkyl, haloalkenyl, cyano, nitro, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R15-OR14, -R15-OC (O) -R14, -R15-N (R14) 2, -R15-C (O) R14, - R 5-C (O) OR 14, -R 15 -C (O) N (R 14) 2, -R 15 -N (R 14) C (O) OR 16, -R 15 -N (R 14) C (O) R 16, -R 15 -N (R14) (S (O) tR16) (wherein t is 1 to 2), -R15-S (O) tOR16 (where t is 1 to 2), -R15-S (O) tR16 (where t is from 0 to 2), and -R15-S (O) tN (R 4) 2 (wherein t is from 1 to 2) wherein each R 14 is independently hydrogen, alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl , aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl; each R15 is independently a straight or a straight or branched alkylene or alkenylene chain; and each R16 is alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl, and wherein each of the above substituents is unsubstituted. "Cycloalkyl of 3 to 6 carbon atoms" refers to a cycloalkyl radical as defined above having from three to six carbon atoms. The cycloalkyl radical of 3 to 6 carbon atoms may be optionally substituted as defined above for a cycloalkyl group. "Cycloalkyl of 3 to 12 carbon atoms" refers to a cycloalkyl radical as defined above having from three to twelve carbon atoms. The cycloalkyl radical of 3 to 12 carbon atoms may be optionally substituted as defined above by a cycloalkyl group. "Cycloalkylalkyl" refers to a radical of the formula -RaRd wherein Ra is an alkyl radical as defined above and Rd is a cycloalkyl radical as defined above. The cycloalkyl part of the cycloalkyl radical may be optionally substituted as defined above by a cycloalkyl radical. The alkyl part of the cycloalkyl radical may be optionally substituted as defined above by an alkyl radical. "Cycloalkylalkyl of 4 to 12 carbon atoms" refers to a cycloalkyl radical as defined above having from four to twelve carbon atoms. The cycloalkylalkyl radical of 4 to 12 carbon atoms may be optionally substituted as defined above by a cycloalkylalkyl group.

"Halogen" refers to bromine, chlorine, fluorine or iodine. "Haloalkyl" refers to an alkyl radical, as defined above, which is substituted by one or more halogen radicals, as defined above, for example, trifluoromethyl, difluoromethyl, trichloromethyl, 2,2,2-trifluoroethyl, 1-fluoromethyl -2-ethyl fluorine, 3-bromo-2-fluoro-pro pyl, 1-bromomethyl-2-bromoethyl, and the like. The alkyl part of the halogen radical may be optionally substituted as defined above by an alkyl group. "Haloalkenyl" refers to an alkenyl radical, as defined above, which is substituted by one or more halogen radicals, as defined above, for example, 2-bromoethenyl, 3-bromoprop-1-enyl, and the like. The alkenyl part of the haloalkenyl radical may be optionally substituted as defined above by an alkyl group. "Heterocyclyl" refers to a non-aromatic ring radical of 3 to 18 members consisting of carbon atoms and one to five heterogeneous atoms selected from the group consisting of nitrogen, oxygen and sulfur. For purposes of this invention, the heterocyclyl radical may be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which may include fused or bridged ring systems; and the nitrogen, carbon and sulfur atoms in the heterocyclyl radical may be optionally oxidized; the nitrogen atom may optionally be quaternized; and the heterocyclyl radical may be partially or completely saturated.

Examples of heterocyclyl radicals include, but are not (imitated a, dioxolanyl, decahydroisoquinolyl, imidazolinyl, imidazolidinyl, isothiazolidyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl. , 4-piperidonyl, pyrrolidinyl, pyrazolidinyl, thiazolidinyl, tetrahydrofuryl, trityanil, tetrahydropyranyl, thiomorpholinyl, thiamorpholinyl, 1-oxo-thiomorpholinyl, and 1,1-dioxo-thiomorpholinyl. Unless specifically stated otherwise in the specification, the term "heterocyclyl" is intended to include heterocyclyl radicals as defined above which are optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, halogen, haloalkyl, haloalkenyl, cyano, oxo, thioxo, nitro, aryl, aralkyl, cycloalkyl, cycloalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or, heteroarylalkyl, -R15-OR14, -R15-OC (O) -R1 R • 115S-N (R14) 2, -R, 1? 5s-C (O) R? R'a-C (O) OR .14 • R, 15 C (O) N (R14) - R13-N (R14) C (O) OR 16 -R1S-N (R14) C (0) R, 16 -R 15 N (R 4) (S (O) tR 16) (where t is from 1 to 2), -R15-S (0), OR16 (where t is from 1 to 2), -R15-S (O) tR16 (where t is from 0 to 2), and -R15-S (O) tN (R14) 2 (where t is from 1 to 2) wherein each R14 is independently hydrogen, alkyl, alkenyl, haloalkyl, cycloalkyl , cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl; each R15 is independently a straight or a straight or branched alkylene or alkenylene chain; and each R16 is alkyl, alkenyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl, and wherein each of the above substituents is unsubstituted. "Heterocyclyl of 3 to 12 carbon atoms" refers to a heterocyclyl radical as defined above having from three to twelve carbons. The heterocyclyl radical of 3 to 12 carbon atoms may be optionally substituted as defined above by a heterocyclyl group. "Heterocyclylalkyl" refers to a radical of the formula -RaRe wherein Ra is an alkyl radical as defined above and Re is a heterocyclyl radical as defined above, and if the heterocyclyl is a heterocyclyl containing nitrogen, the heterocyclyl can be linked to the alkyl radical at the nitrogen atom. The alkyl portion of the heterocyclylalkyl radical may be optionally substituted as defined above by an alkyl group. The heterocyclyl part of the heterocyclylalkyl radical may be optionally substituted as defined above by a heterocyclyl group. "Heterocyclylalkyl of 3 to 12 carbon atoms" refers to a heterocyclylalkyl radical as defined above having from three to twelve carbons. The heterocyclylalkyl radical of 3 to 12 carbon atoms may be optionally substituted as defined above by a heterocyclylalkyl group. "Heteroaryl" refers to an aromatic ring radical of 5 to 18 members consisting of carbon atoms and one to five heterogeneous atoms selected from the group consisting of nitrogen, oxygen and sulfur. For purposes of this invention, the heteroaryl radical may be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which may include fused or bridged ring systems; and the nitrogen, carbon or sulfur atoms in the heteroaryl radical may be optionally oxidized; the nitrogen atom may optionally be quaternized. Examples include, but are not limited to, azepinyl, acridinyl, benzimidazolyl, benzothiazolyl, benzolotolyl, benzothiadiazolyl, benzonaphtofuranyl, benzoxazolyl, benzodioxolyl, benzodioxinyl, benzopyranyl, benzopyranonyl, benzofuranyl, benzofuranonyl, benzothienyl (benzothiophenyl), benzotriazolyl, benzo [4,6 ] imidazo [1,2-ajpyridinyl, carbazolyl, cinolinyl, dibenzofuranyl, furanyl, furanonyl, isothiazolyl, imidazolyl, indolyl, indazolyl, isoindolyl, indolinyl, isoindolinyl, indolizinyl, isoxazolyl, naphthyridinyl, oxadiazolyl, 2-oxoazepinyl, oxazolyl, oxiranyl, phenazinyl , phenothiazinyl, phenoxazinyl, phthalazinyl, pteridinyl, purinyl, pyrrolyl, pyrazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, quinazolinyl, quinoxalinyl, quinolinyl, quinuclydinyl, isoquinolinyl, thiazolyl, thiadiazolyl, triazolyl, tetrazolyl, triazinyl, and thiophenyl. Unless specifically stated otherwise in the specification, the term "heteroaryl" is intended to include heteroaryl radicals as defined above that are optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, halogen, haloalkyl, haloalkenyl, cyano, oxo, thioxo, nitro, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R15-OR14, -R15-OC (O) -R14, -R15-N (R14) 2, -R15 -C (O) R14, -R15-C (O) OR14, -R15-C (O) N (R14) 2, -R15-N (R14) C (O) OR16, -R15-N (R14) C (O) R16, -R 5 -N (R14) (S (O) tR16) (wherein t is 1 to 2), -R15-S (O) tOR16 (where t is 1 to 2), -R15-S (O) tR16 (where t is from 0 to 2), and -R15-S (O) tN (R14) 2 (where t is from 1 to 2) wherein each R14 is independently hydrogen, alkyl, alkenyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl; each R15 is independently a straight or a straight or branched alkylene or alkenylene chain; and each R16 is alkyl, alkenyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl, and wherein each of the above substituents is unsubstituted.

"Heteroaryl of 1 to 12 carbon atoms" refers to a heteroaryl radical as defined above having from one to twelve carbon atoms. The heteroaryl group of 1 to 12 carbon atoms may be optionally substituted as defined above by a heteroaryl group. "Heteroaryl of 5 to 12 carbon atoms" refers to a radical-heteroaryl radical as defined above having from five to twelve carbon atoms. The heteroaryl group of 5 to 12 carbon atoms may be optionally substituted as defined above by a heteroaryl group.

"Heteroarylalkyl" refers to a radical of the formula -RaRf wherein Ra is an alkyl radical as defined above and Rf is a heteroaryl radical as defined above. The heteroaryl part of the heteroarylalkyl radical may be optionally substituted as defined above by a heteroaryl group. The alkyl portion of the heteroarylalkyl radical may be optionally substituted as defined above by an alkyl group. "Heteroarylalkyl of 3 to 12 carbon atoms" refers to a heteroarylalkyl radical as defined above having from three to twelve carbon atoms. The heteroarylalkyl group of 3 to 12 carbon atoms may be optionally substituted as defined above by a heteroarylalkyl group. "Heteroarylcycloalkyl" refers to a radical of the formula-RdRf wherein Rd is a cycloalkyl radical as defined above and Rf is a heteroaryl radical as defined above. The cycloalkyl portion of the heteroarylcycloalkyl radical may be optionally substituted as defined above by a cycloalkyl group. The heteroaryl portion of the heteroarylcycloalkyl radical may be optionally substituted as defined above by a heteroaryl group. "Heteroarylalkenyl" refers to a radical of the formula -RbRf wherein R is an alkenyl radical as defined above and Rf is a heteroaryl radical as defined above. The heteroaryl portion of the heteroarylalkenyl radical may be optionally substituted as defined above by a heteroaryl group. The alkenyl part of the heteroarylalkenyl radical may be optionally substituted as defined above by an alkenyl group. "Hydroxyalkyl" refers to a radical of the formula -Ra-OH wherein Ra is an alkyl radical as defined above. The hydroxy group may be linked to the alkyl radical at any carbon within the alkyl radical. The alkyl part of the hydroxyalkyl group may be optionally substituted as defined above by an alkyl group. "Hydroxyalkyl of 2 to 12 carbon atoms" refers to a hydroxyalkyl radical as defined above containing from two to twelve carbon atoms. The alkyl part of the hydroxyalkyl radical of 2 to 12 carbon atoms may be optionally substituted as defined above by an alkyl group. "Hydroxyalkyl of 3 to 12 carbon atoms" refers to a hydroxyalkyl radical as defined above containing from three to twelve carbon atoms. The alkyl part of the hydroxyalkyl radical of 3 to 12 carbon atoms may be optionally substituted as defined above by an alkyl group. "Hydroxyalkyl of 7 to 12 carbon atoms" refers to a hydroxyalkyl radical as defined above containing from seven to twelve carbon atoms. The alkyl part of the hydroxyalkyl radical of 7 to 12 carbon atoms may be optionally substituted as defined above by an alkyl group. "Hydroxyalkenyl" refers to a radical of the formula -Rc-OH wherein Rc is an alkenyl radical as defined above. The hydroxy group can be linked to the alkenyl radical at any carbon within the alkenyl radical. The part of the alkenyl of the hydroxyalkenyl group may be optionally substituted as defined above by an alkenyl group. "Hi.droxyalkenyl of 2 to 12 carbon atoms" refers to a hydroxyalkenyl radical as defined above contai from two to twelve carbon atoms. The alkenyl part of the hydroxyalkenyl radical of 2 to 12 carbon atoms may be optionally substituted as defined above by an alkenyl group. "Hydroxyalkenyl of 3 to 12 carbon atoms" refers to a hydroxyalkenyl radical as defined above contai from three to twelve carbon atoms. The alkenyl part of the hydroxyalkenyl radical of 3 to 12 carbon atoms may be optionally substituted as defined above by an alkenyl group. "Hydroxy-alkyl of 1 to 6 carbon atoms" refers to a radical of the formula -Rh-OH wherein R is an unbranched alkyl radical having from one to six carbons and the hydroxy radical is linked to the terminal carbon . "Trihaloalkyl" refers to an alkyl radical, as defined above, which is substituted by three halogen radicals, as defined above, for example, trifluoromethyl. The alkyl part of the trihaloalkyl radical may be optionally substituted as defined above by an alkyl group. "Trihaloalkyl of 1 to 6 carbon atoms" refers to a trihaloalkyl radical as defined above having from one to six carbon atoms. The trihaloalkyl of 1 to 6 carbon atoms may be optionally substituted as defined above by a trihaloalkyl group. "Trihaloalkoxy" refers to a radical of the formula -ORg wherein Rg is a trihaloalkyl group as defined above.

The trihaloalkyl portion of the trihaloalkoxy group may be optionally substituted as defined above by a trihaloalkyl group. "Trihaloalkoxy of 1 to 6 carbon atoms" refers to a trihaloalkoxy radical as defined above having from one to six carbon atoms. The trihaloalkoxy group of 1 to 6 carbon atoms group may be optionally substituted as defined above by a trihaloalkoxy group. "A multi-ring structure" refers to a multicyclic ring system comprising two to four rings in the rings are independently selected from cycloalkyl, aryl, heterocyclyl or heteroaryl as defined above. Each cycloalkyl may be optionally substituted as defined above by a cycloalkyl group. Each aryl may be optionally substituted as defined above by an aryl group. Each heterocyclyl may be optionally substituted as defined above by a heterocyclyl group. Each heteroaryl may be optionally substituted as defined above by a heteroaryl group. The rings can be linked to each other through direct links or some or all of the rings can be fused together. Examples include, but are not limited to a cycloalkyl radical substituted by an aryl group; a cycloalkyl group substituted by an aryl group, which, in turn, is replaced by another aryl group; and so on. "Prodrugs" are intended to indicate a compound that can be converted under physiological conditions through solvolysis to a biologically active compound of the invention. Thus, the term "prodrug" refers to a metabolic precursor of a compound of the invention that is pharmaceutically acceptable. A prodrug may be inactive when administered to a subject in need thereof, but is converted in vivo into an active compound of the invention. Prodrugs are typically easily transformed in vivo to produce the parent compound of the invention, for example, through hydrolysis in the blood. The prodrug compound generally offers advantages of solubility, tissue compatibility, or delayed release in a mammalian organism (see, Bundgard, H., Design of Prodrugs (1985), pp. 7-9, 21-24 (Elsevier , Amsterdam) A discussion of prodrugs is provided in Higuchi, T., et al., "Pro-drugs as Novel Delivery Systems," ACS Symposium Series, Vol. 14, and in Bioreversible Carriers in Drug Design, ed. Roche, American Pharmaceutical Association and Pergamon Press, 1987, both of which are incorporated herein by reference.

The term "prodrug" is also intended to include any covalently linked carriers that release the active compound of the invention in vivo when said prodrug is administered to a mammalian subject. The prodrugs of a compound of the invention can be prepared through the modification of the functional groups present in the compound of the invention in such a way that the modifications are divided, either in routine manipulation or in vivo, in the parent compound. of the invention. Prodrugs include compounds of the invention wherein a hydroxy, amino or mercapto group is linked to any group which, when the prodrug of the compound of the invention is administered to a mammalian subject is divided to form a free hydroxy, free amino or mercapto group free, respectively. Examples of prodrugs include, but are not limited to, acetate derivatives, alcohol formeate and benzoate or amine functional groups in the compounds of the invention and the like. "Stable compound" and "stable structure" are meant to indicate a compound that is sufficiently robust to survive the isolation to a useful degree of purity of a reaction mixture, and the formulation into an effective therapeutic agent. "Mammal" includes humans and pets, such as cats, dogs, pigs, cattle, sheep, goats, horses, rabbits and the like. "Optional" or "optionally" means that the subsequently described event of circumstances may or may not occur, and the instances in which it does not occur. For example, "optionally substituted" means that the aryl radical may or may not be substituted and that the description includes both the substituted aryl radicals and the aryl radicals that do not have substitution. "Carrier, diluent, pharmaceutically acceptable excipient" includes without limitation any auxiliary, carrier, excipient, glidant, sweetening agent, diluent, preservative, dye / dye, flavor improver, surface active agent, wetting agent, dispersing agent, dispersing agent, suspension, stabilizer, isotonic agent, solvent or emulsifier that has been approved by the United States Food and Drug Administration as being acceptable for use in humans and pets. "Pharmaceutically acceptable salt" includes both acid addition salts and base salts. "Pharmaceutically acceptable acid addition salts" refers to those salts that retain the effectiveness of the biological activity and the properties of the free bases, which are biologically or otherwise undesirable, and which are formed with inorganic acids such as , but not limited to, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, and organic acids such as, but not limited to, acetic acid, 2,2-dichloroacetic acid, adipic acid, alginic acid , ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, 4-acetamidobenzoic acid, camphoric acid, camphor-10-sulphonic acid, capric acid, caproic acid, caprylic acid, carbonic acid, cinnamic acid, citric acid, cyclamic acid, acid dodecyl sulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, 2-hydroxyethane sulfonic acid, formic acid, fumaric acid ico, galactárico acid, gentísico acid, glycoheptonic acid, gluconic acid, glucurónico acid, glutamic acid, glutaric acid, 2-oxo-glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid , maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, mucic acid, naphthalene-1, 5-disulfonic acid, napphthalene-2-sulfonic acid, 1-hydroxy-2-naphthoic acid, nicotinic acid, oleic acid, orotic acid, oxalic acid, palmitic acid, pamoic acid, propionic acid, pyroglutamic acid, pyruvic acid, salicylic acid, 4-aminosalicylic acid, sebacic acid, stearic acid, succinic acid, tartaric acid, thiocyanic acid, p-toluenesulfonic acid, acid trifluoroacetic acid, undecylenic acid, and the like.

"Pharmaceutically acceptable base addition salts" refers to those salts that retain the effectiveness and biological properties of the free acids, which are not biologically or otherwise undesirable. These salts are prepared from the addition of an inorganic base or an organic base to the free acid. Salts derived from inorganic bases include, but are not limited to, salts of sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like. The preferred inorganic salts are the ammonium, sodium, potassium, calcium, and magnesium salts. Salts derived from organic bases include, but are not limited to, primary, secondary and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as ammonia resins, isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, diethanolamine, ethanolamine, deanol, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, benetamine, benzathine, ethylenediamine, glucosamine, methylglucamine, theobromine, triethanolamine, tromethamine, purines, piperazine, piperidine, N-ethylpiperidine, polyamine and the like. Particularly preferred organic bases are isopropylamine, diethylamine, ethanolamine, trimethylamine, dicyclohexylamine, choline and caffeine. In general, crystallizations produce a solvate of the compound of the invention. As used herein, the term "solvate" refers to an aggregate comprising one or more molecules of a compound of the invention with one or more molecules of the solvent. The solvent can be water, in which case the solvate can be a hydrate. Alternatively, the solvent may be an organic solvent. In this way, the compounds of the present invention can exist as a hydrate, including a monohydrate, dihydrate, hemihydrate, sesquihydrate, trihydrate, tetrahydrate and the like, as well as the corresponding solvate forms. The compound of the invention can be a true solvent, while in other cases, the compound of the invention can merely retain spontaneous water or be a mixture of water plus some spontaneous solvent. A "pharmaceutical composition" refers to a formulation of a compound of the invention and a means generally accepted in the art for the distribution of the biologically active compound to mammals, e.g., humans. Said medium includes all pharmaceutically acceptable carriers, diluents or excipients thereof. "Therapeutically effective amount" refers to that amount of compound of the invention which, when administered to a mammal, preferably a human being, is sufficient to effect the treatment, as defined below, of a disease or condition mediated by SCD in the mammal, preferably a human being. The amount of a compound of the invention that constitutes a "therapeutically effective amount" will vary depending on the compound, the condition, and its severity, and the age of the mammal to be treated, but can be determined routinely by one skilled in the art. in the technique you have with respect to your own knowledge and this description. "Treating" or "treatment" as used herein covers the treatment of the disease or condition of interest in a mammal, preferably a human being, that has the disease or disorder, and includes: (i) preventing the occurrence of the disease or condition in a mammal, in particular, when said mammal is predisposed to the condition but has not yet been diagnosed as having it; (ii) inhibit the disease or condition, that is, stop its development; or (iii) alleviating the disease or condition, that is, causing the regression of the disease or condition. As used herein, the terms "disease" and "condition" may be used interchangeably or may be different in that the condition or condition may not have a known causative agent (so the etiology has not yet worked) and therefore is not yet recognized as a disease, but only as an undesirable condition or syndrome, where a more or less specific group of symptoms has been identified by physicians. The compounds of the invention, or their pharmaceutically acceptable salts, may contain asymmetric centers and may be in the form of giving rise to enantiomers, diastereomers, and other stereoisomeric forms which may be defined, in terms of absolute stereochemistry, as (R) - or (S) - or, as (D) - or (L) - for amino acids. The present invention is intended to include all such isomers, as well as their racemic and optically pure forms. The optically active isomers (+) and (-), (R) - and (S) -, or (D) ~ and (L) - can be prepared using chiral synthons, or chiral reagents, or resolved using conventional techniques, such as HPLC using a chiral column. When the compounds described herein contain olefinic double bonds or other centers of geometric asymmetry, and unless otherwise specified, the compounds are intended to include both geometric isomers E and Z. Likewise, it is intended to include all tautomeric forms. A "stereoisomer" refers to a compound made from the same atoms linked through the same bonds but having different three-dimensional structures, which are not interchangeable. The present invention contemplates several stereoisomers and mixtures thereof and includes "enantiomers", which refer to two stereoisomers whose molecules are mirror images not superimposed on one another. A "tautomer" refers to a proton exchange from one atom of one molecule to another atom of the same molecule. The present invention includes tautomers of any of said compounds. The protocol for chemical naming and structure diagrams used here employ and are based on chemical naming characteristics as used by Chemdraw version 7.0.1 (available from Cambridgesoft Corp., Cambridge, MA). For the complex chemical names used herein, a substituent group is called before the group to which it is linked. For example, cyclopropylethyl comprises an ethyl determination with the cyclopropyl substituent. In chemical structure diagrams, all bonds are identified, except for some carbon atoms that are assumed to be bound with enough hydrogen atoms to complete the valence. As an example, the compounds of the formula (IV), as stated above in the Compendium of the Invention, where x e and each is 1; Va is -C (O) -, each R1 is hydrogen; R4, R5, R6, R7, R7a, R8, R8a, R9, R9a, R10, and R10a each hydrogen; R2 is benzyl and R3 is 2-trifluoromethylphenyl, that is, the compound of the following formula it is referred to here as 1-Benzyl-3-. { 6- [4- (2-trifluoromethi I benzoyl) pi pe razin-1-yl] - pyridin-3-yl} urea. Certain radical groups of the compounds of the invention are described herein as links between two parts of the compounds of the invention. For example, in the following formula (I): W is described, for example, as being -C (O) N (R1) - or -N (R1) C (O) N (R1) -; and V is described as -C (O) -. This description is intended to describe a group W linked to the group R2 as follows: R2-C (O) N (R1) - or R2-N (R1) C (O) N (R1) -; and is intended to describe a group V linked to the group R3 as follows: -C (O) R3. In other words, the description of the linking groups W and V are intended to be read from left to right in view of the formula (I) as described above.

Modalities of the Invention In one embodiment of the invention, the compounds of the formula (lia), as set forth above in the Compendium of the Invention, are directed to compounds wherein x e and each independently 1,2 or 3; R1 is selected from the group consisting of hydrogen, alkyl of 1 to 12 carbon atoms, hydroxyalkyl of 2 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms and aralkyl of 7 to 19 carbon atoms; R2 is selected from the group consisting of alkyl of 7 to 12 carbon atoms, alkenyl of 3 to 12 carbon atoms, hydroxyalkyl of 7 to 12 carbon atoms, alkoxyalkyl of 2 to 12 carbon atoms, hydroxyalkenyl of 3 to 12 atoms of carbon, cycloalkyl of 3 to 12 carbon atoms, cycloalkyl of 4 to 12 carbon atoms, aralkyl of 13 to 19 carbon atoms, heteroaryl of 1 to 12 carbon atoms, heterocyclylalkyl of 3 to 12 carbon atoms, heterocyclyl of 3 to 12 carbon atoms and heteroarylalkyl of 3 to 12 carbon atoms, provided that R2 is not pyrazinyl, pyridinonyl, pyrrole idonone or imidazolyl; R3 is selected from the group consisting of alkyl of 3 to 12 carbon atoms, alkenyl of 3 to 12 carbon atoms, hydroxyalkyl of 3 to 12 carbon atoms, hydroxyalkyl of 3 to 12 carbon atoms, alkoxy of 3 to 12 atoms carbon, alkoxyalkyl of 3 to 12 carbon atoms, cycloalkylalkyl of 3 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms, aryl, aralkyl of 7 to 19 carbon atoms, heterocyclyl of 3 to 12 carbon atoms, heterocyclylalkyl of 3 to 12 carbon atoms, heteroaryl of 1 to 12 carbon atoms and heteroarylalkyl of 3 to 12 carbon atoms; R4, R5 and R6 are each independently selected from hydrogen, bromine, fluorine, chlorine, methyl, methoxy, trifluoromethyl, cyano, nitro or -N (R13) 2; R10, R10a, R7, R7a, R8, R8a, R9, and R9a are each independently selected from hydrogen or alkyl of 1 to 3 carbon atoms; and each R13 is independently selected from hydrogen or alkyl of 1 to 6 carbon atoms. One modality of this mode are compounds of the formula (lia) wherein x e and each is 1; R1 is selected from the group consisting of hydrogen or alkyl of 1 to 12 carbon atoms; R2 is selected from the group consisting of alkyl of 7 to 12 carbon atoms, alkenyl of 3 to 12 carbon atoms, cycloalkyl of 3 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms, aralkyl of 13 to 19 atoms carbon, heteroaryl of 1 to 12 carbon atoms, heterocyclylalkyl of 3 to 12 carbon atoms and heteroarylalkyl of 3 to 12 carbon atoms; R3 is selected from the group consisting of alkyl of 3 to 12 carbon atoms, cycloalkyl of 3 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms, aryl, aralkyl of 7 to 19 carbon atoms, heterocyclyl of 3 to 12 carbon atoms, heterocyclylalkyl of 3 to 12 carbon atoms, heteroaryl of 1 to 12 carbon atoms and heteroarylalkyl of 3 to 12 carbon atoms; R4, R5 and R6 are each independently selected from hydrogen, bromine, fluorine, chlorine, methyl, methoxy, trifluoromethyl, cyano, nitro or -N (R13) 2; R7, R7a, R8, R8a, R9, R9a, R10, and R10a are each independently selected from hydrogen or alkyl of 1 to 3 carbon atoms; and each R13 is independently selected from hydrogen or alkyl of 1 to 6 carbon atoms. One embodiment of this embodiment are compounds of the formula (lia) wherein R2 is cycloalkyl of 3 to 12 carbon atoms or cycloalkylalkyl of 4 to 12 carbon atoms; R3 is selected from the group consisting of cycloalkyl of 3 to 12 carbon atoms or cycloalkylalkyl of 4 to 12 carbon atoms; R4, R5 and R6 each hydrogen; and R7, R7a, R8, R8a, R9, R9a, R10, and R10a each hydrogen or alkyl of 1 to 3 carbon atoms. One embodiment of this embodiment are the compounds of the formula (lia) wherein R2 is cycloalkyl of 3 to 12 carbon atoms; and R3 is cycloalkyl of 3 to 12 carbon atoms. In another embodiment of the invention, compounds of formula (llb), as set forth above in the Compendium of the Invention, are directed to compounds wherein x e and each independently 1, 2 or 3; R1 is selected from the group consisting of hydrogen, alkyl of 1 to 12 carbon atoms, hydroxyalkyl of 2 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms and aralkyl of 7 to 19 carbon atoms; R2 is selected from the group consisting of alkyl of 1 to 12 carbon atoms, alkenyl of 2 to 12 carbon atoms, hydroxyalkyl of 2 to 12 carbon atoms, hydroxyalkenylalkyl of 2 to 12 carbon atoms, alkoxy of 1 to 6 atoms of carbon, alkoxyalkyl of 3 to 12 carbon atoms, cycloalkyl of 3 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms, aralkyl of 7 to 19 carbon atoms, heterocyclyl of 3 to 12 carbon atoms, heterocyclylalkyl of 3 to 12 carbon atoms, heteroaryl of 1 to 12 carbon atoms and heteroarylalkyl of 3 to 12 carbon atoms; R3 is phenyl optionally substituted by one or more substituents selected from the group consisting of halogen, cyano, nitro, hydroxy, alkyl of 1 to 6 carbon atoms, Trihaloalkyl of 1 to 6 carbon atoms, trihaloalkoxy of 1 to 6 carbon atoms , alkylsulfonyl of 1 to 6 carbon atoms, -N (R12) 2, -OC (O) R12, -C (O) OR12, -S (O) 2N (R12) 2, cycloalkyl, heterocyclyl, heteroaryl and heteroarylcycloalkyl, provided that R3 is not phenyl substituted with optionally substituted thienyl; R4, R5 and R6 are each independently selected from hydrogen, bromine, fluorine, chlorine, methyl, methoxy, trifluoromethyl, cyano, nitro or -N (R3) 2; R10, R10a, R7, R7a, R8, R8a, R9, and R9a are each independently selected from hydrogen or alkyl of 1 to 3 carbon atoms, or R10 and R10a together form an oxo group and the remainder of R7, R7a, R8, R8a, R9, and R9a each hydrogen; each R12 is independently selected from hydrogen, alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms, aryl or aralkyl; and each R13 is independently selected from hydrogen or alkyl of 1 to 6 carbon atoms. One embodiment of this embodiment are compounds of the formula (lb) wherein x e and each is 1; R1 is hydrogen or alkyl of 1 to 12 carbon atoms; R2 is selected from the group consisting of alkyl of 1 to 12 carbon atoms, alkenyl of 2 to 12 carbon atoms, hydroxyalkyl of 2 to 12 carbon atoms, hydroxyalkenylalkyl of 2 to 12 carbon atoms, alkoxy of 1 to 6 atoms of carbon, alkoxyalkyl of 3 to 12 carbon atoms, cycloalkyl of 3 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms, aralkyl of 7 to 10 carbon atoms, heterocyclyl of 3 to 12 carbon atoms, heterocyclylalkyl of 3 to 12 carbon atoms, heteroaryl of 1 to 12 carbon atoms and heteroarylalkyl of 3 to 12 carbon atoms; R3 is phenyl optionally substituted by one or more substituents selected from the group consisting of halogen, cyano, nitro, hydroxy, alkyl of 1 to 6 carbon atoms, trihaloalkyl of 1 to 6 carbon atoms, trihaloalkoxy of 1 to 6 carbon atoms , alkylsulfonyl of 1 to 6 carbon atoms, -N (R12) 2, -OC (O) R12, -C (O) OR12, -S (O) 2N (R12) 2, cycloalkyl, heterocyclyl, heteroaryl and heteroarylcycloalkyl, provided that R3 is not phenyl substituted with optionally substituted thienyl R4, R5 and R6 each hydrogen; R7, R7a, R8, R8a, R9, R9a, R0, and R10 each one hydrogen; or R10 and R10a together form an oxo group and the rest of R7, R7a, R8, R8a, R9, R9a, each hydrogen; and each R12 is independently selected from hydrogen, alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms, aryl or aralkyl. One embodiment of this embodiment are compounds of the formula (IIb) wherein R2 is alkyl of 1 to 12 carbon atoms; and R3 is phenyl optionally substituted by one or more substituents selected from halogen, alkyl of 1 to 6 carbon atoms, trihaloalkyl of 1 to 6 carbon atoms and trihaloalkoxy of 1 to 6 carbon atoms. Another embodiment of this embodiment are compounds of the formula (IIb) wherein R2 is cycloalkyl of 3 to 12 carbon atoms; and R3 is phenyl optionally substituted by one or more substituents selected from halogen, alkyl of 1 to 6 carbon atoms, trihaloalkyl of 1 to 6 carbon atoms and trihaloalkoxy of 1 to 6 carbon atoms. Another embodiment of this embodiment are compounds of the formula (lb) wherein R2 is aralkyl of 7 to 12 carbon atoms optionally substituted by one or more substituents selected from halogen, alkyl of 1 to 6 carbon atoms, trihaloalkyl of 1 to 6 carbon atoms and trihaloalkoxy of 1 to 6 carbon atoms; and R3 is phenyl optionally substituted by one or more substituents selected from halogen, alkyl of 1 to 6 carbon atoms, trihaloalkyl of 1 to 6 carbon atoms and trihaloalkoxy of 1 to 6 carbon atoms. In another embodiment of the invention, compounds of formula (llb), as set forth above in the Compendium of the Invention, are directed to compounds wherein x e and each independently 1, 2 or 3; Va is -C (O) - or -C (S) ~; R1 is selected from the group consisting of hydrogen, alkyl of 1 to 12 carbon atoms, hydroxyalkyl of 2 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms and aralkyl of 7 to 19 carbon atoms; R2 is selected from the group consisting of alkyl of 1 to 12 carbon atoms, alkenyl of 2 to 12 carbon atoms, hydroxyalkyl of 2 to 12 carbon atoms, hydroxyalkenylalkyl of 2 to 12 carbon atoms, alkoxy of 1 to 6 atoms of carbon, alkoxyalkyl of 3 to 12 carbon atoms, cycloalkyl of 3 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms, aryl, aralkyl of 7 to 19 carbon atoms, Heterocyclyl of 3 to 12 carbon atoms, hydroxyalkyl of 3 to 12 carbon atoms, heteroaryl of 1 to 12 carbon atoms and heteroarylalkyl of 3 to 12 carbon atoms; R3 is selected from the group consisting of alkyl of 1 to 12 carbon atoms, alkenyl of 2 to 12 carbon atoms, hydroxyalkyl of 2 to 12 carbon atoms, hydroxyalkyl of 2 to 12 carbon atoms, alkoxy of 1 to 6 carbon atoms. carbon, alkoxyalkyl of 2 to 12 carbon atoms, cycloalkyl of 3 to 12 carbon atoms, cycloalkyl of 4 to 12 carbon atoms, aryl, aralkyl of 7 to 19 carbon atoms, heterocyclyl of 3 to 12 carbon atoms, heterocyclyl from 3 to 12 carbon atoms, heteroaryl of 1 to 12 carbon atoms and heteroarylalkyl of 3 to 12 carbon atoms; R4, R5 and R6 are each independently selected from hydrogen, bromine, fluorine, chlorine, methyl, methoxy, trifluoromethyl, cyano, nitro or -N (R13) 2; R7, R7a, R8, R8a, R9, R9a, R10, and R10a are each independently selected from hydrogen or alkyl of 1 to 3 carbon atoms; and each R13 is independently selected from hydrogen or alkyl of 1 to 6 carbon atoms. One modality of this modality are compounds of the formula (III) wherein x e and each is 1; Va is -C (O) -; R1 is hydrogen or alkyl of 1 to 12 carbon atoms; R2 is selected from the group consisting of alkyl of 1 to 12 carbon atoms, alkenyl of 2 to 12 carbon atoms, hydroxyalkyl of 2 to 12 carbon atoms, hydroxyalkyl of 2 to 12 carbon atoms, alkoxy of 1 to 6 atoms carbon, alkoxyalkyl of 2 to 12 carbon atoms, cycloalkyl of 3 to 12 carbon atoms, cycloalkyl of 4 to 12 carbon atoms, aryl, aralkyl of 7 to 19 carbon atoms, heterocyclyl of 3 to 12 carbon atoms, heterocyclyl of 3 to 12 carbon atoms, heteroaryl of 1 to 12 carbon atoms and heteroarylalkyl of 3 to 12 carbon atoms; R3 is naphthyl or phenyl, each optionally substituted by one or more substituents selected from the group consisting of halogen, cyano, nitro, hydroxy, alkyl of 1 to 6 carbon atoms, trihaloalkyl of 1 to 6 carbon atoms, trihaloalkoxy of 1 to 6 carbon atoms, alkylsulfonyl of 1 to 6 carbon atoms, -N (R12) 2, -OC (O) R12, -C (O) OR12, -S (O) 2N (R12) 2, cycloalkyl, heterocyclyl , heteroaryl and heteroarylcycloalkyl; R4, R5 and R6 each hydrogen; R7, R7a, R8, R8a, R9, R9a, R10, and R10a each hydrogen; and each R12 is independently selected from hydrogen, alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms, aryl or aralkyl. One embodiment of this embodiment are compounds of formula (III) wherein it is alkyl of 1 to 12 carbon atoms or aralkyl of 7 to 12 carbon atoms optionally substituted by one or more substituents selected from the group consisting of halogen, 1 to 6 carbon atoms, trihaloalkyl of 1 to 6 carbon atoms and trihaloalkoxy of 1 to 6 carbon atoms; R3 is naphthyl or phenyl, each optionally substituted by one or more substituents selected from the group consisting of halogen, alkyl of 1 to 6 carbon atoms, trihaloalkyl of 1 to 6 carbon atoms and trihaloalkoxy of 1 to 6 carbon atoms. Another embodiment of this embodiment are compounds of the formula (III) wherein R2 is cycloalkylalkyl of 4 to 12 carbon atoms, aralkyl of 7 to 19 carbon atoms, heterocyclylalkyl of 3 to 12 carbon atoms or heteroarylalkyl of 3 to 12 atoms of carbon; and R3 is naphthyl or phenyl, each optionally substituted by one or more substituents selected from the group consisting of halogen, alkyl of 1 to 6 carbon atoms, trihaloalkyl of 1 to 6 carbon atoms and trihaloalkoxy of 1 to 6 carbon atoms. In another embodiment of the invention, compounds of the formula (IV), as set forth above in the Compendium of the Invention, are directed to compounds wherein x e and each is independently 1, 2 or 3; Va is -C (O) -, -C (S) -, -C (O) N (R1) -, -C (S) N (R1) -, -C (O) O-, -C (S ) O-, -S (O) t- (where t is 1 or 2) or -S (O) tN (R1) - (where t is 1 or 2); each R1 is independently selected from the group consisting of hydrogen, alkyl of 1 to 12 carbon atoms, hydroxyalkyl of 2 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms and aralkyl of 7 to 19 carbon atoms; R2 is selected from the group consisting of alkyl of 1 to 12 carbon atoms, alkenyl of 2 to 12 carbon atoms, hydroxyalkyl of 2 to 12 carbon atoms, hydroxyalkyl of 2 to 12 carbon atoms, alkoxyalkyl of 3 to 12 atoms carbon, cycloalkyl of 3 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms, aryl, aralkyl of 7 to 19 carbon atoms, heterocyclyl of 3 to 12 carbon atoms, heterocyclylalkyl of 3 to 12 carbon atoms, heteroaryl of 1 to 12 carbon atoms and heteroarylalkyl of 3 to 12 carbon atoms; R3 is selected from the group consisting of alkyl of 1 to 12 carbon atoms, alkenyl of 2 to 12 carbon atoms, hydroxyalkyl of 2 to 12 carbon atoms, hydroxyalkyl of 2 to 12 carbon atoms, alkoxyalkyl of 2 to 12 atoms carbon, cycloalkyl of 3 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms, aryl, aralkyl of 7 to 19 carbon atoms, heterocyclyl of 3 to 12 carbon atoms, heterocyclylalkyl of 3 to 12 carbon atoms, heteroaryl of 1 to 12 carbon atoms and heteroarylalkyl of 3 to 12 carbon atoms; R4, R5 and R6 are each independently selected from hydrogen, bromine, fluorine, chlorine, methyl, methoxy, trifluoromethyl, cyano, nitro or -N (R) 2; R7, R7a, R8, R8a, R9, R9a, R10, and R10a are each independently selected from hydrogen or alkyl of 1 to 3 carbon atoms; and each R13 is independently selected from hydrogen or alkyl of 1 to 6 carbon atoms. One modality of this modality are compounds of the formula (IV) where x and y each is 1; Va is -C (O) -; each R1 is independently hydrogen or alkyl of 1 to 6 carbon atoms; R2 is selected from the group consisting of alkyl of 1 to 12 carbon atoms, alkenyl of 2 to 12 carbon atoms, hydroxyalkyl of 2 to 12 carbon atoms, hydroxyalkyl of 2 to 12 carbon atoms, alkoxyalkyl of 3 to 12 atoms carbon, cycloalkyl of 3 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms, aryl, aralkyl of 7 to 19 carbon atoms, heterocyclyl of 3 to 12 carbon atoms, heterocyclylalkyl of 3 to 12 carbon atoms, heteroaryl of 1 to 12 carbon atoms and heteroarylalkyl of 3 to 12 carbon atoms; R3 is selected from the group consisting of alkyl of 3 to 12 carbon atoms, alkenyl of 3 to 12 carbon atoms, hydroxyalkyl of 3 to 12 carbon atoms, hydroxyalkenyl of 3 to 12 carbon atoms, alkoxy of 3 to 12 atoms carbon, alkoxyalkyl of 3 to 12 carbon atoms, cycloalkyl of 3 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms, aryl, aralkyl of 7 to 17 carbon atoms, heterocyclyl of 3 to 12 carbon atoms, heterocyclylalkyl of 3 to 12 carbon atoms, heteroaryl of 1 to 12 carbon atoms and heteroarylalkyl of 3 to 12 carbon atoms; R4, R5 and R6 each hydrogen; R7, R7a, R8, R8a, R9, R9a, R10, and R10a each hydrogen; and each R12 is independently selected from hydrogen, alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms, aryl or aralkyl. One embodiment of this embodiment are compounds of the formula (IV) wherein R2 is alkyl of 1 to 12 carbon atoms or aralkyl of 7 to 12 carbon atoms optionally substituted by one or more substituents selected from the group consisting of halogen, alkyl from 1 to 6 carbon atoms, trihaloalkyl of 1 to 6 carbon atoms and trihaloalkoxy of 1 to 6 carbon atoms; and R3 is selected from the group consisting of cycloalkyl of 3 to 12 carbon atoms, aryl, heterocyclyl of 3 to 12 carbon atoms or heteroaryl of 1 to 12 carbon atoms. One embodiment of this embodiment are the compounds of the formula (IV) wherein R 3 is cycloalkyl of 3 to 12 carbon atoms.

Another embodiment of this embodiment are compounds of formula (IV) wherein R3 is phenyl optionally substituted by one or more substituents selected from the group consisting of halogen, alkyl of 1 to 6 carbon atoms, trihaloalkyl of 1 to 6 carbon atoms and trihaloalkoxy of 1 to 6 carbon atoms. Another embodiment of this embodiment are compounds of the formula (IV) wherein R3 is piperidinyl optionally substituted by alkyl of 1 to 6 carbon atoms or aralkyl of 7 to 12 carbon atoms, wherein the aralkyl group of 7 to 12 carbon atoms carbon is optionally substituted by one or more substituents selected from the group consisting of halogen, alkyl of 1 to 6 carbon atoms, trihaloalkyl of 1 to 6 carbon atoms and trihaloalkoxy of 1 to 6 carbon atoms. Another embodiment of this embodiment are the compounds of the formula (IV) wherein R3 is pyridinyl optionally substituted by one or more substituents selected from the group consisting of halogen or alkyl of 1 to 6 carbon atoms. In another embodiment of the invention, compounds of the formula (V), as set forth above in the Compendium of the Invention, are directed to compounds wherein x e and each is independently 1,2 or 3; Wa is -O-, -N (R1) - or -S (O) t- (where t is 0, 1 or 2); Va is -C (O) -, -C (S) -, -C (O) N (R1) -, -C (S) N (R1) -, -C (O) O-, -C (S ) O-, -S (O) t- t- (where t is 1 or 2) or -S (O) -tN (R1) - (where t is 1 or 2); each R1 are independently selected from the group consisting of hydrogen, alkyl of 1 to 12 carbon atoms, hydroxyalkyl of 2 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms and aralkyl of 7 to 19 carbon atoms; R2 is selected from the group consisting of alkyl of 1 to 12 carbon atoms, alkenyl of 2 to 12 carbon atoms, hydroxyalkyl of 2 to 12 carbon atoms, hydroxyalkenylalkyl of 2 to 12 carbon atoms, alkoxyalkyl of 3 to 12 atoms carbon, cycloalkyl of 3 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms, aryl, aralkyl of 7 to 19 carbon atoms, Heterocyclyl of 3 to 12 carbon atoms, heterocyclylalkyl of 3 to 12 carbon atoms, heteroaryl of 1 to 12 carbon atoms and heteroarylalkyl of 3 to 12 carbon atoms; R3 is selected from the group consisting of alkyl of 1 to 12 carbon atoms, alkenyl of 2 to 12 carbon atoms, hydroxyalkyl of 2 to 12 carbon atoms, hydroxyalkenylalkyl of 2 to 12 carbon atoms, alkoxyalkyl of 2 to 12 atoms carbon, cycloalkyl of 3 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms, aryl, aralkyl of 7 to 19 carbon atoms, heterocyclyl of 3 to 12 carbon atoms, heterocyclylalkyl of 3 to 12 carbon atoms, heteroaryl of 1 to 12 carbon atoms and heteroarylalkyl of 3 to 12 carbon atoms; R4, R5 and R6 are each independently selected from hydrogen, bromine, fluorine, chlorine, methyl, methoxy, trifluoromethyl, cyano, nitro or -N (R13) 2; R7, R7a, R8, R8a, R9, R9a, R10, and R10a are each independently selected from hydrogen or alkyl of 1 to 3 carbon atoms; and each R13 is independently selected from hydrogen or C 1 -C 6 alkyl. One modality of this mode are compounds of the formula (V) where x e and each is 1; Wa is -O-; Va is -C (O) - or -C (S) -; R2 is selected from the group consisting of alkyl of 1 to 12 carbon atoms, alkenyl of 2 to 12 carbon atoms, hydroxyalkyl of 2 to 12 carbon atoms, hydroxyalkyl of 2 to 12 carbon atoms alkoxyalkyl of 3 to 12 carbon atoms carbon, cycloalkyl of 3 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms, aryl, aralkyl of 7 to 19 carbon atoms, heterocyclyl of 3 to 12 carbon atoms, heterocyclylalkyl of 3 to 12 carbon atoms, heteroaryl from 1 to 12 carbon atoms and heteroarylalkyl of 3 to 12 carbon atoms; R3 is selected from the group consisting of alkyl of 3 to 12 carbon atoms, alkenyl of 3 to 12 carbon atoms, hydroxyalkyl of 3 to 12 carbon atoms, hydroxyalkenyl of 3 to 12 carbon atoms, alkoxy of 3 to 12 carbon atoms, alkoxyalkyl of 3 to 12 carbon atoms, cycloalkyl of 3 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms, aryl, aralkyl of 7 to 19 carbon atoms, heterocyclyl of 3 to 12 carbon atoms, heterocyclylalkyl of 3 to 12 carbon atoms, heteroaryl of 1 to 12 carbon atoms carbon and heteroarylalkyl of 3 to 12 carbon atoms; R4, R5 and R6 each hydrogen; and R7, R7a, R8, R8a, R9, R9a, R10, and R10a each hydrogen. One embodiment of this embodiment are compounds of the formula (V) wherein Va is -C (O) -; R2 is selected from the group consisting of alkyl of 1 to 12 carbon atoms, cycloalkyl of 3 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms, aryl, aralkyl of 7 to 19 carbon atoms, heterocyclyl of 3 to 12 carbon atoms, heterocyclylalkyl of 3 to 12 carbon atoms, heteroaryl of 1 to 12 carbon atoms and heteroarylalkyl of 3 to 12 carbon atoms; and R3 is selected from the group consisting of cycloalkyl of 3 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms, aryl, aralkyl of 7 to 19 carbon atoms, heterocyclyl of 3 to 12 carbon atoms, heterocyclylalkyl of 3 to 12 carbon atoms, heteroaryl of 1 to 12 carbon atoms and heteroarylalkyl of 3 to 12 carbon atoms. Another embodiment of the above embodiment of the compounds of the formula (V) are compounds wherein x e and each is 1; Wa is -N (R1) -; Va is -C (O) - or -C (S) -; R1 is hydrogen or alkyl of 1 to 6 carbon atoms; R 2 is selected from the group consisting of alkyl of 1 to 12 carbon atoms, alkenyl of 2 to 12 carbon atoms, hydroxyalkyl of 2 to 12 carbon atoms, hydroxyalkenylalkyl of 2 to 12 carbon atoms, alkoxyalkyl of 3 to 12 atoms carbon, cycloalkyl of 3 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms, aryl, aralkyl of 7 to 19 carbon atoms, heterocyclyl of 3 to 12 carbon atoms, heterocyclylalkyl of 3 to 12 carbon atoms, heteroaryl of 1 to 12 carbon atoms and heteroarylalkyl of 3 to 12 carbon atoms; R3 is selected from the group consisting of alkyl of 3 to 12 carbon atoms, alkenyl of 3 to 12 carbon atoms, hydroxyalkyl of 3 to 12 carbon atoms, hydroxyalkenyl of 3 to 12 carbon atoms, alkoxy of 3 to 12 atoms carbon, alkoxyalkyl of 3 to 12 carbon atoms, cycloalkyl of 3 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms, aryl, aralkyl of 7 to 19 carbon atoms, heterocyclyl of 3 to 12 carbon atoms, heterocyclylalkyl of 3 to 12 carbon atoms, heteroaryl of 1 to 12 carbon atoms and heteroarylalkyl of 3 to 12 carbon atoms; R4, R5 and R6 each hydrogen; and R7, R7a, R8, R8a, R9, R9a, R10, and R10a each hydrogen. One embodiment of this embodiment are compounds of the formula (V) wherein Va is -C (O) -; R2 is selected from the group consisting of alkyl of 1 to 12 carbon atoms, cycloalkyl of 3 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms, aryl, aralkyl of 7 to 19 carbon atoms, Heterocyclyl of 3 to 12 carbon atoms, heterocyclylalkyl of 3 to 12 carbon atoms, heteroaryl of 1 to 12 carbon atoms and heteroarylalkyl of 3 to 12 carbon atoms; and R3 is selected from the group consisting of cycloalkyl of 3 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms, aryl, aralkyl of 7 to 19 carbon atoms, heterocyclyl of 3 to 12 carbon atoms, heterocyclylalkyl of 3 to 12 carbon atoms, heteroaryl of 1 to 12 carbon atoms and heteroarylalkyl of 3 to 12 carbon atoms. Another embodiment of the above embodiment of the compounds of the formula (V) are compounds wherein x e and each is 1; Wa is -S (O) t- (where t is 0.1 or 2); Va is -C (O) - or -C (S) -; R2 is selected from the group consisting of alkyl of 1 to 12 carbon atoms, alkenyl of 2 to 12 carbon atoms, hydroxyalkyl of 2 to 12 carbon atoms, hydroxyalkenylalkyl of 2 to 12 carbon atoms, alkoxyalkyl of 3 to 12 atoms carbon, cycloalkyl of 3 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms, aryl, aralkyl of 7 to 19 carbon atoms, Heterocyclyl of 3 to 12 carbon atoms, heterocyclylalkyl of 3 to 12 carbon atoms, heteroaryl with 1 to 12 carbon atoms and heteroarylalkyl with 3 to 12 carbon atoms; R3 is selected from the group consisting of alkyl of 3 to 12 carbon atoms, alkenyl of 3 to 12 carbon atoms, hydroxyalkyl of 3 to 12 carbon atoms, hydroxyalkenyl of 3 to 12 carbon atoms, alkoxy of 3 to 12 atoms carbon, alkoxyalkyl of 3 to 12 carbon atoms, cycloalkyl of 3 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms, aryl, aralkyl of 7 to 19 carbon atoms, heterocyclyl of 3 to 12 carbon atoms, heterocyclylalkyl of 3 to 12 carbon atoms, heteroaryl of 1 to 12 carbon atoms and heteroarylalkyl of 3 to 12 carbon atoms; R4, R5 and R6 each hydrogen; and R7, R7a, R8, R8a, R9, R9a, R10, and R10a each hydrogen. One embodiment of this embodiment are compounds of the formula (V) wherein Va is -C (O) -; R2 is selected from the group consisting of alkyl of 1 to 12 carbon atoms, cycloalkyl of 3 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms, aryl, aralkyl of 7 to 19 carbon atoms, Heterocyclyl of 3 to 12 carbon atoms, heterocyclylalkyl of 3 to 12 carbon atoms, heteroaryl of 1 to 12 carbon atoms and heteroarylalkyl of 3 to 12 carbon atoms; and R3 is selected from the group consisting of cycloalkyl of 3 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms, aryl, aralkyl of 7 to 19 carbon atoms, heterocyclyl of 3 to 12 carbon atoms, heterocyclylalkyl of 3 to 12 carbon atoms, heteroaryl of 1 to 12 carbon atoms and heteroarylalkyl of 3 to 12 carbon atoms. In another embodiment of the invention, compounds of the formula (la), as set forth above in the Compendium of the Invention, are directed to compounds wherein x e and each is independently 1, 2 or 3; V is -C (O) - or -C (S) -; R1 is hydrogen, alkyl of 1 to 12 carbon atoms, hydroxyalkyl of 2 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms and aralkyl of 7 to 19 carbon atoms; R2 is selected from the group consisting of alkyl of 1 to 12 carbon atoms, alkenyl of 2 to 12 carbon atoms, hydroxyalkyl of 2 to 12 carbon atoms, hydroxyalkenylalkyl of 2 to 12 carbon atoms, alkoxy of 1 to 12 atoms carbon, alkoxyalkyl of 2 to 12 carbon atoms, cycloalkyl of 3 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms, aryl, aralkyl of 7 to 19 carbon atoms, heterocyclyl of 3 to 12 carbon atoms, heterocyclylalkyl of 3 to 12 carbon atoms, heteroaryl of 1 to 12 carbon atoms, and heteroarylalkyl of 3 to 12 carbon atoms; R3 is selected from the group consisting of alkyl of 1 to 12 carbon atoms, alkenyl of 2 to 12 carbon atoms, hydroxyalkyl of 2 to 12 carbon atoms, hydroxyalkenylalkyl of 2 to 12 carbon atoms, alkoxy of 1 to 12 atoms carbon, alkoxyalkyl of 2 to 12 carbon atoms, cycloalkyl of 3 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms, aryl, aralkyl of 7 to 19 carbon atoms, heterocyclyl of 3 to 12 carbon atoms, heterocyclylalkyl of 3 to 12 carbon atoms, heteroaryl of 1 to 12 carbon atoms and heteroarylalkyl of 3 to 12 carbon atoms; R4, R5 and R6 are each independently selected from hydrogen, bromine, fluorine, chlorine, methyl, methoxy, trifluoromethyl, cyano, nitro -N (R13) 2; R7, R7a, R8, R8a, R9, R9a, R10, and R10a are each independently selected from hydrogen or alkyl of 1 to 3 carbon atoms; and each R13 is independently selected from hydrogen or alkyl of 1 to 6 carbon atoms. One modality of this mode are compounds of the formula (la) where x e and each is 1; V is -C (O) -; R1 is hydrogen, alkyl of 1 to 12 carbon atoms or cycloalkylalkyl of 4 to 12 carbon atoms; R2 is selected from the group consisting of alkyl of 1 to 12 carbon atoms, alkenyl of 2 to 12 carbon atoms, cycloalkyl of 3 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms, aralkyl of 7 to 19 atoms of carbon, heterocyclylalkyl of 3 to 12 carbon atoms and heteroarylalkyl of 3 to 12 carbon atoms; R3 is aryl optionally substituted by one or more substituents selected from the group consisting of halogen, cyano, nitro, hydroxy, alkyl of 1 to 6 carbon atoms, trihaloalkyl of 1 to 6 carbon atoms, trihaloalkoxy of 1 to 6 carbon atoms , alkylsnyl of 1 to 6 carbon atoms, -N (R12) 2, -OC (O) R12, -C (O) OR12, -S (O) 2N (R12) 2, cycloalkyl, heterocyclyl, heteroaryl and heteroarylcycloalkyl; R4, R5 and R6 are each independently selected from hydrogen, bromine, fluorine, chlorine, methyl, methoxy, trifluoromethyl, cyano, nitro or -N (R13) 2; R7, R7a, R8, R8a, R9, R9a, R10, and R10a are each independently selected from hydrogen or alkyl of 1 to 3 carbon atoms; and each R13 is independently selected from hydrogen or C 1 -C 6 alkyl. One modality of this mode are compounds of the formula (la) where x e and each is 1; V is -C (O) -; R1 is hydrogen, alkyl of 1 to 12 carbon atoms or cycloalkylalkyl of 4 to 12 carbon atoms; R 2 is alkyl of 1 to 12 carbon atoms or alkenyl of 2 to 12 carbon atoms; R3 is phenyl optionally substituted by one or more substituents selected from the group consisting of halogen, cyano, nitro, hydroxy, alkyl of 1 to 6 carbon atoms, trihaloalkyl of 1 to 6 carbon atoms, trihaloalkoxy of 1 to 6 carbon atoms , alkylsnyl of 1 to 6 carbon atoms, -N (R12) 2, -OC (O) R12, -C (O) OR12, -S (O) 2N (R12) 2; R4, R5 and R6 are each independently selected from hydrogen, bromine, fluorine or chlorine; and R7, R7a, R8, R8a, R9, R9a, R10, and R10a each hydrogen. Another modality of this modality are compounds of the formula (la) wherein x e and each is 1; V is -C (O) -; R1 is hydrogen, alkyl of 1 to 12 carbon atoms or cycloalkylalkyl of 4 to 12 carbon atoms; R 2 is aralkyl of 7 to 19 carbon atoms, heterocyclylalkyl of 3 to 12 carbon atoms or heteroarylalkyl of 3 to 12 carbon atoms; R3 is phenyl optionally substituted by one or more substituents selected from the group consisting of halogen, cyano, nitro, hydroxy, alkyl of 1 to 6 carbon atoms, trihaloalkyl of 1 to 6 carbon atoms, trihaloalkoxy of 1 to 6 carbon atoms , alkylsnyl of 1 to 6 carbon atoms, -N (R12) 2, -OC (O) R12, -C (O) OR12, -S (O) 2N (R12) 2; R4, R5 and R6 are each independently selected from hydrogen, bromine, fluorine or chlorine; and R7, R7a, R8, R8a, R9, R9a, R0, and R10 each one hydrogen. Another modality of this modality are compounds of the formula (la) wherein x e and each is 1; V is -C (O) -; R1 is hydrogen, alkyl of 1 to 12 carbon atoms or cycloalkylalkyl of 4 to 12 carbon atoms; R 2 is cycloalkyl of 3 to 12 carbon atoms or cycloalkylalkyl of 4 to 12 carbon atoms; R3 is phenyl optionally substituted by one or more substituents selected from the group consisting of halogen, cyano, nitro, hydroxy, alkyl of 1 to 6 carbon atoms, trihaloalkyl of 1 to 6 carbon atoms, trihaloalkoxy of 1 to 6 carbon atoms , alkylsnyl of 1 to 6 carbon atoms, -N (R12) 2, -OC (O) R12, -C (O) OR12, -S (O) 2N (R12) 2; R4, R5 and R6 are each independently selected from hydrogen, bromine, fluorine or chlorine; and R7, R7a, R8, R8a, R9, R9a, R10, and R10 each one hydrogen. One embodiment of this embodiment are compounds of the formula (la) wherein R2 is cycloalkylalkyl of 4 to 12 carbon atoms; R3 is phenyl optionally substituted by one or more substituents selected from halogen, alkyl of 1 to 6 carbon atoms, trihaloalkyl of 1 to 6 carbon atoms and trihaloalkoxy of 1 to 6 carbon atoms; R4 and R6 both are hydrogen; and R5 is hydrogen or bromine. The specific embodiments of the compounds of the invention are described herein in the Reaction Schemes and Examples. In another embodiment, the invention provides methods for treating a disease or condition mediated by stearoyl-Coa desaturase (SCD) in a mammal, wherein the method comprises administering to a mammal in need thereof., a therapeutically effective amount of a compound of the formula (lia), (llb), (III), (IV), (V) or (Ia). In another embodiment, the invention provides pharmaceutical compositions comprising a pharmaceutically acceptable excipient and a therapeutically effective amount of a compound of the formula (lia), (Ib), (III), (IV), (V) or (Ia). In one embodiment, the methods of the invention are directed towards the treatment and / or prevention of diseases mediated by stearoyl-CoA desaturase (SCD), especially human SCD (hSCD), preferably diseases related to dyslipidemia and disorders of lipid metabolism, and especially a disease related to elevated levels of plasma lipid, cardiovascular disease, diabetes, obesity, metabolic syndrome and the like through the administration of an effective amount of a compound of the invention. The present invention also relates to the pharmaceutical composition containing the compounds of the invention. In one embodiment, the invention relates to a composition comprising compounds of the invention in a pharmaceutically acceptable carrier and in an amount effective to modulate the level of triglycerides or to treat diseases related to dyslipidemia and disorders of lipid metabolism, when administered to an animal, preferably a mammal, preferably a patient human being. In one embodiment of said composition, the patient has a high lipid level, such as elevated triglycerides or cholesterol, before the administration of said compound of the invention and the compound of the invention is present in an effective amount to reduce said level of lipid Utility and Testing of the Compounds of the Invention The present invention relates to compounds, pharmaceutical compositions and methods for using the compounds and pharmaceutical compositions for the treatment and / or prevention of diseases mediated by stearoyl-CoA (SCD) desaturase, especially human SCD (hSCD), preferably diseases related to dyslipidemia and disorders of lipid metabolism, and especially a disease related to elevated plasma lipid levels, especially cardiovascular disease, diabetes, obesity, metabolic syndrome and the like, by administration to a patient in the need for such treatment an effective amount of an agent for modulation, especially inhibition of SCD. In general, the present invention provides a method for treating a patient for, or protecting a patient from the development of, a disease related to dyslipidemia and / or a disorder of lipid metabolism, wherein the levels of lipid in an animal, especially a human being, they are outside the normal range (i.e., abnormal lipid level, such as elevated plasma lipid levels), especially higher than normal levels, preferably wherein said lipid is a fatty acid, such as a free fatty acid. or of complex, triglycerides, phospholipids, or cholesterol, such as where the LDL-cholesterol levels are elevated or the HDL-cholesterol levels are reduced, or any combination thereof, wherein said lipid-related condition or disease is a SCD-mediated disease or condition, which comprises administering to an animal, such as a mammal, especially a human being, a therapeutically effective amount of a compound of the invention or a pharmaceutical composition comprising a compound of the invention wherein the compound modulates the activity of SCD, preferably human SCD1. The compounds of the invention modulate, preferably inhibit, the activity of human SCD enzymes, especially human SCD1. The general value of the compounds of the invention in modulation, especially inhibition, SCD activity can be determined using the assay described below in Example 6. Alternatively, the general value of the compounds in the treatment of disorders and diseases is can establish in industry-standard animal models to demonstrate the effectiveness of the compounds in the treatment of obesity, diabetes or high levels of triglycerides or cholesterol or to improve glucose tolerance. Said models include Zucker obese faifa rats (available from Harlan Sprague Dawley, Inc. (Indianapolis, Indiana)), or Zucker diabetic adipose rats (ZDF / GmiCrl-fa / fa) (available from Charles River Laboratories (Montreal, Quebec) ). The compounds of the present invention are inhibitors of delta-9 desaturases and are useful for treating diseases and disorders in humans and other organisms, including all those human diseases and disorders that are the result of the biological activity of aberrant delta-9 desaturase or which can be decreased by modulating the biological activity of delta-9 desaturase. As defined herein, a disease or condition mediated by SCD includes but is not limited to a disease or condition that is, or is related to, cardiovascular disease, dyslipidemias (including but not limited to disorders of serum triglyceride levels, hypertriglyceridemia, VLDL, HDL, LDL, Fatty acid desaturation index (for example the ratio of 18: 1/18: 0 of fatty acids, or other fatty acids, as defined elsewhere in the present), cholesterol, and cholesterol total, hypercholesterolemia, as well as cholesterol disorders (including disorders characterized by defective reverse cholesterol transport), familial combined hyperlipidemia, coronary artery disease, atherosclerosis, heart disease, cerebrovascular disease (including but not limited to shock, ischemic shock, and temporal ischemic attack (TIA)), peripheral vascular disease, and ischemic retinopathy. In a preferred embodiment, the compounds of the invention, in a patient, will increase HDL levels and / or lower triglyceride levels and / or lower levels of LDL or non-HDL cholesterol. A disease or condition mediated by SCD also includes metabolic syndrome (including but not limited to dyslipidemia, obesity and insulin resistance, hypertension, microalbuminemia, hyperuricaemia, and hypercoagulability), Syndrome X, diabetes, insulin resistance, impaired glucose tolerance, diabetes non-insulin-dependent mellitus, Type II diabetes, Type I diabetes, diabetic complications, weight disorders of the body (including, but not limited to, obesity, overweight, cachexia, and anorexia), weight loss, and diseases related to body mass index, and leptin. In a preferred embodiment, the compounds of the invention will be used to treat diabetes mellitus and obesity. As used herein, the term "metabolic syndrome" is a recognized clinical term to describe a condition comprising combinations of Type II diabetes, impaired glucose tolerance, insulin resistance, hypertension, obesity, increased abdominal circumference, hypertriglyceridemia, low HDL. , hyperuricaemia, hypercoagulability and / or microalbuminemia. A disease or condition mediated by SCD also includes fatty liver, hepatic steatosis, hepatitis, non-alcoholic hepatitis, nonalcoholic steatohepatitis (NASH), alcoholic hepatitis, acute fatty liver, fatty liver of pregnancy, drug-induced hepatitis, protoporphyria erythrohepatic, iron overload, hereditary hemochromatosis, liver fibrosis, liver cirrhosis, hepatoma and related conditions. A disease or condition mediated by SCD also includes, but is not limited to, a disease or condition that is, or is related to, primary hypertriglyceridemia, or secondary hypertriglyceridemia with another disorder or disease, such as hyperlipoproteinemias, familial histiocytic reticulosis, deficient lipase lipoprotein, apolipoprotein deficiency (such as ApoCII deficiency or ApoE deficiency), and the like, or hypertriglyceridemia of unknown or unspecified etiology. A disease or condition mediated by SCD also includes a polyunsaturated fatty acid disorder (PUFA), or a skin disorder, including but not limited to eczema, acne, psoariasis, formation or prevention of keloid scar, diseases related to the production or secretions of mucous membranes, such as monounsaturated fatty acid, wax esters and the like. A disease or condition mediated by SCD also includes inflammation, sinusitis, asthma, pancreatitis, osteoarthritis, rheumatoid arthritis, cystic fibrosis, and premenstrual syndrome. A disease or condition mediated by SCD also includes but is not limited to a disease or condition that is, or is related to cancer, neoplasia, malignancy, metastasis, tumors (benign or malignant), carcinogenesis, hepatomas and the like. A disease or condition mediated by SCD also includes a condition wherein the increase of the thin body mass, or thin muscle mass, is desired, as is desirable in improving functioning through the construction of muscles. Myopathies and lipid myopathies such as carnitine palmitoyltransferase deficiency (CPT I or CPT II) are also included here. Said treatments are useful in the conservation of humans and animals, including administration to a bovine, porcine or avian domestic animal, or any other animal to reduce the production of triglycerides and / or provide thinner meat products and / or animals more healthy A disease or condition mediated by SCD also includes a disease or condition that is, or is related to, neurological diseases, psychiatric disorders, multiple sclerosis, eye diseases, and immune disorders. A disease or condition mediated by SCD also includes a disease or condition that is, or is related to, viral diseases or infections, including but not limited to all RNA viruses of positive chain structure, coronaviruses, SARS virus, coronavirus associated with SARS, Togaviruses, Picornaviruses, Coxsaquievirus, Yellow Fever virus, Flaviviridae, ALPHAVIRUS (TOGAVIRIDAE) including rubella virus, Eastern equine encephalitis virus, Western equine encephalitis virus, Venezuelan equine encephalitis virus, Sindbis virus , Semliki forest virus, virus Chikungunya, O'nyong'nyong virus, Ross river virus, Mayaro virus, Alphaviruses; ASTROVIRIDAE including Astrovirus, Human Astroviruses; CALICIVIRIDAE including Vesicular exanthema of swine virus, Norwalk virus, Calicivirus, Bovine calcivirus, Pork calcivirus, Hepatitis E; CORONAVIRIDAE including Coronavirus, SARS virus, Avian infectious bronchitis virus, Bovine coronavirus, Canine coronavirus, Feline infectious peritonitis virus, Human 299E coronavirus, OC43 human coronavirus, murine hepatitis virus, Porcine epidemic diarrhea virus, Porcine Encephalomyelitis Haemagglutination Virus, Porcine Transmissible Gastroenteritis Virus, Coronavirus, Turkey Coronavirus, Rabbit Coronavirus, Berne Virus, Breda Virus; FLAVIVIRIDAE including Hepatitis C virus, West Nile virus, Yellow fever virus, St. Louis encephalitis virus, Dengue group, Hepatitis G virus, Japanese B encephalitis virus, Murray Valley encephalitis virus, Central European tick-borne encephalitis, Far East tick-borne encephalitis virus, Kyasanur forest virus, Louping's disease virus, Powassan virus, Omsk haemorrhagic fever virus, Kumilinge virus, Absetarov hypr anzalova virus, liheus virus, Rocio encephalitis virus, Langat virus, Pestivirus viral diarrhea virus, Bovine viral diarrhea, Hog cholera virus, Rio Bravo Group, Tyuleniy Group, Ntaya Group, Uganda S Group, Modoc Group; PICORNAVIRIDAE including Coxsackie A virus, Rhinovirus, Hepatitis A virus, Encephalomyocarditis virus, Mengovirus, ME virus, Human poliovirus 1, Coxsackie B; POTYVIRIDAE including Potyvirus, Rymovirus, Bimovirus. Additionally there may be a disease or infection caused by or linked to Hepatitis virus, Hepatitis B virus, Hepatitis C virus, Human immunodeficiency virus (HIV) and the like. Treatable viral infections include those in which the virus employs an RNA intermediate as part of the replication cycle (hepatitis or HIV); additionally there may be a disease or infection caused by or linked to RNA negative chain structure viruses such as influenza virus and parainfluenza. The compounds identified in the present specification inhibit the desatuon of several fatty acids (such as the C9-C10 desatuon of stearoyl-CoA) which is achieved through desaturases delta-9, such as stearoyl-CoA1 desaturase (SCD1 ). As such, these compounds inhibit the formation of various fatty acids and metabolites in stream below them. This can lead to an accumulation of stearoyl-CoA or palmitoyl-CoA and other upstream precursors of various fatty acids; which possibly will result in a negative feedback loop causing a global change in the fatty acid metabolism. Any of these consequences may ultimately be responsible for the overall therapeutic benefits provided by these compounds. Typically, a successful SCD inhibitory therapeutic agent will meet some or all of the following criteria. Oral availability should be above 20%. The efficacy of the animal model is less than 2 mg / kg, 1 mg / Kg, or 0.5 mg / Kg and the target human dose is between 50 and 250 mg / 70 Kg, although doses outside this range may be acceptable. ("mg / Kg" means milligrams of the compound per kilogram of the body mass of the subject to whom it is being administered). The therapeutic index (or o of toxic dose to therapeutic dose) should be greater than 100. The potency (as expressed by the IC50 value) should be less than 10 μM, preferably below 1 μM and more preferably below 50 nM. . IC50 ("Inhibitor Concenton - 50%") is a measure of the amount of the compound required to achieve 50% inhibition of SCD activity, for a specific period of time, in a SCD biological activity assay. Any process for measuring the activity of SCD enzymes, preferably mouse or human SCD enzymes, can be used to test the activity of compounds useful in the methods of the invention in inhibiting said SCD activity. The compounds of the invention demonstrate an IC50 in a 15 minute microsomal assay of preferably less than 10 μM, less than 5 μM, less than 2.5 μM, less than 1 μM, less than 750 nM, less than 500 nM, less than 250 nM, less than 100 nM, less than 50 nM, and more preferably less than 20 nM. The compound of the invention can show a reversible inhibition (i.e., competitive inhibition) and preferably does not inhibit other iron binding proteins. The required dose should preferably not be more than once or twice a day or at meals. The identification of the compounds of the invention as SCD inhibitors was easily achieved using the SCD enzyme and the microsomal assay procedure described in Brownie et al., Supra. When tested in this assay, compounds of the invention had less than 50% remaining SCD activity at a concentration of 10 μM of the test compound, preferably less than 40% of the remaining SCD activity of the test compound, more preferably 3.0% of the remaining SCD activity at a concentration of 10 μM of the test compound, and still more preferably 20% of the remaining SCD activity at a concentration of 10 μM of the test compound, thus demonstrating that the The compounds of the invention are potent inhibitors of SCD activity. These results provide the basis for an analysis of the relationship between structure-activity (SAR) between the test compounds and SCD. Certain R groups tend to provide more potent inhibitory compounds. SAR analysis is one of the tools that those skilled in the art can now use to identify preferred embodiments of the compounds of the invention for use as therapeutic agents. Other methods for testing the compounds described herein are also readily available to those skilled in the art. In this way, in addition, such contact can be achieved in vivo. In one such modality, said contact in step (a) is achieved through the administration of said chemical agent to an animal afflicted with a disorder related to triglyceride (TG) or very low density lipoprotein (VLDL) and subsequently detecting a change in the level of triglyceride in the plasma in said animal, therefore a therapeutic agent useful for treating a disorder related to triglyceride (TG) or very low density lipoprotein (VLDL) is identified. In such an embodiment, the animal may be a human being, such as a patient human being afflicted with said disorder and in need of such treatment of said disorder. In specific embodiments of said in vivo processes, said change in SCD1 activity in said animal is a decrease in activity, preferably wherein said SCD1 modulating agent does not substantially inhibit the biological activity of delta-5 desaturase, desaturase de-6. or fatty acid synthetase. Model systems useful for the evaluation of the compound may include, but are not limited to, the use of liver microsomes, such as from mice that have been maintained on a high carbohydrate diet, or from human donors, including persons suffering from of obesity. Immortalized cell lines, such as HepG2 (from human liver), MCF-7 (from human breast cancer) and 3T3-L1 (from mouse adipocytes) can also be used. Primary cell lines, such as primary mouse hepatocytes, are also useful in testing the compounds of the invention. When whole animals are used, mice used as a source of primary hepatocyte cells can also be used where the mice have been maintained on a high carbohydrate diet to increase the SCD activity in microsomes and / or to raise the levels of triglycerides in the plasma (ie, a ratio of 18: 1/18: 0); Alternatively mice with a normal diet, or mice with abnormal triglyceride levels can be used. Mouse models employing transgenic mice designed for hypertriglyceridemia are also available as in the mouse phenome database. Rabbits and hamsters are also useful as animal models, especially those expressing CETP (cholesteryl ester transfer protein). Another suitable method for determining the in vivo efficacy of the compounds of the invention is indirectly to measure their impact on the inhibition of the SCD enzyme through the measurement of the subject's Desaturation index after the administration of the compound. The "Desaturation index" employed in this specification means the proportion of the product on the substrate for the SCD enzyme as measured from a given tissue sample. This can be calculated using three different equations 18: 1n-9/18: 0 (oleic acid on stearic acid); 16: 1n-7/16: 0 (palmitoleic acid on palmitic acid); and / or 16: 1n-7 + 18: 1 n-7/16: 0 (measuring all the reaction products of 16: 0 desaturation on 16: 0 substrate). The desaturation index was mainly measured in triglycerides in the liver or plasma, but it can also be measured in other lipid fractions selected from a variety of tissues. The desaturation index, generally speaking, is a tool for the profiling of the lipid in the plasma. A number of human diseases and disorders are the result of the aberrant biological activity of SCD1 and can be ameliorated by modulating the biological activity of SCD1 using therapeutic agents of the invention. The inhibition of SCD expression can also affect the fatty acid composition of membrane phospholipids, as well as the production or levels of triglycerides and cholesterol esters. The fatty acid composition of phospholipids ultimately determines the fluidity of the membrane, while the effects on the composition of triglycerides and cholesterol esters can affect the metabolism and adiposity of lipoprotein. In carrying out the methods of the present invention it will of course be understood that the particular reference to pH regulators, media, reagents, cells, culture conditions and the like is not meant to be limiting, but they will be read to include all the related materials that one skilled in the art would recognize as being of interest or value in the particular context in which this discussion is presented. For example, it is possible to replace one pH regulating system or culture medium with another and still achieve similar results, if not identical. Those skilled in the art will have sufficient knowledge of such systems and methodologies to be able, without improper experimentation, to make such substitutions that optimally serve their purposes in using the methods and procedures described herein.

Pharmaceutical Compositions of the Invention and Administration The present invention also relates to a pharmaceutical composition containing the compounds of the invention described herein. In one embodiment, the present invention relates to a composition comprising compounds of the invention in a pharmaceutically acceptable carrier and in an amount effective to modulate the level of triglycerides or to treat diseases related to dyslipidemia and disorders of lipid metabolism, when administers to an animal, preferably a mammal, preferably a patient human being. In one embodiment of said composition, the patient has a high lipid level, such as elevated triglycerides or cholesterol, before the administration of said compound of the invention and the compound of the invention is present in an effective amount to reduce said level of lipid Pharmaceutical compositions useful herein also contain a pharmaceutically acceptable carrier, including any suitable diluent or excipient, which includes any pharmaceutical agent that does not itself induce the production of antibodies harmful to the individual receiving the composition, and which can be administered without a undue toxicity. Pharmaceutically acceptable carriers include, but are not limited to, liquids, such as water, saline, glycerol and ethanol, and the like. A detailed discussion of the pharmaceutically acceptable carriers, diluents, and other excipients is presented in REMINGTON'S PHARMACEUTICAL SCIENCES (Mack Pub. Co., N.J. current edition). Those skilled in the art know how to determine suitable doses of the compounds for use in the treatment of the diseases and disorders contemplated herein. Therapeutic doses are usually identified through a dose scale study in humans based on preliminary evidence derived from animal studies. Doses should be sufficient to result in a desired therapeutic benefit without causing unwanted side effects to the patient. The preferred dose scale for an animal is 0.001 mg / Kg to 10,000 mg / Kg, including 0.5 mg / Kg, 1.0 mg / Kg and 2.0 mg / Kg, although doses outside this range may be acceptable. The scheduling of the dosage can be once or twice a day, although more often or less often it can be satisfactory. Those with skill in the art are also familiar with the methods of administration (oral, intravenous, inhalation, subcutaneous, etc.), dosage forms, pharmaceutically suitable excipients and other relevant subjects in the distribution of the compounds to a subject in need. thereof. In an alternative use of the invention, the compounds of the invention can be used in in vitro or in vivo studies as illustrative agents for comparative purposes to find other compounds also useful in the treatment of, or protection from, the various diseases described herein.

Preparation of the Compounds of the Invention It is understood that in the following description, the combinations of the substituents and / or variables of the formula described are permissible only if said contributions result in stable compounds. It will also be appreciated by those skilled in the art that in the process described below the functional groups of intermediary compounds may need to be protected through suitable protecting groups. Said functional groups include hydroxy, amino, mercapto and carboxylic acid. Said protecting groups for hydroxy include trialkylsilyl or diarylalkysilyl (for example, t-butyldimethylsilyl, t-butyldiphenylsilyl or trimethylsilyl), tetrahydropyranyl, benzyl, and the like. Suitable protecting groups for amino, amidino and guanidino include t-butoxycarbonyl, benzyloxycarbonyl, and the like. Suitable protecting groups for mercapto include -C (O) -R11 (wherein R11 is alkyl, aryl or arylalkyl), p-methoxybenzyl, trifly and the like. Suitable protecting groups for carboxylic acid include alkyl, aryl or arylalkyl esters. Protective groups can be added or removed according to standard techniques, which are well known to those skilled in the art and are described herein. The use of protecting groups is described in detail in Green, T. W. and P. G. M. Wutz, Protective Groups in Organic Synthesis (1999), 3a. Ed., Wiley. The protecting group can also be a polymer resin such as a Wang resin or a 2-chlorotryl chloride resin. It will also be appreciated by those skilled in the art that while said protected derivatives of compounds of this invention may not possess pharmacological activity as such, they may be administered to a mammal and then metabolized in the body to form the compounds of the invention. which are pharmacologically active. Said derivatives can therefore be described as "prodrugs". All prodrugs of the compounds of this invention are included within the scope of the invention. The following Reaction Schemes illustrate methods for making the compounds of this invention. It is understood that one skilled in the art will be able to make these compounds through similar methods known to one skilled in the art. In general, the starting components can be obtained from sources such as Sigma Aldrich, Lancaster Synthesis, Inc., Maybridge, Matrix Scientific, TCI, and Fluorochem USA, etc. or synthesized according to the sources known to those skilled in the art (see, for example, Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, 5th edition (Wiley, December 2000)) or prepared as described in this invention. R \ R2, R3, R4, R5, R6, R7, R7a, R8, R8a, R9, R9a, R10, R10a and V are defined as in the Specification unless specifically defined. X is selected from Cl or Br. PG represents a protecting group such as BOC, benzyl group and the like. In general, the compounds of formula (I) of the invention wherein W is -C (O) N (R-1) - and V is -C (O) -, -S (O) 2- or - C (R11) H- can be synthesized following the general procedure as described in Reaction Scheme 1.

REACTION SCHEME 1 (101) (103) The starting materials of the above reaction scheme are commercially available or can be prepared according to methods known to a person skilled in the art or by methods described herein In general, the compounds of the invention were prepared in the above reaction scheme as follows: Compound 103. To a stirred solution of the amine of the formula (101) (1 equivalent) in a solvent such as dichloromethane or toluene was added the solution of a compound of the formula ( 102) (1 equivalent) in a solvent such as dichloromethane or toluene in the presence of a base such as triethylamine or Hunigs base The resulting mixture was stirred at room temperature for a suitable period and then quenched with water. washed with H2O, brine, dried over and then concentrated in vacuo to give the product of the formula (103) Compound 104. A solution of the compound of the formula (103) obtained above was dissolved in a suitable solvent and the PG protecting group was removed under standard deprotection conditions such as hydrolysis or hydrogenation to obtain the amine of the formula (104). Compound 106. The mixture of a pyridine compound of the formula (105) (1 equivalent) and the compound of the formula (104) obtained above (1.5 equivalents) in a suitable solvent was heated to reflux for 4-24 hours. A basic solution such as a NaOH solution was added to the reaction mixture. The aqueous layer was extracted by an organic solvent such as dichloromethane or ethyl acetate. The combined organic phase was dried, then evaporated to dryness. The crude compound was purified by column chromatography or crystallization to give the compound of the formula (106). Compound of the formula (1): Method A: To a stirred solution of the compound of the formula (106) (1 equivalent) in a solvent such as dichloromethane, acetonitrile or toluene was added the solution of a compound of the formula (107) (1 equivalent) in the presence of a base such as triethylamine or Hunigs base (1 equivalent) at 0 ° C. The resulting mixture was stirred at room temperature for 8-24 hours and then quenched with water. The organic phase was washed with H2O, brine, dried and then concentrated in vacuo to give the compound of the formula (I) wherein W is -C (O) N (R1) - and V is -C (O) -, -S (O) 2- or -C (R11) H-. Method B: To a solution of the compound of the formula (108) (1 equivalent) (R12 = H) in a solvent such as dichloromethane, toluene or THF was added a base such as triethylamine or Hunigs base (2.5 equivalents), followed by the addition of a coupling agent such as (3-dimethylaminopropyl) ethyl carbodiimide (1.1 equivalent). The resulting mixture was stirred for 15 minutes to one hour and an amine of the formula (106) (1.1 equivalent) was added. The mixture was stirred at room temperature for 8-24 hours, then washed with water, dried and concentrated in vacuo. Purification through column chromatography or crystallization from a suitable solvent gave the compound of formula (I) wherein W is -C (O) N (R1) - and V is -C (O) -, - S (O) 2- or -C (R11) H-. Alternatively, the compounds of formula (I) of the invention wherein W is -NHC (O) N (R1) - and V is -C (O) -, -S (O) 2- or -C (R11) H- can be synthesized following the general procedure as described in Reaction Scheme 2.

REACTION SCHEME 2 (106) R2- N- C = 0 (109) Formula (I) The starting materials of the above reaction scheme are commercially available or can be prepared according to methods known to one skilled in the art or by methods described herein. In general, the compounds of the invention were prepared in the above reaction scheme as follows: Compound of the formula (I). To an agitated solution of the compound of the formula (106) (1 equivalent) in an anhydrous solvent such as dimethylformamide was added an isocyanate of the formula (109) (3 equivalent), and the mixture was then heated to 60-80 ° C for 4-24 hours. The mixture was concentrated in vacuo. Purification of the crude product through column chromatography or crystallization from a suitable solvent gave the compound of the formula (I) -NHC (O) N (R1) - and V is -C (O) -, -S (O) 2- or -C (R11) H-. Alternatively, the compounds of the formula (I) of the invention wherein W is -S (O) 2N (R1) - and V is -C (O) -, -S (O) 2- or -C (R11) H- can be synthesized following the general procedure as described in Reaction Scheme 3.

REACTION SCHEME 3 Formula (I) The starting materials of the above reaction scheme are commercially available or can be prepared according to methods known to one skilled in the art or by methods described herein. In general, the compounds of the invention were prepared in the above reaction scheme as follows: Compound of the formula (I): To a solution of the compound of the formula (106) (1 equivalent) in a solvent such as dichloromethane, acetonitrile or toluene was slowly added a compound of the formula (110) (1 equivalent) at 0 ° C. The resulting mixture was stirred at room temperature for 8-24 hours and then quenched with water. After removal of the solvent, the product was purified by chromatography to give the compound of the formula (I) wherein W is -S (O) 2N (R1) - and V is -C (O) -, - S (O) 2- or -C (R11) H-. Alternatively, the intermediate compound of the formula (106) can be prepared following the general procedure as described in Reaction Scheme 4.

REACTION SCHEME 4 (111) (105) (112) (106) Compound 112. The mixture of a pyridine compound of the formula (105) (1 equivalent) and the compound of the formula (III) (1.5 equivalents) in a suitable solvent was heated to reflux for 4-24 hours. A basic solution such as NaOH solution was added to the reaction mixture. The aqueous layer was extracted through an organic solvent such as dichloromethane or ethyl acetate. The combined organic phase was dried, then evaporated to dryness. The crude compound was purified by column chromatography or crystallization to give the compound of the formula (112). Compound 113. A solution of the compound of the formula of (112) obtained above was dissolved in a suitable solvent and the PG protecting group was removed under standard deprotection conditions such as hydrolysis or hydrogenation to obtain the amine of the formula (113). Compound 106. To a stirred solution of the amine of the formula (113) (1 equivalent) in a solvent such as dichloromethane or toluene was added the solution of a compound of the formula (102) (1 equivalent) in a solvent such as dichloromethane or toluene in the presence of a base such as triethylamine or Hunigs base. The resulting mixture was stirred at room temperature for a suitable period and then quenched with water. The organic phase was washed with H2O, brine, dried over and then concentrated in vacuo to give the product of the formula (106). Alternatively, the compounds of formula (I) of the invention wherein W is -C (O) NH- and V is -C (O) -, -S (O) 2- or -C (R11) H- is they can be synthesized following the general procedure as in Reaction Scheme 5. REACTION SCHEME 5 (117) The starting materials of the above reaction scheme are commercially available or can be prepared according to methods known to one skilled in the art or by methods described herein. In general, the compounds of the invention were prepared in the above reaction scheme as follows: Compound 116. To a stirred solution of the amine of the formula (114) (1 equivalent) in a solvent such as dichloromethane or toluene was added the solution of a compound of the formula (115) (1 equivalent) in a solvent such as dichloromethane or toluene in the presence of a base such as triethylamine or Hunigs base. The resulting mixture was stirred at room temperature for a suitable period and then quenched with water. The organic phase was washed with H2O, brine, dried over and then concentrated in vacuo to give the product of formula (116). Compound 117. A solution of the compound of the formula (116) obtained above was dissolved in a suitable solvent and the PG protecting group was removed under standard deprotection conditions such as hydrolysis or hydrogenation to obtain the amine of the formula (117). Compound 119. The mixture of a pyridine compound of the formula (117) (1 equivalent) and the compound of the formula (118) (1.5 equivalents) in a suitable solvent was heated to reflux for 4-24 hours. A basic solution such as NaOH solution was added to the reaction mixture. The aqueous layer was extracted through an organic solvent such as dichloromethane or ethyl acetate. The combined organic phase was dried, then evaporated to dryness. The crude compound was purified by column chromatography or crystallization to give the compound of the formula (119). Compound 120. The nitro compound of formula (119) can be reduced to the corresponding amine compound of formula (120) using a standard hydrogenation process known to one skilled in the art. Compound of the formula (I): Method A: To a stirred solution of the compound of the formula (120) (1 equivalent) in a solvent such as dichloromethane, acetonitrile or toluene was added the solution of a compound of the formula (121) (1 equivalent) in the presence of a base such as triethylamine or Hunigs base (1 equivalent) at 0 ° C. The resulting mixture was stirred at room temperature for 8-24 hours and then quenched with water. The organic phase was washed with H2O, brine, dried and then concentrated in vacuo to give the compound of the formula (I) wherein W is -C (O) NH- and V is -C (O) -, - S (O) 2- or -C (R11) H-. Method B: To a solution of the compound of the formula (122) (1 equivalent) in a solvent such as dichloromethane, toluene or THF is added a base such as triethylamine or Hunigs base (2.5 equivalents), followed by the addition of a coupling agent such as (3-dimethylaminopropyl) -ethyl carbodiimide (1.1 equivalents). The resulting mixture was stirred for 15 minutes to one hour and an amine of formula (120) (1.1 equivalents) was added. The mixture was stirred at room temperature for 8-24 hours, then washed with water, dried and concentrated in vacuo. Purification through column chromatography or crystallization from a suitable solvent gave the compound of the formula (I) wherein W is -C (O) NH- and V is -C (O) ~, -S (O ) 2- or -C (R11) H-. Alternatively, the compounds of the formula (I) of the invention wherein W is -NHC (O) NH- and V is ~ C (O) ~, -S (O) 2- or -C (R11) H- is they can be synthesized following the general procedure as described in Reaction Scheme 6.

REACTION SCHEME 6 (120) R2- N = C = 0 (123) Formula (I) The starting materials of the above reaction scheme are commercially available or can be prepared according to methods known to one skilled in the art or by methods described herein. In general, the compounds of the invention were prepared in the above reaction scheme as follows: Compound of the formula (I). To an agitated solution of the compound of the formula (120) (1 equivalent) in an anhydrous solvent such as dimethylformamide was added an isocyanate of the formula (123) (3 equivalent), and the mixture was then heated to 60-80 ° C. for 4-24 hours. The mixture was concentrated in vacuo. Purification of the crude product through column chromatography or crystallization from a suitable solvent gave the compound of formula (I) W is -NHC (O) NH- and V is -C (O) -, -S ( O) 2- or -C (R1) H-. Alternatively, the compounds of formula (1) of the invention wherein W is -S (O) 2NH- and V is -C (O) -, -S (O) 2- or -C (R11) H- is they can be synthesized following the general procedure as described in Reaction Scheme 7.

REACTION SCHEME 7 Formula (I) The starting materials of the above reaction scheme are commercially available or can be prepared according to methods known to one skilled in the art or by methods described herein. In general, the compounds of the invention were prepared in the above reaction scheme as follows: Compound of the formula (I): To a solution of the compound of the formula (120) (1 equivalent) in a solvent such as dichloromethane, acetonitrile or toluene was slowly added the solution of the compound of the formula (124) (1 equivalent) at 0 ° C. The resulting mixture was stirred at room temperature for 8-24 hours and then quenched with water. After removal of the solvent, the product was purified by chromatography to give the compound of the formula (I) W is -S (O) 2 NH- and V is -C (O) -, -S (O) 2 - or -C (R11) H-. Alternatively, the compounds of the formula (I) of the invention wherein W is -NH- and V is -C (O) -, -S (O) 2- or -C (R11) H- can be synthesized following the general procedure as described in the Reaction Scheme 8.

REACTION SCHEME 8 Formula (I) The reaction of the amine (120) with an appropriate aldehyde in the presence of a reducing agent such as, but not limited to sodium borohydride in a solvent such as, but not limited to, ethanol produces the compound of the formula (I) (W = -NH-). Alternatively, the compounds of the formula (I) of the invention wherein W is -O- and V is -C (O) -, -S (O) 2- or -C (R11) H- can be synthesized following the general procedure as described in Reaction Scheme 9.

REACTION SCHEME 9 (125) Formula (I) Reaction of the amine (120) with sodium nitrite in the presence of a Lewis acid such as, but not limited to boron trifluoride diethyl etherate in a solvent such as, but not limited to N, N-dimethylformamide, generates a Diazonium intermediate that can be converted to the acetoxy compound (125) by quenching the above reaction mixture with acetic anhydride. Hydrolysis of the ester compound (125) in the presence of a base such as, but not limited to, sodium hydroxide, produces a hydroxy intermediate that can be converted to the desired product of the formula (I) (W = -O -) with an appropriate R2X in the presence of a base such as, but not limited to, sodium hydride in a solvent such as, but not limited to tetrahydrofuran or N, N-dimethylformamide. Alternatively, the compounds of the formula (1) of the invention wherein W is -S (O) t- (where t is 0.1 or 2) and V is -C (O) -, -S (O) 2- or -C (R) H- can be synthesized following the general procedure as described in Reaction Scheme 10.

REACTION SCHEME 10 (126) (127) The reaction of the amine (120) with sodium nitrite in the presence of a Lewis acid such as, but not limited to diethyl boron trifluoride etherate in a solvent such as, but not limited to N, N-dimethylformamide, generates a diazonium intermediate that can be converted to the compound (126) through the extinction of the above reaction mixture with acetyl sulfide. Hydrolysis of the thioester compound (126) in the presence of a base such as, but not limited to, sodium hydroxide, produces an intermediate thiol which can be converted to the desired sulfide product (127) (formula (I), W = -S-) with an appropriate R2X in the presence of a base such as, but not limited to, sodium hydride in a solvent such as, but not limited to tetrahydrofuran, 1,4-dioxane or N, N-dimethylformamide. Treatment of the compound (127) with an oxidizing agent such as, but not limited to, sodium periodate in a mixture of methanol and water gave the sulfoxide compound (128) (formula (I), W = -S (O) -). Alternatively, the sulfide compound (127) can be treated with trifluoroacetic anhydride and acid peroxide in a solvent such as, but not limited to, dichloromethane to give the sulfone product (129) (formula (I), W = -S (O )2-). Alternatively, the compounds of formula (1) of the invention wherein W is -NHS (O) 2- and V is -C (O) -, -S (O) 2- or -C (R11) H- is they can be synthesized following the general procedure as described in Reaction Scheme 11.

REACTION SCHEME 11 (130) (131) Formula (I) The reaction of the pyridyl sulfonyl chloride (130) with an appropriate amine (R2NH2) in the presence of a base such as, but not limited to, triethylamine and a catalytic amount of N, N-dimethylformamide in a solvent such as, but not limited to dichloromethane produces the sulfonamide compound (131). Treatment of (131) with a piperazine compound (104) in the presence of a base such as, but not limited to, potassium carbonate and tetrabutylammonium bromide in a solvent such as, but not limited to, dioxane leads to the formation of the compound of the formula (I) (W = -NHS (O) 2-). Alternatively, the chloride or bromide compound (131, X = Cl or Br) can be reacted with a piperazine compound (104) under Buchwaid amination reaction conditions (J. Org. Chem. 1997, 62, 4197) to form the desired product of the formula (I). Although anyone skilled in the art is capable of preparing the compounds of the invention in accordance with the general techniques described above, more specific details of synthetic techniques for compounds of the invention are provided elsewhere in this specification for convenience. Again, all the reactants and reaction conditions employed in the synthesis are well known to those of ordinary skill in the art and are available from commercially normal sources. The synthesis of the compounds of this invention are illustrated by, but are not limited to the following examples.

PREPARATION 1 SYNTHESIS OF f4- (5-AMINOPIRIDIN-2-IL) PIPERAZIN-1 -IL1- (2- TRIFLUOROMETILFENIL) METANONE A. A solution of 2-chloro-5-nitropyridine (1.58 g, 10.0 mmol) in 15 mL of DMF was treated with 1-Boc-piperazine (1.96 g, . 5 mmoles) in the presence of 3 ml of DBU and Bu4NI (0.185 g, 0.5 mmoles) at 80 ° C for 18 hours. The reaction mixture was diluted with ethyl acetate at 25 ° C. The organic phase was washed with H2O, saturated NaCl, dried over MgSO4 and then concentrated in vacuo to give 4- (5-nitropyridin-2-yl) piperazine-1-carboxylic acid tert -butyl ester as a yellow solid, which was used for the reaction of the next step without further purification. MS (ES +) m / z 309.4 (M + 1). B. 4- (5-Nitropyridin-2-yl) piperazine-1-carboxylic acid tert -butyl ester (3.08 g, 10 mmol) with 15% TFA in 50 ml of dichloromethane was treated. ° C for 1 hour. The solution was concentrated in vacuo to provide 1- (5-nitropyridin-2-yl) piperazine as a brown solid (2.0 g, 96% yield in two steps). MS (ES +) m / z 209.4 (M + 1). C. 2- (Trifluoromethyl) benzoyl chloride (2.0 mL, 11.0 mmol) was slowly added to a solution of 1- (5-n-itropyridin-2-yl) piperazine (2.0 g, 10 mmol) and diisopropylethylamine (3.5 mL). , 20 mmol) in 15 ml of Dichloromethane at 0 ° C under argon. The mixture was then stirred at 25 ° C for 2 hours. The reaction was quenched with H2O. The aqueous phase was extracted with ethyl acetate. The organic phase was washed with saturated NaCl and dried over anhydrous MgSO 4. The organic phase was concentrated and then purified by column chromatography to yield [4- (5-nitropyridin-2-yl) piperazin-1-yl] ~ (2-tpfluoromethylphenyl) methanone as a yellow solid (1.55 g, 41% yield). MS (ES +) m / z 381.1 (M + 1). D. A mixture of [4- (5-nitropyridin-2-yl) piperazin-1-yl] - (2-trifluoromethylphenyl) -methanone (0.15 g, 0.4 mmol) and Pd-C (76 mg) in 5 ml of THF and 5 ml of MeOH were exposed to a hydrogen atmosphere at 25 ° C for 2 hours. The reaction mixture was filtered and the solution was concentrated in vacuo to provide the title compound as a dark purple solid (0.121 g, 86% yield). MS (ES +) m / z 351.0 (M + 1).

EXAMPLE 1 SYNTHESIS OF 1 -PENTIL-3-f 6-r4- (2-TRIFLUOROMETILBENZOIL) PIPERAZIN-1-IL1PIRIDIN-3-IDUREA Pentylisocyanate (0.034 g, 0.30 mmol) was added slowly to a solution of [4- (5-aminopyridin-2-yl) piperazin-1-yl] - (2-trifluoromethylphenyl) methanone (0.050 g, 0.15 mmoles) in 2 ml of dichloromethane at 0 ° C. The mixture was stirred at 25 ° C for 16 hours. After removal of dichloromethane, the residue was purified by column chromatography to yield the title compound as a light purple solid (24.5 mg, 35% yield). 1 H NMR (300 MHz, CDCl 3) d 7.99, 7.71, 7.58, 7.33, 6.62, 6.28, 4.69, 3.91, 3.58, 3.43, 3.28, 3.18, 1.45, 1.27, 0.88. MS (ES +) m / z 464.2 (M + 1). The following compounds were synthesized similarly as described in Example 1.

EXAMPLE 1.1 1-Butyl-3-. { 6- [4- (2-trifluoromethylbenzoyl) piperazin-1-yl] -pyridin-3-yl} urea; 1 H NMR (CDCl 3) d 7.98, 7.71, 7.63-7.51, 7.33, 6.62, 6.44, 4.79, 4.30, 3.97-3.85, 3.57, 3.44-3.41, 3.30-3.27, 3.22-3.16, 1.49-0.83. MS (ES +) m / z 450.3 (M + 1).

EXAMPLE 1.2 1-Fenethil-3-. { 6- [4- (2-trifluoromethylbenzoyl) piperazin-1-yl] pyridin-3-yl} urea; 1 H NMR (300 MHz, CDCl 3) d 9.09, 8.23, 8.11, 7.79, 7.72-7.58, 7.46-7.17, 6.60, 4.25-4.10, 3.95-3.85, 3.85-3.15, 2.87. MS (ES +) m / z 498.4 (M + 1).

EXAMPLE 1.3 1 - . 1 -Be nci I -3. { 6- [4- (2-trifluoromethyl benzoyl) piperazin-1-i I] -pyrid i n -3-yl} urea; 1 H NMR (300 MHz, CDCl 3) d 9.21, 8.18, 7.83, 7.73, 7.70-7.50, 7.15-7.05, 6.39, 4.27, 4.15-3.95, 3.85-3.65, 3.55-3.20. MS (ES +) m / z 484.1 (M + 1).

EXAMPLE 1.4 1- [6- (4-Cyclohexanedcarbonylpiperazin-1-yl) pyridin-3-yl] -3-pentylurea; 1 H NMR (300 MHz, CDCl 3) d 8.01, 7.61, 6.63, 4.78, 3.73-3.24, 3.21-3.16, 2.54-2.47, 1.83-1.77, 1.72-1.32, 1.30-1.25, 0.91-0.86. MS (ES +) m / z 401.9 (M).

EXAMPLE 1.5 1- [6- (4-Cyclopentanecarbonylpiperazin-1-yl) pyridin-3-yl] -3-pentylurea; H NMR (CDCI3) d 8.04, 7.58, 6.65, 4.53, 3.78-3.45, 3.25-3.19, 2.97-2.94, 1.89-1.74, 1.55-1.47, 1.34-1.26, 0.92-0.89. MS (ES +) m / z 388.3 (M + 1).

EXAMPLE 1.6 1-Pentil-3-. { 6- [4- (pyridine-4-carbonyl) piperazin-1-yl] -pyridin-3-yl} urea; 1 H NMR (300 MHz, CDCl 3) d 8.71, 8.02, 7.62-7.6, 7.16-7.1, 6.62-6.61, 6.22, 4.62, 3.85-3.82, 3.62-3.45, 3.23-3.18, 1.46-1.4, 1.39-1.22, 0.88 . MS (ES +) m / z 397.0 (M + 1).

EXAMPLE 1.7 1-Pentil-3-. { 6- [4- (pyridine-2-carbonyl) piperazin-1-yl] -pyridin-3-yl} urea; 1 H NMR (300 MHz, CDCl 3) d 8.6, 8.00, 7.83, 7.80, 7.78-7.65, 7.38-7.24, 6.60, 6.50, 4.84, 3.93, 3.75, 3.60, 3.53, 3.18, 1.75, 1.47, 1.34-1.23, 0.90 . MS (ES +) m / z 397.0 (M + 1).

EXAMPLE 1.8 1- (4-Fluoro-benzyl) -3-. { 6- [4- (2-trifluoromethyl-benzoyl) -piperazin-1-yl] -pyridin-3-yl} -urea; 1 H NMR (300 MHz DMSO-d 6) d 9.25, 8.28, 7.85, 7.77, 7.67, 7.55, 7.31, 7.23, 7.13, 7.06, 4.28, 3.66, 3.24.

EXAMPLE 2 SYNTHESIS OF. { 6-r4- (2-TRIFLUOROMETILBENZOIL) PIPERAZIN-1-IL1 PIRIDIN-3-IDAMIDE OF PENTAN-1-SULPHONIC ACID 1-Pentanesulfonyl chloride (0.034 g, 0.30 mmol) was added slowly to a solution of [4- (5-aminopyridin-2-yl) piperazin-1-yl] - (2-trifluoromethyl-phenyl) methanone in 2 ml of pyridine. 0 ° C. The mixture was stirred at 25 ° C for 16 hours and then diluted with dichloromethane. The organic phase was washed with water and saturated NaCl solution, dried over anhydrous MgSO 4. After removal of dichloromethane, the product was purified by column chromatography to give the title compound in 4% yield (2.7 mg). H NMR (300 MHz, CDCI3) d 8.02, 7.87, 7.74, 7.61, 7.36, 6.94, 4.47, 4.11, 3.87, 3.68, 3.60, 3.42, 2.99, 1.77, 1.32, 0.88. MS (ES +) m / z 485.2 (M + 1). The following were synthesized similarly as described in Example 2.

EXAMPLE 2.1 . { 6- [4- (2-trifluoromethylbezoyl}. Piperazin-1-yl] pyridin-3-yl}. Butan-1-sulfonic acid amide; 1 H NMR (300 MHz, CDCl 3) d 8.02, 7.72, 7.61. -7.50, 7.35, 6.63, 6.24, 3.95-3.87, 3.66-3.60, 3.50-3.47, 3.30-3.28, 3.03-2.98, 1.84-1.79, 1.44 1.39, 0.93 MS (ES +) m / z 471.2 (M + 1).

EXAMPLE 2.2 . { 6- [4- (2-trifluoromethylbenzoyl) -piperazin-1-yl] pyridin-3-yl} amide of Hexan-1-sulfonic acid: 1 H NMR (300 MHz, CDCl 3) d 8.02, 7.73, 7.50-7.62, 7.36, 6.62, 6.02, 3.81-4.02, 3.59-3.76, 3.50, 3.31, 3.00, 1.77-1.88, 1.50-1.71, 1.20-1.46, 0.86. MS (ES +) m / z 499 (M + 1).

EXAMPLE 2.3 . { 6- [4- (2-bromobenzoyl) piperazin-1-yl] pyridin-3-yl} pentan-1-suphonic acid amide; 8.00, 7.58, 7.50, 7.35, 7.30-7.20, 6.64, 6.38, 4. 05-3.95, 3.95-3.80, 3.75-3.25, 3.05-2.95, 1.90-1.75, 1.59, 1.45-1.25, 0.90. MS (ES +) m / z 494.9 (M), 496.0 (M).

EXAMPLE 2.4 . { 6- [4- (2,5-dichlorobenzoyl) piperazin-1-yl] pyridin-3-yl} hexan-1-sulfonic acid amide; 1 H NMR (CDCl 3) d 8.02, 7.58-7.45, 7.4-7.22, 6.73, 4.01-3.8, 3.65-3.24, 3.04-2.98, 1.9-1.78, 1.65-1.44, 1.42-1.2, 0.88. MS (ES +) m / z 499.2 (M).

EXAMPLE 2.5 . { 6- [4- (2,5-dichlorobenzoyl) piperazin-1-yl] pyridin-3-yl} pentane-1-sulfonic acid amide; 1 H NMR (CDCl 3) d 8.07, 7.58, 7.39-7.31, 6.62, 6.15, 3.98-3.82, 3.72-3.51, 3.48-3.35, 3.00, 1.89-1.80, 1.42-1.29, 0.90. MS (ES +) m / z 484.8 (M).

EXAMPLE 2.6 . { 6- [4 (naphthalene-1-carbonyl) piperazin-1-yl] pyridin-3-yl} hexan-1-sulfonic acid amide; 1H NMR (CDCl3) d 8.02, 7.92-7.80, 7.48-7.4, 6.79, 6.02, 4.18-3.98, 3.68-3.64, 3.48-3.25, 3.03-2.98, 1.9-1.88, 1.62-1.44, 1.42-1.22, 0.88. MS (ES +) m / z 481. 2 (M + 1).

EXAMPLE 2.7 . { 6- [4- (naphthalene-1-carbonyl) -piperazin-1-yl] pyridin-3-yl} pentane-1-sulfonic acid amide; 1H NMR (300 MHz, CDCl3) d 8.01, 7.97-7.81, 7.56-7.41, 6.61, 6.08, 4.18-3.95, 3.78-3.62, 3.48-3.25, 2.98, 1.84-1.78, 1.39-1.26, 0.92. MS (ES +) m / z 466.9 (M).

EXAMPLE 3 SYNTHESIS OF 3-PHENYL-N-f6-r4- (2-TRIFLUOROMETILBENZOIL) PIPERAZIN-1-IL1PIRIDIN-3-IDPROPIONAMIDE (2-trifluoromethylphenyl) methanone (0.070 g, 0.20 mmol) - to a solution of [4- (5-aminopyridin-2-yl) piperazin-1-yl] hydrocinnamoyl (0.037 ml, 0.25 mmol) was added in dichloromethane in 2 ml of dichloromethane and 0.087 ml of diisopropylethylamine at 0 ° C. The mixture was stirred at 25 ° C for 16 hours and then diluted with dichloromethane. The organic phase was washed with water and saturated NaCl solution, dried over anhydrous MgSO. After removal of dichloromethane, the title compound was obtained with a 7.6% yield (7.3 mg) after column purification. 1 H NMR (300 MHz, CDCl 3) d 7.99, 7.80, 7.71, 7.56, 7.27, 6.91, 6.61, 3.91, 3.57, 3.43, 3.27, 3.04, 2.64. MS (ES +) m / z 483.0 (M + 1). The following were synthesized similarly as described in Example 3.

EXAMPLE 3.1 . { 6- [4- (2-trifluoromethylbenzoyl) -piperazin-1-yl] pyridin-3-yl} 4-Methy1-pentanoic acid amide; 1 H NMR (CDCl 3) d 8.10, 7.88, 7.70, 7.68-7.52, 7.35, 6.98, 6.63, 3.92-3.89, 3.57, 3.43-3.42, 3.27, 2.34, 1.64-0.87. MS (ES +) m / z 448.8 (M + 1).

EXAMPLE 3.2 . { 6- [4- (2-trifluoromethylbenzoyl) piperazin-1-yl] pryidin-3-yl} hexanoic acid amide; 1 H NMR (300 MHz, CDCl 3) d 9.48, 8.56-8.37, 8.00, 7.78, 7.75-7.54, 7.38, 6.95, 4.18-3.34, 2.26, 1.68-1.54, 1.37-1.20, 0.88. MS (ES +) m / z 449.0 (M + 1).

EXAMPLE 3.3 . { 6- [4- (2-trifluoromethyl-benzoyl) piperazin-1-yl] pyridin-3-yl} heptanoic acid amide; 1 H NMR (300 MHz, CDCl 3) d 8.16, 7.95, 7.76, 7.62-7.48, 7.35, 7.18, 6.60, 4.02-3.80, 3.62-3.25, 2.34, 1.80-1.45, 1.42-1.18, 0.97. MS (ES +) m / z 462.9 (M + 1).

EXAMPLE 3.4 . { 6- [4- (2,5-dichlorobenzoyl) piperazin-1-yl] pyridin-3-yl} a flow of heptanoic acid; 1 H NMR (300 MHz, CDCl 3) d 8.16, 7.92, 7.34, 6.64, 3.80-4.00, 3.25-3.63, 2.37, 1.72, 1.20-1.42, 0.84. MS (ES +) m / z 463.2 (M + 1).

EXAMPLE 3.5 . { 6- [4- (naphthalene-1-carbonyl) piperazin-1-yl] pyridin-3-yl} hexanoic acid amide; 1 H NMR (300 MHz, CDCl 3) d 8.10, 7.89, 7.40-7.59, 7.11, 6.60, 3.91-4.19, 3.60-3.79, 3.20-3.43, 2.35, 1.50-1.78, 1.20-1.40, 0.87. MS (ES +) m / z 431.4 (M + 1).

EXAMPLE 3.6 . { 6- [4- (2,5-dichlorobenzoyl) piperazin-1-yl] pyridin-3-yl} hexanoic acid amide; 1 H NMR (300 MHz, CDCl 3) d 8. 17, 7.93, 7.34, 6.63, 3.81-4.00, 3.24-3.62, 2.37, 1.74, 1.20-1.40, 0.88. MS (ES +) m / z 449.2 (M + 1).

EXAMPLE 3.7 . { 6- [4- (naphthalene-1-carbonyl) piperazin-1-yl] pyridin-3-yl} heptanoic acid amide; 1 H NMR (300 MHz, CDCl 3) d 8.09, 7.87, 7.40-7.58, 7.10, 6.60, 3.91-4.19, 3.59-3.80, 3.21-3.42, 2.35, 1.50-1.79, 1.20-1.40, 0.86. MS (ES +) m / z 445.4 (M + 1).

EXAMPLE 3.8 [Cyclohexanecarboxylic acid 6- (4-cyclohexancarbonyl) piperazin-1-yl) pyridin-3-yl] -amide; 1 H NMR (300 MHz, CDCl 3) d 8.13, 7.91, 7.32, 6.62, 3.74-3.40, 2.51, 2.24, 1.97-1.72, 1.69-1.51, 1.32-1.25. MS (ES +) m / z 399.3 (M + 1).

EXAMPLE 3.9 . { 6- [4- (2-trifluoromethylbenzoyl) piperazin-1-yl] pyridin-3-yl} cyclohexanecarboxylic acid amide; 1H NMR (300 MHz, CDCl3) d 8.03, 7.82, 7.64, 7.50-7.40, 7.25, 6.57, 3.96-3.82, 3.60-3.50, 3.45-3.35, 3.30-3.20, 2.30-2.15, 2.00-1.60, 1.60-1.40 , 1.35-1.20. MS (ES +) m / z 399.3 (M + 1).

Example 4 Synthesis of (2- cyclopropylethyl) -amide 5-bromo- 6-r4- (5-FLUORO-2- TRIFLUOROMETILBENZOIDPIPERAZIN-1 -I 1- pyridin-3-SULFONIC A. To a stirred solution of 3-bromo-2-chloropyridine-5-sulfonyl chloride (1,000 g, 3437 mmol) in 20.0 ml of dichloromethane was added 2-cyclopropylethylamine (0.440 g)., 5.167 mmoles), triethylamine (0.72 ml, 5.167 mmoles) and 3 three drops of DMF. The resulting mixture was stirred at room temperature for 24 hours and then concentrated in vacuo. 20.0 ml of diethyl ether were added to the crude compound and the solution was filtered. The solid obtained was used without further purification (0.432 g, 37%). 1 H NMR (300 MHz, CDCl 3) d 8.760, 8.34, 4.74-4.70, 3.15-3.08, 1.45-1.39, 0.64-0.53, 0.48-0.42, 0.07-0.02. B. To a stirred solution of 5-bromo-6-chloro-pyridine-3-sulfonic acid (2-cyclopropylethyl) (0.432 g, 1.272 mmol) in 15.0 mL of dioxane was added (5-fluoro-2-trifluoromethylphenyl) ) piperazin-1-yl-methanone (0.386 g, 1399 mmol), potassium carbonate (0.703 g, 5080 mmol) and tetrabutylammonium bromide (0.042 g, 0.130 mmol). The resulting mixture was stirred at reflux for 48 hours, filtered and then concentrated in vacuo. The crude product was purified through column chromatography, eluting with a solvent gradient of 35% ethyl acetate and 65% hexane to give a yield of the desired product (0.235 g, 32%). H NMR (300 MHz, CDCI3) d 8.59-8.58, 8.16-8.15, 7.74-7.69, 7.24-7.18, 7.08-7.04, 4.97-4.93, 4.03-3.85, 3.60-3.55, 3.43-3.33, 3.07-2.99, 1.41 -1.34, 0.60-0.53, 0.43-0.37, 0.025-0.015. 3C NMR (75 MHz, CDCI3) 2 166.1, 162.6, 145.4, 141.1, 130.5, 129.6, 129.5, 116.7, 116.4, 114.9, 114.7, 110.3, 48.8, 48.6, 46.9, 43.5, 41.6, 34.5, 8.2, 4.2. MS (ES +) m / z 581 (M).

EXAMPLE 5 SYNTHESIS OF (2-CICLOPROPYLTHYL) ACID AMID 6-r4- (5- FLUORO-2-TRIFLUOROMETILBENZOIL) PIPERAZIN-1- IL1 PYRIDINE-3- SULPHONIC To a stirred solution. 5-Bromo-6- [4- (5-fluoro-2-trifluoromethyl-benzoyl) -piperazin-1-yl] -pyridine-3-sulfonic acid (2-cyclopropylethyl) -amide (0.100 g, 0.173 mmol) in 5.0 mL of methanol Pd / C (0.050 g, 12 moles) was added The mixture was placed under a hydrogen atmosphere for 24 hours.The reaction mixture was filtered through celite and concentrated in vacuo.The crude product was purified through flash chromatography. column, eluting with a solvent gradient of 35% ethyl acetate and 65% hexane to yield the desired product (0.020 g, 24%). 1 H NMR (300 MHz, CDCl 3) d 8.58-8.57, 7.87-7.83, 7.76-7.71, 7.26-7.23, 7.08-7.04, 6.65-6.62, 4.60-4.56, 4.00-3.93, 3.86-3.64, 3.32-3.28, 3.04-2.97, 1.40-1.33, 0.59-0.53, 0.43-0.37, 0.025- 0.008, 13 C NMR (75 MHz, CDCl 3) d 166.1, 162. 6, 159.7, 148.2, 136.7, 129.7, 125.1, 124.7, 116. 8, 116.5, 114.9, 114. 7, 105.8, 46.5, 44.3, 44.2, 43.4, 41.4, 34.4, 8.2, 4.2. MS (ES +) m / z 501 (M + 1).

EXAMPLE 6 MEASUREMENT OF THE DESATURASE INHIBITION ACTIVITY OF ESTEAROILO-COA FROM A TEST COMPOUND USING MOUSE LIVESTER MICROSOMES The identification of the compounds of the invention as SCD inhibitors was easily accomplished using SCD enzymes and the microsomal assay procedure described in Brownie et al., PCT published patent application, WO 01/62954.

Preparation of Mouse Liver Microsomes: Male ICR mice were sacrificed, with a low-fat, high-carbohydrate diet, under anesthesia with haloten light (15% in mineral oil) through exsanguination during periods of high enzyme activity. The livers were immediately rinsed with cold 9% NaCl solution, weighed and shredded with scissors. All procedures were carried out at 4 ° C, unless otherwise specified. The livers were homogenized in a solution (1: 3 w / v) containing 0.25M sucrose, 62 mM potassium pH buffer (pH 7.0), 0.15M KCl, 1.5 mM N-acetylcysteine, 5 mM MgCl2, and 0.1 mM EDTA using 4 traces of a Potter-Elvehjem tissue homogenizer. The homogenate was centrifuged at 10,400 x x portions for 20 minutes to eliminate the mitochondria and cell waste. The supernatant was filtered through a three layer gauze and centrifuged at 105,000 portions x g for 60 minutes. The microsomal pellet was slightly resuspended in the same homogenization solution with a small glass / teflon homogenate and stored at -70 ° C. The absence of mitochondrial contamination was evaluated enzymatically. The concentration of the protein was measured using bovine serum albumin as the standard.

Incubation of Mouse Liver Microsomes with Test Compounds: Reactions were initiated through the addition of 2 ml of microsomal protein in pre-incubator tubes containing 0.20 μCi of the substrate fatty acid (1-14C palmitic acid) at a concentration final 33.3 μM in 1.5 ml of homogenization solution, containing 42 mM NaF, 0.33 mM niacinamide, 1.6 mM ATP, 1.0 mM NADH, 0.1 mM coenzyme A and a concentration of 10 μN of the test compound. The tubes were vigorously vortexed and after 15 minutes incubation in a shaking water bath (37 ° C), the reactions were stopped and the fatty acids were analyzed. The fatty acids were analyzed as follows: The reaction mixture was saponified with 10% KOH to obtain free fatty acids that were also mutilated using BF3 in methanol. The methyl esters of the fatty acid were analyzed through high performance liquid chromatography (HPLC) using a Hewlett Packard 1090 Series II chromatograph, equipped with a diode test detector set at 205 nm, a radioisotope reactor (Model 171, Beckman, CA) with a solid scintillation cartridge (97% efficiency by 14C-detection) and a reverse phase ODS column (C-18) Beckman (250 mm x 4.6 mm id; particle size 5 μm) attached to a pre-column with an insert μBondapak C-18 (Beckman). The fatty acid methyl esters were separated with acetonitrile / water (95: 5 v: v) at a flow rate of 1 ml / minute and identified by comparison with authentic standards. Alternatively, the fatty acid methyl esters can be analyzed through capillary column gas chromatography (GC) or Thin Layer Chromatography (TLC). Those skilled in the art are aware of a variety of modifications to this assay that may be useful for measuring the inhibition of stearoyl-CoA desaturase activity in microsomes through the test compounds. Representative compounds of the invention showed activity as SCD inhibitors when tested in this assay. The activity was defined in terms of percent SCD enzyme activity remaining at the desired concentration of the test compound. All patents of E.U.A. publications of U.S. patent applications, foreign patents, foreign patent applications, and non-patent publications referred to in this specification and / or listed in the Application Data Sheet are hereby incorporated by reference, in their entirety. From the foregoing, it will be appreciated that, although the specific embodiments of the invention have been described herein for purposes of illustration, various modifications may be made without departing from the spirit and scope of the invention. Accordingly, the invention is not limited except by the appended claims.

Claims

1. A method for inhibiting human stearoyl-CoA desaturase (hSCD) activity comprising contacting a source of hSCD with a compound of formula (I): wherein: x and y are each independently 1, 2 or 3; W is -O-, -N (R1) -, -C (R1) 2-, -C (O) -, -OC (O) -, -S (O); (where t is 0, 1 or 2), -N (R1) S (O) t- (where t is 1 or 2), -S (O) 2N (R1) -, -C (O) N (R1) -, -C (S) N (R1) -, -OS (O) 2N (R1) -, -C (O) N (R1) -; -OC (S) N (R1) -, -N (R1) C (O) N (R1) - or -N (R1) C (S) N (R1) -; V is -C (O) -, -C (S) -, -C (O) N (R1) --C (O) O-, -C (S) O-, -S (O) t- ( wherein t is 1 or 2), -S (O) tN (R1) - (where t is 1 or 2) or -C (R11) H; each R1 is independently selected from the group consisting of hydrogen, alkyl of 1 to 6 carbon atoms, hydroxyalkyl of 2 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms and aralkyl of 7 to 19 carbon atoms; R2 is selected from the group consisting of alkyl of 1 to 12 carbon atoms, alkenyl of 2 to 12 carbon atoms, hydroxyalkyl of 2 to 12 carbon atoms, hydroxyalkenyl of 2 to 12 carbon atoms, alkoxyalkyl of 2 to 12 atoms carbon, cycloalkyl of 3 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms, aryl, aralkyl of 7 to 12 carbon atoms, heterocyclyl of 3 to 12 carbon atoms, heterocyclylalkyl of 3 to 12 carbon atoms, heteroaryl of 1 to 12 carbon atoms, and heteroarylalkyl of 3 to 12 carbon atoms; or R2 is a multi-ring structure having from 2 to 4 rings, wherein the rings are independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl and wherein some or all of the rings may be fused together with the other; R3 is selected from the group consisting of alkyl of 1 to 12 carbon atoms, alkenyl of 2 to 12 carbon atoms, hydroxyalkyl of 2 to 12 carbon atoms, hydroxyalkenyl of 2 to 12 carbon atoms, alkoxyalkyl of 2 to 12 carbon atoms. carbon, cycloalkyl of 3 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms, aryl, aralkyl of 7 to 12 carbon atoms, heterocyclyl of 3 to 12 carbon atoms, heterocyclylalkyl of 3 to 12 carbon atoms, heteroaryl from 1 to 12 carbon atoms and heteroarylalkyl of 3 to 12 carbon atoms; or R3 is a multi-ring structure having from 2 to 4 rings, wherein the rings are independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl and wherein some or all of the rings may be fused together with the other; R4, R5 and R6 are each independently selected from hydrogen, fluoro, chloro, methyl, methoxy, trifluoromethyl, cyano, nitro or -N (R3) 2; R7, R7a, R8, R8a, R9, R9a, R10 and R10a are each independently selected from hydrogen or alkyl of 1 to 3 carbon atoms; or R7 and R7a together, or R8 and R8a together, or R9 and R9a or R10 and R10a together are an oxo group, provided that when V is -C (O) -, R7 and R7a together or R8 and R8a together do not form a oxo group, while the rest of R7, R7a, R8, R8a, R9, R9a, R10 and R10a each is independently selected from hydrogen, or alkyl of 1 to 3 carbon atoms; or one of R10 and R10a, R7, and R7a together with one of R8, R8a, R9 and R9a form an alkylene bridge, while the remainder of R10 and R10a, R7, R7a, R8, R8a, R9, and R9a each it is independently selected from hydrogen or alkyl of 1 to 3 carbon atoms; R11 is hydrogen or alkyl of 1 to 3 carbon atoms; and each R13 is independently selected from hydrogen or alkyl of 1 to 6 carbon atoms; a stereoisomer, enantiomer or tautomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable composition thereof or a prodrug thereof.

2. A method for treating a disease or condition mediated by stearoyl-CoA desaturase (SCD) in a mammal, wherein the method comprises administering to the mammal in need thereof a therapeutically effective amount of a compound of the formula (I): wherein: x and y are each independently 1, 2 or 3; W is -O-, -N (R1) -, -C (R1) 2-, -C (O) -, -OC (O) -, -S (O), -; (where t is 0, 1 or 2), -N (R1) S (O) t- (where t is 1 or 2), -S (O) 2N (R1) -, -C (O) N (R1) -, -C (S) N (R1) -, -OS (O) 2N (R1) -, -C (O) N (R1) -; -OC (S) N (R1) -, -N (R1) C (O) N (R1) - or -N (R1) C (S) N (R1) -; V is -C (O) -, -C (S) -, -C (O) N (R1) --C (O) O-, -C (S) O-, -S (O) t- ( wherein t is 1 or 2), -S (O) tN (R1) - (where t is 1 or 2) or -C (R11) H; each R1 is independently selected from the group consisting of hydrogen, alkyl of 1 to 6 carbon atoms, hydroxyalkyl of 2 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms and aralkyl of 7 to 19 carbon atoms; R2 is selected from the group consisting of alkyl of 1 to 12 carbon atoms, alkenyl of 2 to 12 carbon atoms, hydroxyalkyl of 2 to 12 carbon atoms, hydroxyalkenyl of 2 to 12 carbon atoms, alkoxyalkyl of 2 to 12 atoms carbon, cycloalkyl of 3 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms, aryl, aralkyl of 7 to 12 carbon atoms, heterocyclyl of 3 to 12 carbon atoms, heterocyclylalkyl of 3 to 12 carbon atoms, heteroaryl of 1 to 12 carbon atoms, and heteroarylalkyl of 3 to 12 carbon atoms; or R2 is a multi-ring structure having from 2 to 4 rings, wherein the rings are independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl and wherein some or all of the rings may be fused together with the other; R3 is selected from the group consisting of alkyl of 1 to 12 carbon atoms, alkenyl of 2 to 12 carbon atoms, hydroxyalkyl of 2 to 12 carbon atoms, hydroxyalkenyl of 2 to 12 carbon atoms, alkoxyalkyl of 2 to 12 carbon atoms, cycloalkyl of 3 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms, aryl, aralkyl of 7 to 12 carbon atoms, heterocyclyl of 3 to 12 carbon atoms carbon, heterocyclylalkyl from 3 to 12 carbon atoms, heteroaryl of 1 to 12 carbon atoms and heteroarylalkyl of 3 to 12 carbon atoms; or R3 is a multi-ring structure having from 2 to 4 rings, wherein the rings are independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl and wherein some or all of the rings may be fused together with the other; R4, R5 and R6 are each independently selected from hydrogen, fluoro, chloro, methyl, methoxy, trifluoromethyl, cyano, nitro or -N (R13) 2; R7, R7a, R8, R8a, R9, R9a, R10 and R10a are each independently selected from hydrogen or alkyl of 1 to 3 carbon atoms; or R7 and R7a together, or R8 and R3a together, or R9 and R9a or R10 and R10a together are an oxo group, provided that when V is -C (O) -, R7 and R7a together or R8 and R8a together do not form a oxo group, while the rest of R7, R7a, R8, R8a, R9, R9a, R10 and R10a each is independently selected from hydrogen, or alkyl of 1 to 3 carbon atoms; or one of R10 and R10a, R7, and R7a together with one of R8, R8a, R9 and R9a form an alkylene bridge, while the remainder of R10 and R10a, R7, R7a, R8, R8a, R9, and R9a each it is independently selected from hydrogen or alkyl of 1 to 3 carbon atoms; R11 is hydrogen or alkyl of 1 to 3 carbon atoms; and each R13 is independently selected from hydrogen or alkyl of 1 to 6 carbon atoms; a stereoisomer, enantiomer or tautomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable composition thereof or a prodrug thereof.

3. The method according to claim 2, wherein the mammal is a human being.

The method according to claim 3, wherein the disease or condition is selected from the group consisting of Type II diabetes, fatty liver, non-alcoholic steatohepatitis, impaired glucose tolerance, insulin resistance, obesity, dyslipidemia and syndrome metabolic and or any combination of these.

5. The method according to claim 4, where the disease or condition is Type II diabetes.

6. The method according to claim 4, wherein the disease or condition is obesity.

The method according to claim 4, wherein the disease or condition is metabolic syndrome.

The method according to claim 4, wherein the disease or condition is fatty liver.

The method according to claim 4, wherein the disease or condition is non-alcoholic steatohepatitis.

10. A compound of the formula (lia): wherein: x and y are each independently 1, 2 or 3; R1 is selected from the group consisting of hydrogen, alkyl of 1 to 12 carbon atoms, hydroxyalkyl of 2 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms and aralkyl of 7 to 19 carbon atoms; R2 is selected from the group consisting of alkyl of 7 to 12 carbon atoms, alkenyl of 3 to 12 carbon atoms, hydroxyalkyl of 7 to 12 carbon atoms, alkoxyalkyl of 2 to 12 carbon atoms, hydroxyalkenyl of 3 to 12 atoms of carbon, cycloalkyl of 3 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms, aralkyl of 13 to 19 carbon atoms, heteroaryl of 1 to 12 carbon atoms, heterocyclylalkyl of 3 to 12 carbon atoms, heterocyclyl of 3 to 12 carbon atoms, and heteroarylalkyl of 3 to 12 carbon atoms, provided that R2 is not pyrazinyl, pyridinonyl, pi rrol id in on i lo or imidazolyl; or R2 is a multi-ring structure having from 2 to 4 rings wherein the rings are independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl, wherein some or all of the rings may be fused with each other; R3 is selected from the group consisting of alkyl of 3 to 12 carbon atoms, alkenyl of 3 to 12 carbon atoms, hydroxyalkyl of 3 to 12 carbon atoms, hydroxyalkenyl of 3 to 12 carbon atoms, alkoxy of 3 to 12 atoms carbon, alkoxyalkyl of 3 to 12 carbon atoms, cycloalkyl of 3 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms, aryl, aralkyl of 7 to 19 carbon atoms, heterocyclyl of 3 to 12 carbon atoms, heterocyclylalkyl of 3 to 12 carbon atoms, heteroaryl of 1 to 12 carbon atoms and heteroarylalkyl of 3 to 12 carbon atoms; or R3 is a multi-ring structure having from 2 to 4 rings wherein the rings are independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl and wherein some or all of the rings may be fused with each other; R4, R5 and R6 are each independently selected from hydrogen, bromine, fluorine, chlorine, methyl, methoxy, trifluoromethyl, cyano, nitro or -N (R13) 2; R7, R7a, R8, R8a, R9, R9a, R10 and R10a are each independently selected from hydrogen or alkyl of 1 to 3 carbon atoms; or R9 and R a together, or R10 and R10a together form an oxo group, while the remainder of R7, R7a, R8, R8a, R9, R9a, R10, and R10a are each independently selected from hydrogen or alkyl from 1 to 3 carbon atoms; or one of R7, R7a, R10, and R10a, together with one of, R8, R8a, R9, R9a, they form an alkylene bridge, while the rest of R10, R10a R7, R7a, R8, R8a, R9, and R9a each are independently selected from hydrogen or alkyl of 1 to 3 carbon atoms; and each R13 is independently selected from hydrogen or alkyl of 1 to 6 carbon atoms; a stereoisomer, enantiomer or tautomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically composition thereof or a prodrug thereof.

The compound according to claim 10 wherein: x e and each independently 1, 2 or 3; R1 is selected from the group consisting of hydrogen, alkyl of 1 to 12 carbon atoms, hydroxyalkyl of 2 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms and aralkyl of 7 to 19 carbon atoms; R2 is selected from the group consisting of alkyl of 7 to 12 carbon atoms, alkenyl of 3 to 12 carbon atoms, hydroxyalkyl of 7 to 12 carbon atoms, alkoxyalkyl of 2 to 12 carbon atoms, hydroxyalkenyl of 3 to 12 atoms of carbon, cycloalkyl of 3 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms, aralkyl of 13 to 19 carbon atoms, heteroaryl of 1 to 12 carbon atoms, heterocyclylalkyl of 3 to 12 carbon atoms, heterocyclyl of 3 to 12 carbon atoms and heteroarylalkyl of 3 to 12 carbon atoms, provided that R2 is not pyrazinyl, pyridinonyl, pyrrolidone, or imidazolyl; R3 is selected from the group consisting of alkyl of 3 to 12 carbon atoms, alkenyl of 3 to 12 carbon atoms, hydroxyalkyl of 3 to 12 carbon atoms, hydroxyalkenyl of 3 to 12 carbon atoms, alkoxyalkyl of 3 to 12 atoms carbon, cycloalkyl of 3 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms, aryl, aralkyl of 7 to 19 carbon atoms, heterocyclyl of 3 to 12 carbon atoms, heterocyclylalkyl of 3 to 12 carbon atoms, heteroaryl of 1 to 12 carbon atoms and heteroarylalkyl of 3 to 12 carbon atoms; R4, R5 and R6 are each independently selected from hydrogen, bromine, fluorine, chlorine, methyl, methoxy, trifluoromethyl, cyano, nitro or -N (R13) 2; R7, R7a, R8, R8a, R9, R9a, R10 and R10a are each independently selected from hydrogen or alkyl of 1 to 3 carbon atoms; and each R13 is independently selected from hydrogen or alkyl of 1 to 6 carbon atoms.

12. The compound according to claim 11 wherein: x e and each is 1; R1 is selected from the group consisting of hydrogen or alkyl of 1 to 12 carbon atoms; R 2 is selected from the group consisting of alkyl of 7 to 12 carbon atoms, alkenyl of 3 to 12 carbon atoms, cycloalkyl of 3 to 12 carbon atoms, cycloalkyl or ylalkyl of 4 to 12 carbon atoms, aralkyl of 13 to 19 carbon atoms, heteroaryl of 1 to 12 carbon atoms, heterocyclylalkyl of 3 to 12 carbon atoms and heteroarylalkyl of 3 to 12 carbon atoms; R3 is selected from the group consisting of alkyl of 3 to 12 carbon atoms, cycloalkyl of 3 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms, aryl, aralkyl of 7 to 19 carbon atoms, heterocyclyl of 3 to 12 carbon atoms, heterocyclylalkyl of 3 to 12 carbon atoms, heteroaryl of 1 to 12 carbon atoms and heteroarylalkyl of 3 to 12 carbon atoms; R4, R5 and R6 are each independently selected from hydrogen, bromine, fluorine, chlorine, methyl, methoxy, trifluoromethyl, cyano, nitro -N (R13) 2; R7, R7a, R8, R8a, R9, R9a, R10 and R10 each are independently selected from hydrogen or alkyl of 1 to 3 carbon atoms; and each R13 is independently selected from hydrogen or alkyl of 1 to 6 carbon atoms.

The compound according to claim 12 wherein: R 2 is cycloalkyl of 3 to 12 carbon atoms or cycloalkylalkyl of 4 to 12 carbon atoms; R3 is selected from the group consisting of cycloalkyl of 3 to 12 carbon atoms or cycloalkylalkyl of 4 to 12 carbon atoms; R4, R5 and R6 each hydrogen; and R7, R7a, R8, R8a, R9, R9a, R10 and R10a are each hydrogen or alkyl of 1 to 3 carbon atoms.

14. The compound according to claim 13 wherein: R2 is cycloalkyl of 3 to 12 carbon atoms; and R3 is cycloalkyl of 3 to 12 carbon atoms.

15. The compound according to claim 14, mainly cyclohexanecarboxylic acid [6- (4-cyclohexanecarbonyl-piperazin-1-yl) pyridin-3-yl] -amide.

16. A method for treating a disease or condition mediated by stearoyl-CoA desaturase (SCD) in a mammal, wherein the method comprises administering to a mammal in need thereof a therapeutically effective amount of a compound according to claim 10.

17. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a therapeutically effective amount of a compound according to claim 0.

18. A compound of the formula (lb): where: x e and each independently 1.2 or 3; R1 is selected from the group consisting of hydrogen, alkyl of 1 to 12 carbon atoms, hydroxyalkyl of 2 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms and aralkyl of 7 to 19 carbon atoms; R2 is selected from the group consisting of alkyl of 1 to 12 carbon atoms, alkenyl of 2 to 12 carbon atoms, hydroxyalkyl of 2 to 12 carbon atoms, hydroxyalkenyl of 2 to 12 carbon atoms, alkoxy of 1 to 6 atoms of carbon, alkoxyalkyl of 3 to 12 carbon atoms, .cycloalkyl of 3 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms, aralkyl of 7 to 19 carbon atoms, heterocyclyl of 3 to 12 carbon atoms, heterocyclylalkyl from 3 to 12 carbon atoms, heteroaryl of 1 to 12 carbon atoms and heteroarylalkyl of 3 to 12 carbon atoms; or R2 is a multi-ring structure having from 2 to 4 rings wherein the rings are independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl, wherein some or all of the rings may be fused with each other; R3 is phenol optionally substituted by one or more substituents selected from the group consisting of halogen, cyano, nitro, hydroxy, alkyl of 1 to 6 carbon atoms, trihaloalkyl of 1 to 6 carbon atoms, trihaloalkoxy of 1 to 6 carbon atoms , alkylsulfonyl of 1 to 6 carbon atoms, -N (R12) 2, -OC (O) R12, -C (O) OR12, -S (O) 2N (R 2) 2, cycloalkyl, heterocyclyl, heteroaryl and heteroarylchloroalkyl , provided that R3 is not phenyl substituted with optionally substituted thienyl; R4, R5 and R6 are each independently selected from hydrogen, bromine, fluorine, chlorine, methyl, methoxy, trifluoromethyl, cyano, nitro or -N (R13) 2; R7, R7a, R8, R8a, R9, R9a, R10, and R10a are each independently selected from hydrogen or alkyl of 1 to 3 carbon atoms; or R9 and R9a together, or R10 and R10a together form an oxo group, while the remainder of R7, R7a, R8, R8a, R9, R9a, R10, and R0a are each independently selected from hydrogen or alkyl from 1 to 3 carbon atoms; or one of R7, R7a, R10 and R10a, together with one of R8, R8a, R9 and R9a, they form an alkylene bridge, while the rest of R10, R10a, R7, R7a, R8, R8a, R9, and R9a each are independently selected from hydrogen or alkyl of 1 to 3 carbon atoms; and each R12 is independently selected from hydrogen, alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms, aryl or aralkyl; and each R13 is independently selected from hydrogen or alkyl of 1 to 6 carbon atoms; a stereoisomer, enantiomer or tautomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically composition thereof or a prodrug thereof.

19. The compound according to claim 18 wherein: x e and each independently 1, 2 or 3; R1 is selected from the group consisting of hydrogen, alkyl of 1 to 12 carbon atoms, hydroxyalkyl of 2 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms and aralkyl of 7 to 19 carbon atoms; R2 is selected from the group consisting of alkyl of 1 to 12 carbon atoms, alkenyl of 2 to 12 carbon atoms, hydroxyalkyl of 2 to 12 carbon atoms, idroxyalkenyl of 2 to 12 carbon atoms, alkoxy of 1 to 6 atoms of carbon, alkoxyalkyl of 3 to 12 carbon atoms, cycloalkyl of 3 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms, aralkyl of 7 to 19 carbon atoms, heterocyclyl of 3 to 12 carbon atoms, heterocyclylalkyl of 3 to 12 carbon atoms, heteroaryl of 1 to 12 carbon atoms and heteroarylalkyl of 3 to 12 carbon atoms; R3 is phenyl optionally substituted by one or more substituents selected from the group consisting of halogen, cyano, nitro, hydroxy, alkyl of 1 to 6 carbon atoms, trihaloalkyl of 1 to 6 carbon atoms, trihaloalkoxy of 1 to 6 carbon atoms , alkylsulfonyl of 1 to 6 carbon atoms, -N (R12) 2, -OC (O) R12, -C (O) OR12, -S (O) 2N (R12) 2, cycloalkyl, heterocyclyl, heteroaryl and heteroarylcycloalkyl, provided that R3 is not phenyl substituted with optionally substituted thienyl; R4, R and R6 are each independently selected from hydrogen, bromine, fluorine, chlorine, methyl, methoxy, trifluoromethyl, cyano, nitro or -N (R3) 2; R7, R7a, R8, R8a, R9, R9a, R10 and R10a are each independently selected from hydrogen or alkyl of 1 to 3 carbon atoms, or R10 and R10a together form an oxo group and the remainder of R7, R7a, R8 , R8a, R9, R9a, each is hydrogen; each R12 is independently selected from hydrogen, alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms, aryl or aralkyl; and each R13 is independently selected from hydrogen or alkyl of 1 to 6 carbon atoms.

20. The compound according to claim 19 wherein: x e and each is 1; R1 is hydrogen or alkyl of 1 to 12 carbon atoms; R2 is selected from the group consisting of alkyl of 1 to 12 carbon atoms, alkenyl of 2 to 12 carbon atoms, hydroxyalkyl of 2 to 12 carbon atoms, hydroxyalkenyl of 2 to 12 carbon atoms, alkoxy of 1 to 6 atoms of carbon, alkoxyalkyl of 3 to 12 carbon atoms, cycloalkyl of 3 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms, aralkyl of 7 to 19 carbon atoms, heterocyclyl of 3 to 12 carbon atoms, heterocyclylalkyl of 3 to 12 carbon atoms, heteroaryl of 1 to 12 carbon atoms and heteroarylalkyl of 3 to 12 carbon atoms; R3 is phenyl optionally substituted by one or more substituents selected from the group consisting of halogen, cyano, nitro, hydroxy, alkyl of 1 to 6 carbon atoms, trihaloalkyl of 1 to 6 carbon atoms, trihaloalkoxy of 1 to 6 carbon atoms , alkylsulfonyl of 1 to 6 carbon atoms, -N (R12) 2, -OC (O) R12, -C (O) OR12, -S (O) 2N (R12) 2, cycloalkyl, heterocyclyl, heteroaryl and heteroarylcycloalkyl, provided that R3 is not phenyl substituted with optionally substituted thienyl; R4, R and R each hydrogen; R7, R7a, R8, R8a, R9, R9a, R0 and R10a each is hydrogen; or R10 and R10a together form an oxo group and the rest of R7, R7a, R8, R8a, R9, R9a each hydrogen; and each R12 is independently selected from hydrogen, alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms, aryl or aralkyl.

21. The compound according to claim 20 wherein: R2 is alkyl of 1 to 12 carbon atoms; and R3 is phenyl optionally substituted by one or more substituents selected from halogen, alkyl of 1 to 6 carbon atoms, trihaloalkyl of 1 to 6 carbon atoms and trihaloalkoxy of 1 to 6 carbon atoms.

22. The compound according to claim 21 selected from the group consisting of the following:. { 6- [4- (2-trifluoromethylbenzoyl) piperazin-1-yl] plridin-3-yl} 4-methylpentanoic acid amide; . { 6- [4- (2-trifluoromethylbenzoyl) piperazin-1-yl] pyridin-3-yl} hexanoic acid amide; . { 6- [4- (2-trifluoromethylbenzoyl) piperazin-1-yl] pyridin-3-yl} heptanoic acid amide; . { 6- [4- (2,5-dichlorobenzoyl) piperazin-1-yl] pyridin-3-yl} heptanoic acid amide; Y . { 6- [4- (2,5-dichlorobenzoyl) piperazin-1-yl] pyridin-3-yl} hexanoic acid amide.

23. The compound according to claim 20 wherein: R2 is cycloalkyl of 3 to 12 carbon atoms; and R3 is phenyl optionally substituted by one or more substituents selected from halogen, alkyl of 1 to 6 carbon atoms, trihaloalkyl of 1 to 6 carbon atoms and trihaloalkoxy of 1 to 6 carbon atoms.

24. The compound according to claim 23, mainly,. { 6- [4- (2-trifluoromethylbenzoyl) piperazin-1-yl] pyri din-3-y1} cyclohexanecarboxylic acid amide.

25. The compound according to claim 20 wherein: R2 is aralkyl of 7 to 12 carbon atoms optionally substituted by one or more substituents selected from halogen, alkyl of 1 to 6 carbon atoms, trihaloalkyl of 1 to 6 carbon atoms carbon and trihaloalkoxy of 1 to 6 carbon atoms; and R3 is phenyl optionally substituted by one or more substituents selected from halogen, alkyl of 1 to 6 carbon atoms, trihaloalkyl of 1 to 6 carbon atoms and trihaloalkoxy of 1 to 6 carbon atoms.

26. The compound according to claim 25 selected from the group consisting of the following: 3-Phenyl-N-. { 6- [4- (2-tri-fluoro-methylbenzoyl) p i pera zin-1-yl] -pyridin-3-yl} propionamide; 4-Phenyl-N-. { 6- [4- (2-trifluoromethylbenzoyl) piperazin-1-yl] -pyridin-3-ylbutyramide; and N-. { 6- [2-Oxo-4- (2-trifluoromethylbenzoyl) piperazin-1-yl] -pyridin-3-yl} -4-phenylbutyramide.

27. A method for treating a disease or condition mediated by stearoyl-CoA desaturase (SCD) in a mammal, wherein the method comprises administering to a mammal in need thereof a therapeutically effective amount of a compound according to claim 18.

28. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a therapeutically effective amount of a compound according to claim 8.

29. The compound of the formula (III): where: x e and each independently 1, 2 or 3; Va is -C (O) -, -C (S) -, -C (O) N (R1) -, -C (S) N (R1) -, -C (O) O-, -C (S ) O-, -S (O) t- (where t is 1 or 2) or -S (O) tN (R1) - (where t is 1 or 2); each R1 are independently selected from the group consisting of hydrogen, alkyl of 1 to 12 carbon atoms, hydroxyalkyl of 2 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms and aralkyl of 7 to 19 carbon atoms; R2 is selected from the group consisting of alkyl of 1 to 12 carbon atoms, alkenyl of 2 to 12 carbon atoms, hydroxyalkyl of 2 to 12 carbon atoms, hydroxyalkenylalkyl of 2 to 12 carbon atoms, alkoxy of 1 to 6 atoms carbon, alkoxyalkyl of 3 to 12 carbon atoms, cycloalkyl of 3 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms, aryl, aralkyl of 7 to 19 carbon atoms, heterocyclyl of 3 to 12 carbon atoms, heterocyclylalkyl of 3 to 12 carbon atoms, heteroaryl of 1 to 12 carbon atoms and heteroarylalkyl of 3 to 12 carbon atoms; or R2 is a multi-ring structure having from 2 to 4 rings wherein the rings are independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl, wherein some or all of the rings may be fused with each other; R3 is selected from the group consisting of alkyl of 1 to 12 carbon atoms, alkenyl of 2 to 12 carbon atoms, hydroxyalkyl of 2 to 12 carbon atoms, hydroxyalkyl of 2 to 12 carbon atoms, alkoxyalkyl of 2 to 12 atoms carbon, cycloalkyl of 3 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms, aryl, aralkyl of 7 to 19 carbon atoms, heterocyclyl of 3 to 12 carbon atoms, heterocyclylalkyl of 3 to 12 carbon atoms, heteroaryl of 1 to 12 carbon atoms and heteroarylalkyl of 3 to 12 carbon atoms; or R3 is a multi-ring structure having from 2 to 4 rings wherein the rings are independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl and wherein some or all of the rings may be fused with each other; R4, R5 and R6 are each independently selected from hydrogen, bromine, fluorine, chlorine, methyl, methoxy, trifluoromethyl, cyano, nitro or -N (R13) 2; R7, R7a, R8, R8a, R9, R9a, R10, and R10a are each independently selected from hydrogen or alkyl of 1 to 3 carbon atoms; or R7 and R7a together, or R8 and R8a together, or R9 and R9a together, or R0 and R10a together are an oxo group, provided that when Va is -C (O) -, R7 and R7a together or R8 and R8a together do not form an oxo group, while the rest of R7, R7a, R8, R8a, R9, R9a, R10, and R10a are each independently selected from hydrogen or alkyl of 1 to 3 carbon atoms; or one of R10, R10a, R7 and R7a, together with one of R8, R8a, R9 and R9a form an alkylene bridge, while the remainder of R10, R10a, R7, R7a, R8, R8a, R9, and R9a each they are independently selected from hydrogen or alkyl of 1 to 3 carbon atoms; and each R13 is independently selected from hydrogen or alkyl of 1 to 6 carbon atoms; a stereoisomer, enantiomer or tautomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically composition thereof or a prodrug thereof.

30. The compound according to claim 29 wherein: x e and each independently 1,2 or 3; Va is-C (O) - or-C (S) -; R1 is selected from the group consisting of hydrogen, alkyl of 1 to 12 carbon atoms, hydroxyalkyl of 2 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms and aralkyl of 7 to 19 carbon atoms; R2 is selected from the group consisting of alkyl of 1 to 12 carbon atoms, alkenyl of 2 to 12 carbon atoms, hydroxyalkyl of 2 to 12 carbon atoms, hydroxyalkenyl of 2 to 12 carbon atoms, alkoxy of 1 to 6 atoms carbon, alkoxyalkyl of 3 to 12 carbon atoms, cycloalkyl of 3 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms, aryl, aralkyl of 7 to 19 carbon atoms, heterocyclyl of 3 to 12 carbon atoms, heterocyclylalkyl of 3 to 12 carbon atoms, heteroaryl of 1 to 12 carbon atoms and heteroarylalkyl of 3 to 12 carbon atoms; R3 is selected from the group consisting of alkyl of 1 to 12 carbon atoms, alkenyl of 2 to 12 carbon atoms, hydroxyalkyl of 2 to 12 carbon atoms, hydroxyalkenyl of 2 to 12 carbon atoms, alkoxyalkyl of 2 to 12 atoms carbon, cycloalkium of 3 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms, aryl, aralkyl of 7 to 19 carbon atoms, heterocyclyl of 3 to 12 carbon atoms, heterocyclylalkyl of 3 to 12 carbon atoms, heteroaryl of 1 to 12 carbon atoms and heteroarylalkyl of 3 to 12 carbon atoms; R4, R5 and R6 are each independently selected from hydrogen, bromine, fluorine, chlorine, methyl, methoxy, trifluoromethyl, cyano, nitro or -N (R13) 2; R7, R7a, R8, R8a, R9, R9a, R10 and R 0a are each independently selected from hydrogen or alkyl of 1 to 3 carbon atoms; and each R13 is independently selected from hydrogen or alkyl of 1 to 6 carbon atoms.

31. The compound according to claim 30 wherein: x e and each are 1; Va is -C (O) -; R1 is hydrogen or alkyl of 1 to 12 carbon atoms; R2 is selected from the group consisting of alkyl of 1 to 12 carbon atoms, alkenyl of 2 to 12 carbon atoms, hydroxyalkyl of 2 to 12 carbon atoms, hydroxyalkenyl of 2 to 12 carbon atoms, alkoxy of 1 to 6 atoms carbon, alkoxyalkyl of 3 to 12 carbon atoms, cycloalkyl of 3 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms, aryl, aralkyl of 7 to 19 carbon atoms, heterocyclyl of 3 to 12 carbon atoms, heterocyclylalkyl of 3 to 12 carbon atoms, heteroaryl of 1 to 12 carbon atoms and heteroarylalkyl of 3 to 12 carbon atoms; R3 is naphthyl or phenyl, each optionally substituted by one or more substituents selected from the group consisting of halogen, cyano, nitro, hydroxy, alkyl of 1 to 6 carbon atoms, trihaloalkyl of 1 to 6 carbon atoms, trihaloalkoxy of 1 to 6 carbon atoms, alkylsulfonyl of 1 to 6 carbon atoms, -N (R12) 2, -OC (O) R12, -C (O) OR12, -S (O) 2N (R12) 2l cycloalkyl, heterocyclyl, heteroaryl and heteroarylcycloalkyl; R4, R5 and R6 are each hydrogen; R7, R7a, R8, R8a, R9, R9a, R10 and R10a are each hydrogen; and each R12 is independently selected from hydrogen, alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms, aryl or aralkyl.

32. The compound according to claim 31 wherein: R2 is alkyl of 1 to 12 carbon atoms or aralkyl of 7 to 12 carbon atoms optionally substituted by one or more substituents selected from the group consisting of halogen, alkyl of 1 to 6 carbon atoms, trihaloalkyl of 1 to 6 carbon atoms and trihaloalkoxy of 1 to 6 carbon atoms; R3 is naphthyl or phenyl, each optionally substituted by one or more substituents selected from the group consisting of halogen, alkyl of 1 to 6 carbon atoms, trihaloalkyl of 1 to 6 carbon atoms and trihaloalkoxy of 1 to 6 carbon atoms.

33. The compound according to claim 32 selected from the group consisting of the following:. { 6- [4- (2-trifluoromethylbenzoyl) -piperazin-1-yl] pyridin-3-yl} pentane-1-sulfonic acid amide; . { 6- [4- (2-trifluoromethylbenzoyl) -piperazin-1-yl] pyridin-3-yl} butan-1-sulfonic acid amide; . { 6- [4- (2-trifluoromethylbenzoyl) -piperazin-1-yl] pyridin-3 y)} hexan-1-sulfonic acid amide; . { 6- [4- (2-bromobenzoyl) piperazin-1-yl] pyridin-3-yl} pentane-1-sulfonic acid amide; . { 6- [4- (2,5-dichlorobenzoyl) -piperazin-1-yl] pyridin-3-yl} hexan-1-sulfonic acid amide; . { 6- [4- (2,5-dichlorobenzoyl) -piperazin-1-yl] pyridin-3-yl} pentane-1-sulfonic acid amide; . { 6- [4- (naphthalene-1-carbonyl) -piperazin-1-yl] pyridin-3-yl} hexan-1-sulfonic acid amide; . { 6- [4- (naphthalene-1-carbonyl) -piperazin-1-yl] pyridin-3-yl} pentane-1-sulfonic acid amide; Y . { 6- [4- (2-trifluoromethyl-benzoyl) piperazin-1-yl] pyridin-3-yl} 3-phenylpropan-1-sulfonic acid amide.

34. The compound according to claim 31 wherein: R2 is cycloalkylalkyl of 4 to 12 carbon atoms, aralkyl of 7 to 19 carbon atoms, heterocyclylalkyl of 3 to 12 carbon atoms or heteroarylalkyl of 3 to 12 carbon atoms; R3 is naphthyl or phenyl, each optionally substituted by one or more substituents selected from the group consisting of halogen, alkyl of 1 to 6 carbon atoms, trihaloalkyl of 1 to 6 carbon atoms and trihaloalkoxy of 1 to 6 carbon atoms.

35. A method for treating a disease or condition mediated by stearoyl-CoA desaturase (SCD) in a mammal, wherein the method comprises administering to a mammal in need thereof a therapeutically effective amount of a compound according to claim 1. 29.

36. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a therapeutically effective amount of a compound according to claim 29.

37. The compound of the formula (IV): where: x e and each independently 1, 2 or 3; Va is -C (O) -, -C (S) -, -C (O) N (R1) -, -C (S) N (R1) -, -C (O) O-, -C (S ) O-, -S (O) t- (where t is 1 or 2) or -S (O) tN (R1) - (where t is 1 or 2); each R1 is independently selected from the group consisting of hydrogen, alkyl of 1 to 12 carbon atoms, hydroxyalkyl of 2 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms and aralkyl of 7 to 19 carbon atoms; R2 is selected from the group consisting of alkyl of 1 to 12 carbon atoms, alkenyl of 2 to 12 carbon atoms, hydroxyalkyl of 2 to 12 carbon atoms, hydroxyalkenyl of 2 to 12 carbon atoms, alkoxyalkyl of 3 to 12 carbon atoms, cycloalkyl of 3 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms, aryl, aralkyl of 7 to 19 carbon atoms, heterocyclyl of 3 to 12 carbon atoms carbon, heterocyclylalkyl of 3 to 12 carbon atoms, heteroaryl of 1 to 12 carbon atoms and heteroarylalkyl of 3 to 12 carbon atoms; or R2 is a multi-ring structure having from 2 to 4 rings wherein the rings are independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl, wherein some or all of the rings may be fused with each other; R3 is selected from the group consisting of alkyl of 1 to 12 carbon atoms, alkenyl of 2 to 12 carbon atoms, hydroxyalkyl of 2 to 12 carbon atoms, hydroxyalkenyl of 2 to 12 carbon atoms, alkoxyalkyl of 2 to 12 atoms carbon, cycloalkyl of 3 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms, aryl, aralkyl of 7 to 19 carbon atoms, heterocyclyl of 3 to 12 carbon atoms, heterocyclylalkyl of 3 to 12 carbon atoms, heteroaryl of 1 to 12 carbon atoms and heteroarylalkyl of 3 to 12 carbon atoms; or R3 is a multi-ring structure having from 2 to 4 rings wherein the rings are independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl and wherein some or all of the rings may be fused with each other; - R4, R5 and R6 are each independently selected from hydrogen, bromine, fluorine, chlorine, methyl, methoxy, trifluoromethyl, cyano, nitro or -N (R13) 2; R7, R7a, R8, R8a, R9, R9a, R10, and R10a are each independently selected from hydrogen or alkyl of 1 to 3 carbon atoms; or R7 and R7a together, or R8 and R8a together, or R9 and R9a together, or R10 and R10a together are an oxo group, provided that when Va is -C (O) -, R7 and R7a together or R8 and R8a together do not form an oxo group, while the remainder of R7, R7a, R8, R8a, R9, R9a, R10, and R10a each are independently selected from hydrogen or alkyl of 1 to 3 carbon atoms; or one of R10, R10a, R7 and R7a, together with one of R8, R8a, R9 and R9a form an alkylene bridge, while the remainder of R10, R0a, R7, R7a, R8, R8a, R9, and R9a are independently selected from hydrogen or alkyl of 1 to 3 carbon atoms; and each R13 is independently selected from hydrogen or alkyl of 1 to 6 carbon atoms; a stereoisomer, enantiomer or tautomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically composition thereof or a prodrug thereof.

38. The compound according to claim 37 wherein: x e and each independently is 1, 2 or 3; Va is -C (O) -, -C (S) -, -C (O) N (R1) -, -C (S) N (R1) -, -C (O) O-, -S (O ) t- (where t is 1 or 2) or -S (O) tN (R1) - (where t is 1 or 2); each R1 are independently selected from the group consisting of hydrogen, alkyl of 1 to 12 carbon atoms, hydroxyalkyl of 2 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms and aralkyl of 7 to 19 carbon atoms; R2 is selected from the group consisting of alkyl of 1 to 12 carbon atoms, alkenyl of 2 to 12 carbon atoms, hydroxyalkyl of 2 to 12 carbon atoms, hydroxyalkenyl of 2 to 12 carbon atoms, alkoxyalkyl of 3 to 12 atoms carbon, cycloalkyl of 3 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms, aryl, aralkyl of 7 to 19 carbon atoms, heterocyclyl of 3 to 12 carbon atoms, heterocyclylalkyl of 3 to 12 carbon atoms, heteroaryl of 1 to 12 carbon atoms and heteroarylalkyl of 3 to 12 carbon atoms; R3 is selected from the group consisting of alkyl of 1 to 12 carbon atoms, alkenyl of 2 to 12 carbon atoms, hydroxyalkyl of 2 to 12 carbon atoms, hydroxyalkenyl of 2 to 12 carbon atoms, alkoxyalkyl of 2 to 12 atoms carbon, cycloalkyl of 3 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms, aryl, aralkyl of 7 to 19 carbon atoms, heterocyclyl of 3 to 12 carbon atoms, heterocyclylalkyl of 3 to 12 carbon atoms, heteroaryl of 1 to 12 carbon atoms and heteroarylalkyl of 3 to 12 carbon atoms; R4, R5 and R6 are each independently selected from hydrogen, bromine, fluorine, chlorine, methyl, methoxy, trifluoromethyl, cyano, nitro -N (R13) 2; R7, R7a, R8, R8a, R9, R9a, R10 and R10a are each independently selected from hydrogen or alkyl of 1 to 3 carbon atoms; and each R13 is independently selected from hydrogen or alkyl of 1 to 6 carbon atoms.

39. The compound according to claim 38 wherein: x e and each is 1; Va is -C (O) -; each R is independently hydrogen or alkyl of 1 to 6 carbon atoms; R2 is selected from the group consisting of alkyl of 1 to 12 carbon atoms, alkenyl of 2 to 12 carbon atoms, hydroxyalkyl of 2 to 12 carbon atoms, hydroxyalkenyl of 2 to 12 carbon atoms, alkoxyalkyl of 3 to 12 atoms carbon, cycloalkyl of 3 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms, aryl, aralkyl of 7 to 19 carbon atoms, heterocyclyl of 3 to 12 carbon atoms, heterocyclylalkyl of 3 to 12 carbon atoms, heteroaryl of 1 to 12 carbon atoms and heteroarylalkyl of 3 to 12 carbon atoms; R3 is selected from the group consisting of alkyl of 3 to 12 carbon atoms, alkenyl of 3 to 12 carbon atoms, hydroxyalkyl of 3 to 12 carbon atoms, hydroxyalkenyl of 3 to 12 carbon atoms, alkoxyalkyl of 3 to 12 atoms carbon, cycloalkyl of 3 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms, aryl, aralkyl of 7 to 19 carbon atoms, heterocyclyl of 3 to 12 carbon atoms, heterocyclylalkyl of 3 to 12 carbon atoms, heteroaryl with 1 to 12 carbon atoms and heteroarylalkyl with 3 to 12 carbon atoms; R4, R5 and R6 are each hydrogen; R7, R7a, R8, R8a, R9, R9a, R10 and R10a are each hydrogen; and each R12 is independently selected from hydrogen, alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms, aryl or aralkyl.

40. The compound according to claim 39 wherein: R2 is alkyl of 1 to 12 carbon atoms or aralkyl of 1 to 12 carbon atoms optionally substituted by one or more substituents selected from the group consisting of halogen, alkyl of 1 to 6 carbon atoms, trihaloalkyl of 1 to 6 carbon atoms and trihaloalkoxy of 1 to 6 carbon atoms; and R3 is selected from the group consisting of cycloalkyl of 3 to 12 carbon atoms, aryl, heterocyclyl of 3 to 12 carbon atoms or heteroaryl of 1 to 12 carbon atoms.

41. The compound according to claim 40 wherein R3 is cycloalkyl of 3 to 12 carbon atoms.

42. The compound according to claim 41 selected from the group consisting of the following: 1- [6- (4-Cyclohexanecarbonylpiperazin-1-yl) pyridin-3-yl] -3-pentylurea; and 1- [6- (4-Cyclopentanecarbonylpiperazin-1-yl) pyridin-3-yl] -3-pentylurea.

43. The compound according to claim 40, wherein R3 is phenyl optionally substituted by one or more substituents selected from the group consisting of halogen, alkyl of 1 to 6 carbon atoms, trihaloalkyl of 1 to 6 carbon atoms and trihaloalkoxy from 1 to 6 carbon atoms.

44. The compound according to claim 43 selected from the group consisting of the following: 1-Pentyl-3-. { 6- [4 - (2-trifluoro-methyl-benzoyl) -piperazin-1-yl] -p-ri-din-Sil} urea; 1-Butyl-3-. { 6- [4- (2-trifluoromethylbenzoyl) piperazin-1-yl] -pyridin-3-yl} urea; 1-Fenethyl-3-. { 6- [4- (2-trifluoromethylbenzoyl) piperazin-1-yl] pyridin-3-yl} urea; 1-Benzyl-3-. { 6- [4- (2-trifluoromethylbenzoyl) piperazin-1-yl] -pyridin-3-M} urea; and 1- (4-Fluorobenzyl) -3-. { 6- [4- (2-tri-fluoro-methylbenzo-yl) -piperazin-1-yl] -pyrid i n-3-i!} u rea.

45. The compound according to claim 40, wherein R3 is piperidinyl optionally substituted by alkyl of 1 to 6 carbon atoms or aralkyl of 7 to 12 carbon atoms, wherein aralkyl group of 7 to 12 carbon atoms is optionally substituted by one or more substituents selected from the group consisting of halogen, alkyl of 1 to 6 carbon atoms, trihaloalkyl of 1 to 6 carbon atoms and trihaloalkoxy of 1 to 6 carbon atoms.

46. The compound according to claim 45, in particular, 1-. { 6- [4- (1-Benzylpiperidin-4-carbonyl) piperazin-1-yl] -pyridin-3-yl} -3-pentylurea.

47. The compound according to claim 40, wherein R3 is pyridinyl optionally substituted by one or more substituents selected from the group consisting of halogen or alkyl of 1 to 6 carbon atoms.

48. The compound according to claim 47 selected from the group consisting of the following: 1-Pentyl-3-. { 6- [4- (pyridine-2-carbonyl) piperazin-1-yl] -pyridin-3-yl} urea; and 1-Pentil-3-. { 6- [4- (pyridine-4-carbonyl) piperazin-1-yl] -pyridin-3-yl} urea.

49. A method for treating a disease or condition mediated by stearoyl-CoA desaturase (SCD) in a mammal, wherein the method comprises administering to a mammal in need thereof a therapeutically effective amount of a compound according to claim 37.

50. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a therapeutically effective amount of a compound according to claim 37.

51. The compound of the formula (V): where: x e and each independently 1, 2 or 3; Wa is -O-, -N (R1) - or S (O) t- (where t is 0, 1 or 2); Va is -C (O) -, -C (S) -, -C (O) N (R1) -, -C (S) N (R1) -, -C (O) O-, -C (S ) O-, -S (O) t- (where t is 1 or 2) or -S (O) tN (R1) - (where t is 1 or 2); each R1 are independently selected from the group consisting of hydrogen, alkyl of 1 to 12 carbon atoms, hydroxyalkyl of 2 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms and aralkyl of 7 to 19 carbon atoms; R2 is selected from the group consisting of alkyl of 1 to 12 carbon atoms, alkenyl of 2 to 12 carbon atoms, hydroxyalkyl of 2 to 12 carbon atoms, hydroxyalkenyl of 2 to 12 carbon atoms, alkoxyalkyl of 3 to 12 atoms carbon, cycloalkyl of 3 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms, aryl, aralkyl of 7 to 19 carbon atoms, heterocyclyl of 3 to 12 carbon atoms, heterocyclylalkyl of 3 to 12 carbon atoms, heteroaryl of 1 to 12 carbon atoms and heteroarylalkyl of 3 to 12 carbon atoms; or R2 is a multi-ring structure having from 2 to 4 rings wherein the rings are independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl, wherein some or all of the rings may be fused with each other; R3 is selected from the group consisting of alkyl of 1 to 12 carbon atoms, alkenyl of 2 to 12 carbon atoms, hydroxyalkyl of 2 to 12 carbon atoms, hydroxyalkenyl of 2 to 12 carbon atoms, alkoxyalkyl of 2 to 12 atoms carbon, cycloalkyl of 3 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms, aryl, aralkyl of 7 to 19 carbon atoms, heterocyclyl of 3 to 12 carbon atoms, heterocyclylalkyl of 3 to 12 carbon atoms, heteroaryl of 1 to 12 carbon atoms, and heteroarylalkyl of 3 to 12 carbon atoms; or R3 is a multi-ring structure having from 2 to 4 rings wherein the rings are independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl and wherein some or all of the rings may be fused with each other; R4, R5 and R6 are each independently selected from hydrogen, bromine, fluorine, chlorine, methyl, methoxy, trifluoromethyl, cyano, nitro or -N (R13) 2; R7, R7a, R8, R8a, R9, R9a, R10, and R10a are each independently selected from hydrogen or alkyl of 1 to 3 carbon atoms; or R7 and R7a together, or R8 and R8a together, or R9 and R9a together, or R10 and R10a together are an oxo group, provided that when Va is -C (O) -, R7 and R7a together R8 and R8a together do not form an oxo group, while the remainder of R7, R7a, R8, R8a, R9, R9a, R10 , and R10a each are independently selected from hydrogen or alkyl of 1 to 3 carbon atoms; or one of R10, R10a, R7 and R7a, together with one of R8, R8a, R9 and R9a form an alkylene bridge, while the remainder of R10, R10a, R7, R7a, R8, R8a, R9, and R9a each they are independently selected from hydrogen or alkyl of 1 to 3 carbon atoms; and each R 3 is independently selected from hydrogen or alkyl of 1 to 6 carbon atoms; a stereoisomer, enantiomer or tautomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically composition thereof or a prodrug thereof.

52. The compound according to claim 51 wherein: x and y are each independently 1, 2 or 3; Wa is -O-, -N (R1) - or -S (O) t- (where t is 0.1 or 2); Va is -C (O) -, -C (S) -, -C (O) N (R1) -, -C (S) N (R1) -, -C (O) O-, -S (O ) t- (where t is 1 or 2) or -S (O) tN (R1) - (where t is 1 or 2); each R1 are independently selected from the group consisting of hydrogen, alkyl of 1 to 12 carbon atoms, hydroxyalkyl of 2 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms and aralkyl of 7 to 19 carbon atoms; R2 is selected from the group consisting of alkyl of 1 to 12 carbon atoms, alkenyl of 2 to 12 carbon atoms, hydroxyalkyl of 2 to 12 carbon atoms, hydroxyalkenyl of 2 to 12 carbon atoms, alkoxyalkyl of 3 to 12 atoms carbon, cycloalkyl of 3 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms, aryl, aralkyl of 7 to 19 carbon atoms, heterocyclyl of 3 to 12 carbon atoms, heterocyclylalkyl of 3 to 12 carbon atoms, heteroaryl of 1 to 12 carbon atoms and heteroarylalkyl of 3 to 12 carbon atoms; R3 is selected from the group consisting of alkyl of 1 to 12 carbon atoms, alkenyl of 2 to 12 carbon atoms, hydroxyalkyl of 2 to 12 carbon atoms, hydroxyalkenyl of 2 to 12 carbon atoms, alkoxyalkyl of 2 to 12 atoms carbon, cycloalkyl of 3 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms, aryl, aralkyl of 7 to 19 carbon atoms, heterocyclyl of 3 to 12 carbon atoms, heterocyclylalkyl of 3 to 12 carbon atoms, heteroaryl of 1 to 12 carbon atoms and heteroarylalkyl of 3 to 12 carbon atoms; R4, R5 and R6 are each independently selected from hydrogen, bromine, fluorine, chlorine, methyl, methoxy, trifluoromethyl, cyano, nitro or -N (R13) 2; R7, R7a, R8, R8a, R9, R9a, R10 and R10a are each independently selected from hydrogen or alkyl of 1 to 3 carbon atoms; and each R13 is independently selected from hydrogen or alkyl of 1 to 6 carbon atoms.

53. The compound according to claim 52 wherein: x e and each is 1; Wa is -O-; Va is -C (O) - or -C (S) -; R2 is selected from the group consisting of alkyl of 1 to 12 carbon atoms, alkenyl of 2 to 12 carbon atoms, hydroxyalkyl of 2 to 12 carbon atoms, hydroxyalkenyl of 2 to 12 carbon atoms, alkoxyalkyl of 3 to 12 atoms carbon, cycloalkyl of 3 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms, aryl, aralkyl of 7 to 19 carbon atoms, heterocyclyl of 3 to 12 carbon atoms, heterocyclylalkyl of 3 to 12 carbon atoms, heteroaryl of 1 to 12 carbon atoms and heteroarylalkyl of 3 to 12 carbon atoms; R3 is selected from the group consisting of alkyl of 3 to 12 carbon atoms, alkenyl of 3 to 12 carbon atoms, hydroxyalkyl of 3 to 12 carbon atoms, hydroxyalkenyl of 3 to 12 carbon atoms, alkoxy of 3 to 12 atoms carbon, alkoxyalkyl of 3 to 12 carbon atoms, cycloalkyl of 3 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms, aryl, aralkyl of 7 to 19 carbon atoms, heterocyclyl of 3 to 12 carbon atoms, heterocyclylalkyl of 3 to 12 carbon atoms, heteroaryl of 1 to 12 carbon atoms and heteroarylalkyl of 3 to 12 carbon atoms; R4, R5 and R6 each hydrogen; and R7, R7a, R8, R8a, R9, R9a, R10 and R10a are each hydrogen.

54. The compound according to claim 53 wherein: Va is -C (O) -; R2 is selected from the group consisting of alkyl of 1 to 12 carbon atoms, cycloalkyl of 3 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms, aryl, aralkyl of 7 to 19 carbon atoms, heterocyclyl of 3 to 12 carbon atoms, heterocyclylalkyl of 3 to 12 carbon atoms, heteroaryl of 1 to 12 carbon atoms and heteroarylalkyl of 3 to 12 carbon atoms; and R3 is selected from the group consisting of cycloalkyl of 3 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms, aryl, aralkyl of 7 to 19 carbon atoms, heterocyclyl of 3 to 12 carbon atoms, heterocyclylalkyl of 3 to 12 carbon atoms, heteroaryl of 1 to 12 carbon atoms and heteroarylalkyl of 3 to 12 carbon atoms.

55. The compound according to claim 52 wherein: x e and each is 1; Wa is -N (R1) -; Va is -C (O) - or -C (S) -; R1 is hydrogen or alkyl of 1 to 6 carbon atoms; R2 is selected from the group consisting of alkyl of 1 to 12 carbon atoms, alkenyl of 2 to 12 carbon atoms, hydroxyalkyl of 2 to 12 carbon atoms, hydroxyalkenylalkyl of 2 to 12 carbon atoms, alkoxyalkyl of 3 to 12 atoms carbon, cycloalkyl of 3 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms, aryl, aralkyl of 7 to 19 carbon atoms, heterocyclyl of 3 to 12 carbon atoms, heterocyclylalkyl of 3 to 12 carbon atoms, heteroaryl of 1 to 12 carbon atoms and heteroarylalkyl of 3 to 12 carbon atoms; R3 is selected from the group consisting of alkyl of 3 to 12 carbon atoms, alkenyl of 3 to 12 carbon atoms, hydroxyalkyl of 3 to 12 carbon atoms, hydroxyalkenyl of 3 to 12 carbon atoms, alkoxy of 3 to 12 atoms carbon, alkoxyalkyl of 3 to 12 carbon atoms, cycloalkyl of 3 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms, aryl, aralkyl of 7 to 19 carbon atoms, heterocyclyl of 3 to 12 carbon atoms, heterocyclylalkyl of 3 to 12 carbon atoms, heteroaryl of 1 to 12 carbon atoms and heteroarylalkyl of 3 to 12 carbon atoms; R4, R5 and R6 are each hydrogen; and R7, R7a, R8, R8a, R9, R9a, R10 and R10a are each hydrogen.

56. The compound according to claim 55 wherein: Va is -C (O) ~; R2 is selected from the group consisting of alkyl of 1 to 12 carbon atoms, cycloalkyl of 3 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms, aryl, aralkyl of 7 to 19 carbon atoms, heterocyclyl of 3 to 12 carbon atoms, heterocyclylalkyl of 3 to 12 carbon atoms, heteroaryl of 1 to 12 carbon atoms and heteroarylalkyl of 3 to 12 carbon atoms; and R3 is selected from the group consisting of cycloalkyl of 3 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms, aryl, aralkyl of 7 to 19 carbon atoms, heterocyclyl of 3 to 12 carbon atoms, heterocyclylalkyl of 3 to 12 carbon atoms, heteroaryl of 1 to 12 carbon atoms carbon and heteroarylalkyl of 3 to 12 carbon atoms,

57. The compound according to claim 52 wherein: x and y is each 1; Wa is -S (O) t- (where t is 0.1 or 2); Va is -C (O) - or -C (S) -; R2 is selected from the group consisting of alkyl of 1 to 12 carbon atoms, alkenyl of 2 to 12 carbon atoms, hydroxyalkyl of 2 to 12 carbon atoms, hydroxyalkenyl of 2 to 12 carbon atoms, alkoxyalkyl of 3 to 12 atoms carbon, cycloalkyl of 3 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms, aryl, aralkyl of 7 to 19 carbon atoms, heterocyclyl of 3 to 12 carbon atoms, heterocyclylalkyl of 3 to 12 carbon atoms, heteroaryl of 1 to 12 carbon atoms and heteroarylalkyl of 3 to 12 carbon atoms; R3 is selected from the group consisting of alkyl of 3 to 12 carbon atoms, alkenyl of 3 to 12 carbon atoms, hydroxyalkyl of 3 to 12 carbon atoms, hydroxyalkenyl of 3 to 12 carbon atoms, alkoxy of 3 to 12 atoms carbon, alkoxyalkyl of 3 to 12 carbon atoms, cycloalkyl of 3 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms, aryl, aralkyl of 7 to 19 carbon atoms, heteroclclyl of 3 to 12 carbon atoms, heterocyclylalkyl of 3 to 12 carbon atoms, heteroaryl of 1 to 12 carbon atoms and heteroarylalkyl of 3 to 12 carbon atoms; R4, R5 and R6 each is hydrogen; and R7, R7a, R8, R8a, R9, R9a, R10 and R10a each is hydrogen.

58. The compound according to claim 57 wherein: Va is -C (O) -; R2 is selected from the group consisting of alkyl of 1 to 12 carbon atoms, cycloalkyl of 3 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms, aryl, aralkyl of 7 to 19 carbon atoms, heterocyclic of 3 to 12 carbon atoms, heterocyclylalkyl of 3 to 12 carbon atoms, heteroaryl of 1 to 12 carbon atoms and heteroarylalkyl of 3 to 12 carbon atoms; and R3 is selected from the group consisting of cycloalkyl of 3 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms, aryl, aralkyl of 7 to 19 carbon atoms, heterocyclyl of 3 to 12 carbon atoms, heterocyclylalkyl of 3 to 12 carbon atoms, heteroaryl of 1 to 12 carbon atoms and heteroarylalkyl of 3 to 12 carbon atoms.

59. A method for treating a disease or condition mediated by stearoyl-CoA desaturase (SCD) in a mammal, wherein the method comprises administering to a mammal in need thereof a therapeutically effective amount of a compound according to claim 51.

60. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a therapeutically effective amount of a compound according to claim 51.

61. A compound of the formula (la): x e and each independently 1, 2 or 3; W is -N (R1) S (O) t- (where t is 1 or 2); V is -C (O) -, -C (S) -, -C (O) N (R1) -, -C (S) N (R1) -, -C (O) O-, -C (S ) O, -S (O) t- (where t is 1 or 2), -S (O) tN (R1) - (where t is 1 or 2) or -C (R11) H; each R are independently selected from the group consisting of hydrogen, alkyl of 1 to 12 carbon atoms, hydroxyalkyl of 2 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms and aralkyl of 7 to 19 carbon atoms; R2 is selected from the group consisting of alkyl of 1 to 12 carbon atoms, alkenyl of 2 to 12 carbon atoms, hydroxyalkyl of 2 to 12 carbon atoms, hydroxyalkyl of 2 to 12 carbon atoms, alkoxyalkyl of 2 to 12 atoms carbon, cycloalkyl of 3 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms, aryl, aralkyl of 7 to 19 carbon atoms, heterocyclyl of 3 to 12 carbon atoms, heterocyclylalkyl of 3 to 12 carbon atoms, heteroaryl of 1 to 12 carbon atoms, and heteroarylalkyl of 3 to 12 carbon atoms; or R2 is a multi-ring structure having from 2 to 4 rings wherein the rings are independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl and wherein some or all of the rings may be fused with one another; R3 is selected from the group consisting of alkyl of 1 to 12 carbon atoms, alkenyl of 2 to 12 carbon atoms, hydroxyalkyl of 2 to 12 carbon atoms, hydroxyalkenyl of 2 to 12 carbon atoms, alkoxyalkyl of 2 to 12 atoms carbon, cycloalkyl of 3 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms, aryl, aralkyl of 7 to 19 carbon atoms, heterocyclyl of 3 to 12 carbon atoms, heterocyclylalkyl of 3 to 12 carbon atoms, heteroaryl of 1 to 12 carbon atoms and heteroarylalkyl of 3 to 12 carbon atoms; or R3 is a multi-ring structure having from 2 to 4 rings wherein the rings are independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl and wherein some or all of the rings may be fused with each other; R4, R5 and R6 are each independently selected from hydrogen, bromine, fluorine, chlorine, methyl, methoxy, trifluoromethyl, cyano, nitro or -N (R13) 2; R7, R7a, R8, R8a, R9, R9a, R10, and R10a are each independently selected from hydrogen or alkyl of 1 to 3 carbon atoms; or R7 and R7a together, or R8 and R8a together, or R9 and R9a together, or R10 and R10a together are an oxo group, provided that when V is -C (O) -, R7 and R7a together or R8 and R8a together do not they form an oxo group, while the rest of R7, R7a, R8, R8a, R9, R9a, R10, and R10a each are independently selected from hydrogen or alkyl of 1 to 3 carbon atoms; or one R10, R10a, R7 and R7a, together with one of R8, R8a, R9 and R9a form an alkylene bridge, while the remainder of R10, R10a, R7, R7a, R8, R8a, R9, and R9a each are independently selected from hydrogen or alkyl of 1 to 3 carbon atoms; R11 is hydrogen or alkyl of 1 to 3 carbon atoms; and each R 3 is independently selected from hydrogen or alkyl of 1 to 6 carbon atoms; a stereoisomer, enantiomer or tautomer thereof, a pharmaceutically acceptable salt, a pharmaceutically composition thereof or a prodrug thereof.

62. The compound according to claim 61 wherein: x and y are each independently 1, 2 or 3; V is -C (O) - or -C (S) -; R1 is hydrogen, alkyl of 1 to 12 carbon atoms, hydroxyalkyl of 2 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms and aralkyl of 7 to 19 carbon atoms; R2 is selected from the group consisting of alkyl of 1 to 12 carbon atoms, alkenyl of 2 to 12 carbon atoms, hydroxyalkyl of 2 to 12 carbon atoms, hydroxyalkenyl of 2 to 12 carbon atoms, alkoxyalkyl of 2 to 12 atoms carbon, cycloalkyl of 3 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms, aryl, aralkyl of 7 to 19 carbon atoms, heterocyclyl of 3 to 12 carbon atoms, heterocyclylalkyl of 3 to 12 carbon atoms, heteroaryl of 1 to 12 carbon atoms, and heteroarylalkyl of 3 to 12 carbon atoms; R3 is selected from the group consisting of alkyl of 1 to 12 carbon atoms, alkenyl of 2 to 12 carbon atoms, hydroxyalkyl of 2 to 12 carbon atoms, hydroxyalkenyl of 2 to 12 carbon atoms, akoxy of 1 to 12 atoms carbon, alkoxyalkyl of 2 to 12 carbon atoms, cycloalkyl of 3 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms, aryl, aralkyl of 7 to 19 carbon atoms, heterocyclyl of 3 to 12 carbon atoms, heterocyclylalkyl of 3 to 12 carbon atoms, heteroaryl of 1 to 12 carbon atoms and heteroarylalkyl of 3 to 12 carbon atoms; R4, R5 and R6 are each independently selected from hydrogen, bromine, fluorine, chlorine, methyl, methoxy, trifluoromethyl, cyano, nitro or -N (R13) 2; R7, R7a, R8, R8a, R9, R9a, R0 and R10a are each independently selected from hydrogen or alkyl of 1 to 3 carbon atoms; and each R13 is independently selected from hydrogen or alkyl of 1 to 6 carbon atoms.

63. The compound according to claim 62 wherein: x e and each is 1; V is -C (O) -; R1 is hydrogen, alkyl of 1 to 12 carbon atoms or cycloalkylalkyl of 4 to 12 carbon atoms; R2 is selected from the group consisting of alkyl of 1 to 12 carbon atoms, alkenyl of 2 to 12 carbon atoms, cycloalkyl of 3 to 12 carbon atoms, cycloalkylalkyl of 4 to 12 carbon atoms, aralkyl of 7 to 19 atoms carbon, heterocyclylalkyl of 3 to 12 carbon atoms and heteroarylalkyl of 3 to 12 carbon atoms; R3 is aryl optionally substituted by one or more substituents selected from the group consisting of halogen, cyano, nitro, hydroxy, alkyl of 1 to 6 carbon atoms, trihaloalkyl of 1 to 6 carbon atoms, trihaloalkoxy of 1 to 6 carbon atoms , alkylsulfonyl of 1 to 6 carbon atoms, -N (R12) 2, -OC (O) R12, -C (O) OR12, -S (O) 2N (R12) 2, cycloalkyl, heterocyclyl, heteroaryl and heteroarylcycloalkyl; R4, R5 and R6 are each independently selected from hydrogen, bromine, fluorine, chlorine, methyl, methoxy, trifluoromethyl, cyano, nitro or -N (R13) 2; R7, R7a, R8, R8a, R9, R9a, R10 and R 0a are each independently selected from hydrogen or alkyl of 1 to 3 carbon atoms; and each R13 is independently selected from hydrogen or alkyl of 1 to 6 carbon atoms.

64. The compound according to claim 63 wherein: x e and each is 1; V is -C (O) -; R1 is hydrogen, alkyl of 1 to 12 carbon atoms or cycloalkylalkyl of 4 to 12 carbon atoms; R2 is alkyl of 1 to 12 carbon atoms or alkenyl of 2 to 12 carbon atoms; R3 is phenyl optionally substituted by one or more substituents selected from the group consisting of halogen, cyano, nitro, hydroxy, alkyl of 1 to 6 carbon atoms, trihaloalkyl of 1 to 6 carbon atoms, trihaloalkoxy of 1 to 6 carbon atoms , alkylsulfonyl of 1 to 6 carbon atoms, -N (R12) 2, -OC (O) R12, -C (O) OR12, -S (O) 2N (R12) 2; R4, R5 and R6 are each independently selected from hydrogen, bromine, fluorine or chlorine; and R7, R7a, R8, R8a, R9, R9a, R10 and R10a are each hydrogen.

65. The compound according to claim 63, wherein: x e and each is 1; V is -C (O) -; R1 is hydrogen, alkyl of 1 to 12 carbon atoms or cycloalkylalkyl of 4 to 12 carbon atoms; R 2 is cycloalkyl of 3 to 12 carbon atoms or cycloalkylalkyl of 4 to 12 carbon atoms; R3 is phenyl optionally substituted by one or more substituents selected from the group consisting of halogen, cyano, nitro, hydroxy, alkyl of 1 to 6 carbon atoms, trihaloalkyl of 1 to 6 carbon atoms, trihaloalkoxy of 1 to 6 carbon atoms , alkylsulfonyl of 1 to 6 carbon atoms, -N (R 2) 2, -OC (O) R 12, -C (O) OR 12, and -S (O) 2 N (R 12) 2; R4, R5 and R6 are each independently selected from hydrogen, bromine, fluorine or chlorine; and R7, R7a, R8, R8a, R9, R9a, R10 and R10a each is hydrogen.

66. The compound according to claim 65 wherein: R2 is cycloalkylalkyl of 4 to 12 carbon atoms; R3 is phenyl optionally substituted by one or more substituents selected from halogen, alkyl of 1 to 6 carbon atoms, trihaloalkyl of 1 to 6 carbon atoms and trihaloalkoxy of 1 to 6 carbon atoms; R4 and R6 both are hydrogen; and R5 is hydrogen or bromine.

67. The compound according to claim 66 selected from the group consisting of the following: 5-bromo-6- [4- (5-fluoro-2-trifluoromethylbenzoyl) piperazin-1-yl (2-cyclopropylethyl) amide ] -pi ri di n-3-su Ionic; and 6- (4- (5-fluoro-2-trifluoromethylbenzoyl) piperazin-1-yl] pyridine-3-sulfonic acid (2-cyclopropylethyl) amide.

68. The compound according to claim 63 wherein: x e and each is 1; V is -C (O) -; R1 is hydrogen, alkyl of 1 to 12 carbon atoms or cycloalkylalkyl of 4 to 12 carbon atoms; R 2 is aralkyl of 7 to 19 carbon atoms, heterocyclylalkyl of 3 to 12 carbon atoms or heteroarylalkyl of 3 to 12 carbon atoms; R3 is phenyl optionally substituted by one or more substituents selected from the group consisting of halogen, cyano, nitro, hydroxy, alkyl of 1 to 6 carbon atoms, trihaloalkyl of 1 to 6 carbon atoms, trihaloalkoxy of 1 to 6 carbon atoms , alkylsulfonyl of 1 to 6 carbon atoms, -N (R12) 2, -OC (O) R12, -C (O) OR12, and -S (O) 2N (R12) 2l R4, R5 and R6 are each independently selected from hydrogen, bromine, fluorine or chlorine; and, R7, R7a, R8, R8a, R9, R9a, R10 and R10a are each hydrogen.

69. A method for treating a disease or condition mediated by stearoyl-CoA desaturase (SCD) in a mammal, wherein the method comprises administering to a mammal in need thereof a therapeutically effective amount of a compound according to claim 1. 61.

70. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a therapeutically effective amount of a compound according to claim 61.